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ABSTRACT 
Interleukin-2 activates lymphocytes to become highly cytotoxic for a wide 
range of tumour cell types in vitro (Iymphokine activated killer or LAK 
cells), and in animal models. However, only limited therapeutic benefit 
was observed in clinical trials of LAK cell therapy. This project aimed to 
investigate the molecular and cellular interactions involved in the 
production and effector functions of LAK cells, to identify factor(s) which 
might be responsible for the poor clinical responses observed in LAK cell 
therapy. 
Tumour cell lines were heterogeneous in their response to killing by 
cytokines (TNFu, L T, IFNy and IL-1 J3), and purified monocytes or 
lymphocytes, but were consistently highly sensitive to LAK cell 
cytotoxicity. Autologous monocytes and lymphocytes were not killed by 
LAK cells, in contrast to human umbilical vein endothelial cells and 
fibroblasts. Supernatants from LAK cells were considerably less 
cytotoxic than the effector cells, and physical separation of effector and 
target cells resulted in inhibition of killing. Lymphocyte and LAK cell 
cytotoxicity was associated predominantly with the CD8+ (cytotoxic T-
cell) lymphocyte sub-population, and was significantly inhibited by anti-
TNFu and anti-L T, demonstrating that these cytokines were the primary 
effector molecules in this system. LAK cells and A375 melanoma cells 
showed procoagulant activity, predominantly via the tissue factor 
pathway, and LAK cells also possessed surface factor V. In addition, 
A375 cells were highly fibrinolytic. Tumour cell killing by LAK cells was 
inhibited by plasma, and further experiments determined that 
polymerised fibrin, but not fibrin monomer was responsible. 
From these results it was suggested that culture of small numbers of 
cells from tumour biopsies, and the determination of their sensitivity to 
cytotoxic drugs, cytokines and effector cells may lead to more effective 
treatment protocols for immunotherapy of individual tumours. In order to 
enhance the efficacy of immunotherapy, further in vivo research is 
required to elucidate the interactions between immune effector cells and 
the coagulation/fibrinolytic systems. 
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CHAPTER 1 
INTRODUCTION 
1.1.1 Epidemiology of Cancer 
The treatment of most cancers has changed little in the past twenty 
years. Radiation therapy, surgery and cytotoxic drugs, or a combination 
of these, continue to be the most widely used and are thus considered to 
.. 
be the most effective treatments available. Some success has been 
achieved using these therapeutic approaches with a number of the rarer 
cancers, but the overall death rate (USA) due to cancer continues to 
rise. Although the large increase in lung cancer incidence is primarily 
responsible for the observed rise in death rate, other cancers such as 
non-Hodgkin's lymphoma, multiple myeloma, and cancers of the 
prostate, brain, kidney, oesophagus and breast have shown 
considerable increases in incidence and death rate in recent years 
(Bailar and Smith, 1987). 
1.1.2 Malignant Melanoma 
Cutaneous malignant melanoma, which is still one of the rarer cancers, 
is increasing at a faster rate than any other cancer in the USA, Australia, 
northern Europe and Canada (Muir and Nectoux, 1982). The incidence 
of melanoma in the USA has doubled every 10-20 years since 1950 
(Rigel et a/., 1987). Exposure to sunlight appears to be the most 
significant factor involved in the observed increase. This is probably due 
to changes in lifestyle which include altered dress habits, more holidays 
in sunny climates and possibly depletion of the ozone layer. Other risk 
factors, such as fluorescent lights (Maxwe" and Elwood,1983), exposure 
to chemicals and ionising radiation (Wright et al., 1983; Austin and 
Reynolds, 1984; Holman et a/., 1986), steroid hormones (Prentice and 
Thomas, 1987) and diet (Mackie et a/., 1980) would appear to be 
considerably less important than exposure to the sun. Unlike most 
cancers, the incidence of melanoma does not increase linearly with age. 
The incidence curve rises steeply prior to age 50, and increases less 
7 
rapidly in the older age groups (Devesa et a/., 1987). World-wide, the 
incidence of melanoma varies over 100-fold, from a low of 0.2 per 
100,000 person years in parts of Japan, to approximately 40 per 100,000 
person years in Queensland, Australia (Green, 1984; Muir et a/., 1987) . 
Although still comparatively rare, melanoma is rapidly becoming an 
important cause of disease and death among white populations. This 
epidemiological data would suggest that current treatment protocols are 
~ 
not sufficient in themselves to influence significantly the increasing 
death-rate due to the majority of cancers (Bailar and Smith, 1987). 
1.1.3 Clinical Presentation of Melanoma 
Malignant melanoma is a neoplastic disease characterised by 
uncontrolled prOliferation of melanocytes, the pigment producing cells of 
the skin, meninges, substantia nigra, and the eye. There are various 
forms of cutaneous malignant melanoma (Table 1), but the progression 
of disease in each form follows a similar pattern of growth and clinical 
deterioration (Roses et a/., 1983). 
1. Superficial Spreading • Represents 70% of cutaneous melanomas 
• Amelanotic regression areas often seen 
• More prevalent in women than men 
2. Nodular • 15 -30% of cutaneous melanomas 
• More aggressive than superficial spreading and 
quicker developing 
• Incidence greater in men than women 
3. Lentigo Maligna • Less likely to metastasise 
• 4 - 10% of patients 
4. Acral Lentiginous • Occurs principally on palms and soles 
• More frequently presents in older patients 
TABLE 1.1. Growth patterns of cutaneous melanomas. 
The most benign types of melanoma are very slow growing and, apart 
from a visible skin lesion, symptomless. An example of this is lentigo 
maligna, which commonly presents in the sixth and seventh decades of 
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life and may take several years to become invasive. Generally, the first 
sign of invasion by melanoma in terms of growth pattern is an increase in 
melanoma cell proliferation in the horizontal or radial dimension across 
the surface of the skin. An example of a primary melanoma in the radial 
growth phase is superficial spreading melanoma. Further neoplastic 
progression occurs by melanoma cell proliferation in the vertical plane of 
the skin, a feature seen in the presentation of nodular melanoma. Acral 
'\ 
lentiginous and mucosal melanomas are, in most cases, identical to the 
other three main forms of primary skin-associated melanoma. These 
melanomas develop in stratified squamous epithelium but the sites are 
on palms and soles, or on mucosal surfaces respectively. Table 2 shows 
the clinical staging of melanoma progression as agreed by the American 
Joint Committee on Cancer. 
Stage Description 
1a Localised Melanoma <0.75mm 
1b Localised Melanoma ).76mm -1.5mm 
2a Localised melanoma 1.5mm - 4mm 
2b Localised Melanoma >4mm 
3 Limited nodal metastases involving only one regional lymph 
node, or less than 5 in transit metastases but without nodal 
metastases 
4 Advanced regional metastases or any patient with distinct 
metastases 
. . TABLE 1.2. American jOint committee on cancer stagmg scheme. Distances m 
millimetres represent the depth of tumour invasion into the dermis. Higher stage 
numbers indicate worsening prognosis for the patient. 
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1.1.4 Metastasis of Melanoma 
The final growth patterns observed In the progression of melanoma 
include the formation of local and distant metastases which tend to 
proceed rapidly from a vertical growth phase. Frequently, a diagnosis of 
melanoma is not made until metastases are already in abundance and 
some degree of primary tumour site regression may have occurred as 
well. The onset of metastasis in malignant melanoma indicates a very 
poor prognosis for treatment and recovery. Melanoma cells initially 
metastasise locally, forming starburst-like satellite nests of neoplastic 
cells around the primary tumour, and then distant metastases are 
established via the lymph vessels or skin capillaries. In general, distant 
metastasis is likely to have occurred if neoplastic cells have invaded the 
reticular dermis (about 0.7Smm from the dermo-epidermal junction; 
Roses et a/. , 1983). Distant metastases then develop very rapidly, 
involving most internal organs in a diffuse fashion. As yet, no discrete 
patterns of secondary involvement have been observed. In a study of 
216 post-mortems with histologically proven metastatic melanoma, 
involvement of nearly all organs was observed (Patel et a/. , 1978). The 
organs which were most commonly involved were the lung (71.3% ); liver 
(S3.8%); brain (S4.6%)} and bone (48.6%)}. Lymph nodes were involved in 
7sok of cases. An intermediate stage of metastasis is often described as 
in-transit metastasis. This classification describes lesions greater than 
Scm from the primary tumour and is believed to precede distant 
metastasis, although the presence of these lesions usually indicates that 
distant metastatic spread has already occurred. 
1.1.5 Spontaneous Regression of Melanoma 
Melanoma is an unusual cancer in that it exhibits a relatively high level 
of spontaneous regression of the primary growth (7 -8°A> (Smith and 
Stehlin, 1965; McGovern.,1972). The only other malignant tumour that 
has demonstrated this phenomenon to any significant degree is renal 
cell carcinoma, which has a spontaneous primary regression rate of 1-
20A> (de Riese et a/. , 1991). Regression of melanoma may occur to 
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varying degrees, from a slight decrease in the size of the tumour with 
accompanying hypopigmentation and fibrosis, to complete destruction of 
the primary melanoma with residual fibrosis and melanosis (presence of 
numerous melanophages filled with melanin). Unfortunately, primary 
melanoma regression is not usually considered a good prognostic sign, 
as metastases are often observed concurrently or shortly after 
regression. This phenomenon may account for the presentation of 
malignant melanoma in a disseminated form with no detectable primary 
site. A study published in 1972 (McGovern.,1972) reported 7% of 613 
cases of melanoma where metastases were diagnosed with no evidence 
of a primary tumour, showing how commonly complete primary tumour 
regression may occur. 
Histological observations of melanoma regression include a lymphocyte 
infiltration of the papillary dermis that ranges from a sparse perivascular 
population to a full thickness band of lymphocytes in the papillary dermis 
beneath the melanoma (i.e. melanoma still confined to the epidermis). 
Observations indicate that these lymphocytes are capable of cytotoxicity 
to melanoma cells that breach the dermo-epidermal junction and enter 
the papillary dermis and to a lesser extent to the lesion still confined to 
the epidermis. Other accompanying changes following regression are 
thickening and fibrosis of the papillary dermis with dilatation of the 
vascular spaces and variable numbers of dermal melanophages. The 
lymphocyte infiltrate also disappears following regression, implying that 
the response is specifically mounted against the melanoma cells. Table 
3 summarises the clinical manifestations of melanoma regression 
(McGovern, 1972). 
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• Inflammatory nodule with or without pigmentation. 
• Scarring in a primary cutaneous melanoma. 
• Melanoma composed of separate pigmented lesions. 
• Pigmented focus with depigmented halo. 
• Pigmented scar with or without microscopic islands of surviving 
melanoma cells. 
• Metastatic melanoma with no demonstrable primary tumour . 
... 
TABLE 1.3. Clinical Manifestations of Melanoma Regression. 
1.1.6 Conventional Treatment of Melanoma 
Conventional treatment of melanoma falls into two categories. Firstly, the 
treatment of the primary lesion and secondly, the treatment of metastatic 
disease. Primary lesions in the earlier stages of growth without 
metastatic capability are treated surgically with wide excision (usually at 
the same time as biopsy). This is by far the most effective means of 
treatment provided early detection has been possible. In the presence of 
secondary deposits and/or a large primary that makes adequate surgery 
impractical, chemotherapeutic protocols have been used to attempt cure 
or provide palliative treatment. Chemotherapy has included systemic 
administration or local perfusion (arterial cannulation) of limbs with 
Actinomycin-D. Treatment of advanced metastatic melanoma is still one 
of the biggest problems in clinical practice. In terms of chemotherapy 
Actinomycin-D with or without Dacarbazine demonstrates some palliative 
efficacy (Hochster et a/. , 1985). Other cytotoxic drugs used in the 
treatment of advanced melanoma include Melphalan (Coit, 1994) and 
Vinblastine (Elliott et aI, 1994). 
1.2.0 Immunity and Cancer 
1.2.1 Background 
Immunological responses directed against tumours have been 
recognised for over a century, when it was observed by surgeons that 
tumour necrosis and regression occasionally follows bacterial infection in 
cancer patients. In 1893, William Coley, a New York surgeon, began to 
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investigate this phenomenon by producing a filtrate of bacterial cultures 
termed "Coley's Mixed Toxins", and injecting it into patients with various 
types of advanced cancer. The treatment was continued for six months 
to a year for each patient (Coley-Nauts et aI, 1953). He noticed that more 
effective responses to this treatment were obtained when a marked fever 
was induced. Coley carried out clinical trials with his toxins, evaluating 
their efficacy as compared to radium treatment and amputation. In one 
study concerning 170 operable cases of long bone malignancy, he found 
that more effective clinical responses were observed when amputation 
was followed by toxin therapy, which gave a 50% survival rate for 3-33 
years. Amputation alone allowed a maximum survival of 3 years (Coley 
and Coley, 1926). 
Coley's work was later reviewed by his daughter, where she detailed 30 
complete remissions, which were representative of 270 complete 
remissions from 1,200 patients treated with toxins (Coley-Nauts et a/., 
1953). However, by the late 1930's this form of treatment was largely 
abandoned in favour of radiotherapy and chemotherapy, which together 
with surgery are still the major forms of cancer treatment today. 
Since the studies of Coley, research in tumour immunity has progressed 
in animal models, and more recently in human cell lines to identify 
specific tumour antigens which are recognised by either the humoral or 
cellular immune systems, which have been extensively reviewed. 
(Ferrone, 1990, Oettgen, 1989) 
1.2.2 Cellular Immunity and Cancer 
1.2.2.1 Background 
In 1959, Thomas expanded upon an earlier theory of "aberrant germs" 
previously proposed by Ehrlich, to propose that the specific, adaptive 
immune response may have evolved so as to protect the body from 
neoplasia. This theory, termed the immune surveillance theory (Burnet, 
1970) stated: "The thesis is that when aberrant cells with proliferative 
potential arise in the body they will carry new antigenic determinants on 
their cell surfaces. When a significant amount of new antigen has 
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developed, a thymus-dependent immunological response will be initiated 
and eventually eliminates the aberrant cells in essentially the same way 
as an allograft is destroyed." According to this theory cancer would only 
develop due to some failure of immune function, such as 
immunosuppression, or by adoption of immune evasion mechanisms by 
the tumour. Tumour-specific antigens have been relatively difficult to 
identify for most tumour types. Of the few tumours which express specific 
antigens, the majority are associated with viraTly induced cancers, so 
that immune surveillance is currently considered to be directed primarily 
against virus infected cells, rather tnan nascent tumours (Martz and 
Howell, 1989). Only the minority of cancers expressing appreciable 
levels of specific antigen (e.g., melanoma, renal cell carcinoma) are 
considered true candidates for immune surveillance (Klein and Klein, 
1977), although it appears that the immune system 'selects' for the least 
immunogenic clones of a tumour, which then progresses unhindered by 
further immune involvement. Current strategies for cancer treatment 
therefore focus on augmenting the immune system, so as to increase its 
surveillance for, and subsequent destruction cancer cells. In addition to 
the specific cellular immune response to cancer described above, certain 
cytotoxic lymphocytes, Iymphokine-activated killer (LAK) cells, natural 
killer (NK) cells and macrophages recognise and kill tumour cells by a 
mechanism which does not require sensitisation to antigen, and is not 
major histocompatibility complex (MHC) restricted. 
In the late 1980's, clinical trials were undertaken by Rosenberg's and 
other groups (Rosenberg et a/., 1986; Kawakami et aI, 1988; Heo et aI, 
1987), in which tumour infiltrating lymphocytes (TIL) were removed from 
excised tumours and stimulated with Interleukin-2 (IL-2) in the presence 
of cellular material from the tumour (to stimulate antigen-specific 
lymphocytes) for weeks to months. In the majority of tumours tested, the 
predominant population of lymphocytes present were CD3+, CD8+ T-
cells, which were highly cytotoxic for autologous, but not allogeneic, 
tumour cells in vitro. After expansion of this cell population, the cells 
were reinjected into the cancer patient in order to promote tumour 
regression. 
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1.2.3 Effector Cells of the Cellular Immune Response to Cancer 
1.2.3.1 Cytotoxic T -Cells 
Cellular cytotoxicity by lymphocytes was first shown by Govaerts in 1960 
where he described killing of donor kidney epithelial cells in vitro by 
thoracic duct lymphocytes from dogs which had previously rejected a 
kidney allograft. These observations were expanded by other workers to 
include lymphocyte cytotoxicity against virally inf~cted cells (Gardner et 
ai, 1974) and autologous, as well as, transplanted tumours (Clark, 1988). 
The effector cells in these experiments are now known as cytotoxic T 
lymphocytes. 
Cytotoxic T-cells (Tc) are defined as a heterogeneous subpopulation of 
lymphocytes which are able to recognise and kill suitable target cells in 
several distinct ways. The majority of Tc are CD8+ and recognise 
antigen in the presence of MHC Class I molecules, whereas CD4+ 
lymphocytes (comprising approximately 10%) of the Tc population) 
recognise antigen in the presence of MHC Class II (Erb et aI., 1990). 
Specific recognition of antigen by T -cells is achieved via the a~T -cell 
receptor (TCR). A major difference observed between CD8+ Tc and 
CD4+ Tc was that in a population of two or more different target cells 
CD8+ Tc would only kill those target cells which express specific 
antigen, whereas CD4+ Tc also killed other cells mixed with cells 
bearing specific antigen ("bystander killing"; Gromkowski et aI., 1988). 
More recent evidence has demonstrated that both specific (ce" contact 
dependent), and bystander killing (release of soluble effector molecules), 
can be induced by both CD8+ (Burrows et aI., 1993; Hakim et al., 1991) 
and CD4+ T-cells (Gravelle and Ochi, 1989; Yasukawa, et aI., 1993). 
Some CD8+ Tc may also kill target cells in an non-MHC restricted 
fashion, particularly after stimulation with IL-2 in tissue culture (see 
section 1.3.3). These cells are cytotoxiC to a wide range of tumour cell 
lines, including many which are insensitive to NK cell killing. Cytotoxicity 
is not mediated by the TCR, but by the induction of cell surface NK-like 
receptors (e.g., CD56) on these cells in culture. In addition, killing of NK 
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resistant target cells may be mediated via LFA-1, CD2 (Chan et ai, 1989) 
and CD45 (Starling, et a/., 1989; Bell et a/., 1993) 
Another T-cell subpopulation possessing the y8TCR (y8T-cells), is 
cytotoxic for allogeneic target cells after recognition via their TCR. 
Although this would seem to be antigen specific MHC dependent killing, 
recent reports suggest that y8T-celis recognise a limited number of 
antigens which are associated with CD1c (Faure et a/., 1990), which 
"' resembles MHC Class I molecules and binds to J32-microglobulin. In 
addition, some y8T -cells are cytotoxic for tumour cells in an MHC 
unrestricted fashion, triggered directly via the y8TCR, or alternatively by 
the recognition of non-polymorphic MHC-related molecules (e.g. CD1). 
These functions of y8T -cells may represent distinct functional 
subpopulations within the y8T -cell subset. 
1.2.3.2 Natural Killer Cells and K Cells 
Natural killer cell (NK cells) comprise about 15% of human blood 
lymphocytes, and constitute the large granular lymphocyte (LGL) 
population in peripheral blood. They are characterised by their 
expression of CD16 (FcyRIII) and CD56, and are distinguished from T-
and B-cells by the absence of either surface immunoglobulin or TCR. 
Little is known about the lineage of NK cells, though they and T -cells are 
thought to arise from a common precursor in the bone marrow (Sanchez, 
et ai, 1994). The main functions of NK cells include inhibition of the early 
stages of viral infection, as well as resistance to tumours and other 
infectious diseases. They adhere to antibody coated target cells via 
CD16-Fc binding, and induce cell death by antibody-dependent cellular 
cytotoxicity (ADCC, Perussia et ai, 1984). A subpopulation of LGL are 
only able to mediate cytotoxicity via ADCC and are defined as K-cells 
(Wahlin and Perlmann, 1983). In addition to ADCC, the majority (95%) of 
LGL also kill target cells via a CD16 independent pathway (i.e., 
independent of Fc receptor binding to antibody coated target cells), 
which has not been fully characterised, although recent evidence 
suggests that a specific NK receptor exists. (Daniels et a/., 1994). The 
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molecular nature of the ligand(s) for this receptor are unknown, but there 
is evidence that NK cells bind to specific carbohydrate residues on cell 
surface glycoproteins (Bezouska et a/. , 1994), as well as laminin 
(Gismondi et a/., 1992) and sulphated glycolipids (Young et a/., 1980; 
Yogeeswaran et a/. , 1981). Although NK cells are cytotoxic for a wide 
variety of tumour cells, some target cell lines are resistant to NK activity, 
implying a degree of specificity. Thus, it has been postulated that various 
subpopulations of NK cells exist, with different" target cell specificities. 
Since natural killer cells are rarely seen in solid tumours, their main 
antitumour activity may involve the suppression of metastatic tumour 
cells entering the circulation (Hanna and Fidler, 1980). 
1.2.3.3 Lymphokine Activated Killer (LAK) Cells 
Lymphokine activated killer cells were first described by Yron in 1980, 
and were originally thought to be a new class of lymphocyte derived 
cytotoxic cell (Grimm et a/., 1982). Incubation of lymphoid cells with IL-2 
results in non-antigen dependent, non-MHC restricted cytotoxicity 
against a wider range of tumour cells than observed for NK cells or Tc. 
Since LAK cells are derived from a variety of lymphoid precursors, the 
term LAK is a description of a cellular activity rather than a specific cell 
type, i.e., Iymphokine-activated killer (LAK) cell activity (Maghazachi et 
a/., 1988). Other cytokines such as tumour necrosis factor-a (TNFa), 
Iymphotoxin (L T) and interleukin-1 (IL-1) augment LAK activity by 
synergising with IL-2, probably by upregulating the a-chain (p55) of the 
IL-2 rec~ptor. Lymphokine activated killer cell production is inhibited in 
man (but augmented in mice) by IL-4, possibly by the inhibition of 
transcription of a number of genes including that coding for the a-chain 
of the IL-2 receptor (Peace et al., 1988). Lymphokine activated killer 
cells differ from NK cells in their cytotoxicity for NK resistant cells (e.g., 
Oaudi, Raji), including freshly isolated tumour cells (which are rarely 
susceptible to NK cell cytotoxicity). In addition, LAK cells require 
induction for at least 24-48h (but will remain active for months if 
continuously cultured in the presence of IL-2) to show optimal activity, 
17 
whereas NK cells are cytotoxic to suitable target cells immediately after 
isolation from peripheral blood. 
1.2.3.4 Monocytes and Macrophages 
Mononuclear phagocytes perform a wide variety of functions ranging 
from microbicidal, phagocytic, immunoregulatory (Unanue et a/ 1984) 
and tumouricidal (Colotta et a/., 1985). They can also modulate the 
~ 
function of other immune cells such as T - and B-cells, i. e. in antigen 
presentation, the production of mitogenic factors, suppression of cell 
proliferation (Varesio et a/., 1979), cytokine production (Varesio and 
Holden, 1980a) and protein synthesis in lymphocytes (Varesio and 
Holden, 1980b). However, the mechanisms by which macrophages exert 
these effects are not fully understood. There may be several 
macrophage subpopulations, as differences in cell morphology, surface 
markers and density have been observed (Fishman, 1980). However this 
heterogeneity may also be ascribed to differences in anatomical location 
and the various states of macrophage activation (Springer et a/., 1979). 
Cells of the macrophage lineage have the ability in vitro to become 
cytostatic or cytotoxic to certain tumour cell lines but are not cytotoxic to 
non-transformed cells. These effects may either be spontaneous 
(Tagliabue et a/., 1979) or may be stimulated by specific activation 
agents. Tumouricidal activity has been reported for non-activated 
monocytes and macrophages (Tagliabue et a/., 1979), but there is some 
controversy as to the validity of these claims (Adams, 1980). It has been 
proposed: (1.) that monocyte preparations might be contaminated with 
NK cells (Freundlich et a/., 1984); (2.) that the effector cells are 
unintentionally activated by the cell separation procedure chosen, or (3.) 
that the reagents used in the assays are contaminated with endotoxin. 
Monocytes and macrophages can be activated to the tumouricidal state 
by a variety of substances such as supernatants from mitogen stimulated 
lymphocytes, lipopolysaccharide (LPS) (Kildahl-Andersen and Nissen-
Meyer, 1984; Horwitz et a/., 1979; Chen et a/., 1986), muramyldipeptide 
(MOP) (Lopez-Berestein et aI., 1983), interferons (Jett et a/., 1979; 
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Fischer et a/1983; Feinman et a/., 1985), interleukin 1 (IL 1) (Onozaki et 
a/., 1985), interleukin-2 (Malkovsky et a/., 1987), double stranded RNA 
(dsRNA) and the calcium ionophore A23187 (Drysdale et a/., 1983). 
From studies into the mechanisms of action of these compounds four 
discrete stages of macrophage activation have been proposed (Johnson 
et a/., 1983) (Adams and Marino, 1981): (1.) resident macrophages 
which do not possess markers of inflammatory macrophages, (low 
~ 
phagocytosis of immunoglobulin coated erythrocytes, secretion of 
plasminogen activator and increased levels of 5' nucleotidase) and 
which do not secrete cytotoxic proteases. These cells are not 
tumouricidal; (2.) in response to a stimulant the macrophages express 
the markers of inflammatory macrophages and can be triggered to 
become tumouricidal; (3.) macrophages will bind to tumour cells but are 
still unable to kill them. At this stage cytotoxic activity can be triggered by 
LPS; (4.) activated cells which will kill tumour cells without further 
stimulation. An example of primed (stage 3) cells are pyran copolymer-
induced macrophages which require LPS in order to become 
tumouricidal, whereas Bacillus Cal mette-Guerin (BCG) elicited 
peritoneal macrophages are cytotoxic without the addition of LPS (stage 
4) (Johnson et a/., 1983). However, this pathway of macrophage 
activation may not be the only one which leads to tumouricidal activity. It 
has been shown that polyinosinic:polycytodylic acid (poly(I,C)), but not 
cytokine is able to stimulate tumouricidal activity in a few hours in the 
absence of LPS (Taramelli and Varesio, 1981). Cycloheximide can also 
inhibit the activation of macrophages by a- and P- but not y-IFN or 
cytokines (Blasi and Varesio, 1984). 
Macrophage cytotoxicity is a relatively short lived event, and cells 
cultured in vitro for longer than 3-4 days lose their cytolytic activity, 
although this time may vary according to the activator used and/or the 
assay conditions employed (e.g., Iymphokine-activated macrophages 
retain cytolytic activity longer than LPS activated cells (Russel et a/., 
1977; Fidler et a/., 1976; Ruco and Meltzer, 1978; Taffet and Russell, 
1981 a,b). After this period the cells cannot be re-stimulated to become 
19 
tumouricidal, implying that there is a regulatory mechanism which leads 
to the suppression of tumouricidal activity. The molecular mechanisms 
involved in this decline are not known, but prostaglandin-E2 (PGE2) has 
been implicated in abolishing the tumouricidal activity of LPS-stimulated 
macrophages (Taffet and Russell, 1981 a,b). 
Corticosteroids have also been found to inhibit tumour cell killing by 
macrophages (Oimitriu, 1976), and tumour cells may produce factors 
.. 
which inhibit macrophage function (Szuro-Sudol and Nathan, 1982). The 
mechanism may also involve other cells such as T -cells since 
Iymphokine-activated macrophages become suppressor cells which 
inhibit T-cell activation and hence further production of Iymphokine. This 
may be the basis of a possible negative control mechanism of 
tumouricidal activity (Taramelli et al., 1980). 
There is evidence that the activation of macrophages in vivo to become 
tumouricidal has some effect on the tumour cells. Treatment of tumour 
(metastasising) bearing mice with macrophage activating factor (MAF) or 
muramyl dipeptide (MOP) enclosed within liposomes led to a significant 
regression in tumour load of the animals (Fidler et al., 1982; Lopez-
Berestein et aI., 1983). The reason for the use of liposomes was two-
fold: (1.) MOP is rapidly excreted from the system «60min) and 
encapsulation prolongs the retention time; (2.) the monocytes and 
macrophages phagocytose these particles and subsequently become 
activated by them (Fidler et a/. , 1982). Liposome encapsulated MOP has 
also been demonstrated to activate alveolar macrophages in vitro (Sone 
and Tsubura, 1982). 
The nature and relative significance of the role of macrophages in 
tumour cell killing independent of, or in concert with other tumouricidal 
effector cells is still not clear. The numbers of macrophages present in 
tumours may vary considerably with the tumour type, but few 
macrophages are usually present in most murine tumours (Fidler et a/. , 
1982), and some tumours may be able to prevent macrophage infiltration 
by producing factors which inhibit macrophage chemotaxis. As a further 
complication, macrophage products (IL-1, TNFa) have been reported to 
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stimulate the growth of some tumour cell lines in vitro (Lachman et a/., 
1987). 
1.2.4 Mechanisms of Tumour Cell Destruction 
There are three processes by which tumour cells may be destroyed. 
These are necrosis, lysis and apoptosis. Necrosis primarily occurs as a 
result of anoxia within the tumour mass, due to inadequate 
vascularisation of the tumour. Tumour cells adjacent to the necrotic 
areas (but still distant from capillaries) become hypoxic, resulting in their 
relative insensitivity to conventional therapies such as radiation 
(Thomlinson and Gray, 1955). In contrast to normal tissues, tumour 
capillaries are often spaced more than 2mm apart, resulting in some 
degree of necrosis in nearly all tumours. Agents which inhibit blood flow 
to tumours, by destruction of tumour capillaries (e.g .. flavone acetic acid 
causes selective endothelial cell destruction and haemorrhage in some 
tumours (Murray et a/., 1989)), inhibition of tumour angiogenesis or 
blockage of tumour capillaries (e.g. , by induction of coagulation) induce 
necrosis of tumour cells. Although these treatments often kill over 95% of 
cells within the tumour, the remaining 5% are often sufficient to re-
establish tumour growth. 
Cell lysis occurs when the integrity of the target cell membrane is 
compromised. Membrane damage occurs in two main ways. (1) Release 
of reactive molecules such as reactive oxygen intermediates (ROI), 
proteases, hydrogen peroxide into the intercellular space, or directly 
onto the target cell membrane from granules within the effector cells 
(e.g., macrophages, granulocytes), resulting in irreversible membrane 
damage. This process may be non-specific; (e.g., secretion of cytolytic 
molecules into solution by activated macrophages, which will attack all 
cells in their vicinity), or specific; as in ADCC, where macrophages or 
NK cells initially adhere to antibody coated target cells via their Fc 
receptors and subsequently release cytolytic molecules into the 
intercellular junctions. In this case the process of tumour cell recognition 
and adherence is non-specific, but only antibody coated tumour cells are 
21 
lysed. (2) Tumour cells lysis is also induced by pore forming proteins. In 
the humoral immune system pores are formed in antibody coated target 
cell membranes by the complement components. A membrane attack 
complex (MAC, a polymeric complex of the complement proteins C5b-
C9) is assembled within the membrane forming a pore which allows free 
movement of water and solutes across the membrane, resulting in 
osmotic swelling and cell lysis. In the cellular immune system adherence 
.. 
of effector to target cells results in the release of granules containing 
perforins into the intercellular space. The structure of perforin IS 
homologous with that of C9 and, on polymerisation, forms pores In 
membranes or lipid vesicles 5-20nm in diameter (smaller than those 
produced by the C9 MAC) which act as permanently open ion channels. 
Unlike the C9 MAC, perforins do not require the presence of pre-formed 
elements on the target cell surface to exert their effect and are Ca++ and 
pH dependent. 
Apoptosis, or programmed cell death can be induced by immune effector 
cells. and is thought to be the main way in which the body remodels 
(e.g.. during embryogenesis) and processes tissues (e.g.. clonal 
selection of T-cells in the thymus) during normal life. It is, therefore, an 
important mechanism which maintains correct cell numbers in the body 
by balancing cell death with cell production. Apoptosis may also be a 
control mechanism in cellular positioning in the body (Meredith et a/ 
1993, Frisch and Francis, 1994). Cells undergoing apoptosis in vitro first 
round up, and the endoplasmic reticulum breaks up into vesicles which 
may fuse with the plasma membrane. The chromatin forms dense 
aggregates and there is invagination of the nuclear membrane. At this 
point the plasma membrane also convolutes resulting in the 
characteristic 'blebbing' of cells seen during apoptosis. Membrane bound 
segments of cell (apoptotic bodies) are then budded off into the 
environment (zeiosis). The earliest event in apoptosis is the 
fragmentation of nuclear DNA into approximately 200 base pair 
fragments (corresponding to the number of base pairs between 
nucleosomes), probably caused by calcium dependent endonucleases 
(McConkey et a/., 1988; Kizaki et a/., 1989). The mechanism by which 
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apoptosis is triggered has recently become an important area of 
research. Apoptosis is induced in susceptible target cells by cytokines 
such as TNFa., IL-1 ~ and IFNy. 
1.2.5 Immunotherapy of Cancer 
The various forms of immunotherapy may be classified into two main 
groups: active and passive. Non-specific active immunotherapies include 
.. 
activation of the immune system with agents such as BCG or 
Corynebacterium parvum (adjuvant immunotherapy). Specific active 
immunotherapy involves the inoculation of cancer patients with vaccines 
derived from killed tumour cells or tumour cell extracts. Alternatively, 
purified tumour antigens may be injected to induce a specific immune 
response to the tumour. Reinjection of tumour infiltrating lymphocytes 
which have been cultured in the presence of tumour antigen is also a 
form of specific immunotherapy. 
Passive immunotherapy may be non-specific, specific or a combination 
of both. Non-specific passive immunotherapy includes treatment with 
cytokines or LAK cells which are dealt with in more detail in the later 
sections. Specific passive immunotherapy involves treatment with 
monoclonal antibodies (whole molecules or Fab fragments) directed 
against tumour antigens. Antibodies coupled to cytotoxic drugs, toxins 
(such as ricin) or radioisotopes provide specific delivery systems for 
these cytotoxic effectors. 
1.2.5.1 Cytokine Immunotherapy 
Cytokines are low molecular weight proteins «80-kDa), which function 
as cell regulators in an autocrine or paracrine manner, and are involved 
in the regulation of the amplitude and duration of the immune response. 
They bind to high affinity receptors which are specific for individual 
cytokines or groups of cytokines, and alter cellular behaviour (of immune 
and other normal and neoplastic cells) by changing the patterns of DNA, 
RNA and protein synthesis in cells. Cytokines often have a number of 
regulatory activities, which differ according to their concentration, the 
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cellular composition of their environment, and the presence of other 
cytokines. There are, therefore, a number of ways in which cytokines can 
be used in the treatment of cancer: (1.) direct regulation of cell growth 
(cytostatic, cytotoxic, e.g. the tumour necrosis factors), or synergy with 
other cytokines to modulate cancer cell growth and behaviour (e.g. 
Interferons); (2.) some cytokines cause alterations in the tumour 
vasculature, resulting in nutrient deprivation and tumour cell necrosis 
.. (e.g., TNFa); (3.) stimulation of a host immune response against cancer 
(e.g., IL-2); (4.) therapy with cytokines such as the colony stimulating 
factors has proved useful in the recovery of haemopoiesis after 
conventional treatment with cytotoxic drugs and/or radiotherapy (Brandt 
et aI., 1988); (5.) some cytokines (e.g., IL-1, TNFa (Lachman et a/., 
1987; TNFa is an example of a cytokine which exhibits multiple, and in 
some cases opposite, biological activities), TGFJ3 (Lee et aI., 1987) and 
oncogene products possess autologous tumour growth promoting 
activity. This autocrine growth hypothesis of cancer suggests that 
malignancy may result from uncontrolled production of, or response to, 
these autocrine growth factors. Alternatively, neoplasia may arise from 
the deletion or mutation of a gene for a growth inhibitory protein. In 
either case, cytokine therapy may have a role in the modulation of 
tumour cell growth mediated via these mechanisms. 
The following sections will outline the molecular properties and the role 
of several major cytokines in cancer therapy. 
1.2.5.2 Tumour Necrosis Factor-a and Lymphotoxin 
Following Coley's observations, it was found that endotoxin was the 
factor responsible for inducing necrosis of a range of transplantable 
tumours in mice (Shear and Perrault, 1944), and subsequent 
experiments by O'Malley in 1962 showed that tumour necrosis activity 
could be transferred in the serum of endotoxin treated animals. A factor 
produced by activated T-cells in response to bacterial toxin, which was 
cytotoxic for a number of tumour cell lines, was termed tumour necrosis 
factor (TNF) by Carswell and co-workers (1975). Another tumouricidal 
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product of activated T -cells, called Iymphotoxin (L T, also known as 
TNF~) had also been characterised by Granger and Williams (1968). 
Subsequently, recombinant forms of TNFa (Pennica et a/., 1984) and LT 
(Gray et al., 1984) became available and the cytotoxic activities of these 
molecules was confirmed. 
Tumour necrosis factor-a is a trimer of non-glycosylated 17 -kDa 
subunits, but there is also a 26-kDa transmembrane form of the molecule 
.. (Wingfield et a/. , 1987). It is produced by macrophages, activated T -cells 
and NK cells. Lymphotoxin is a 25-kDa molecule which does not have a 
transmembrane form. Both molecules are coded for on the short arm of 
chromosome 6. A wide range of normal and neoplastic cells have high 
affinity receptors for these cytokines ranging from 1000-10,000 per cell. 
The same receptor is shared between TNFa and L T, but its expression 
does not seem to correlate with the susceptibility of cells to the action of 
these cytokines (Tsujimoto et a/. , 1985; Immamura et a/. , 1987). The 
tumour necrosis factors have a large number of separate activities on 
normal and neoplastic cells in addition to their tumouricidal activity, 
including protection of cells from viruses, neutrophil activation (Shalaby 
et a/., 1985), promotion of osteoclastic bone resorption (Bertolini et a/. , 
1986), alteration of the haemostatic and inflammatory properties of 
endothelial cells (Bevilacqua et a/. , 1986). On endothelial cells TNFa 
inhibits the activity of thrombomodulin, augments the secretion of 
inhibitors of plasminogen activators, and induces the expression and cell 
surface expression of tissue factor procoagulant activity, resulting in a 
shift in endothelial cell function from a normally anticoagulant to a 
procoagulant state. Thus an important role of TNFa treatment may be to 
induce restricted blood flow to tumours. 
The tumour necrosis factors activate phospholipases, particularly 
phospholipase A2 and proteases, which may directly cause cell damage 
or activate other enzymes (Suffys et a/. , 1988). In addition, breakdown of 
DNA occurs (apoptosis) in TNFa and L T susceptible cells, and this 
action is augmented by IFNy. Recent evidence suggests that signal 
transduction by TNFa occurs via the sphingomyelin pathway (Kolesnick 
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and Golde, 1994}. This pathway involves the conversion of plasma 
membrane sphingomyelin to ceramide, which acts as a second 
messenger, via mitogen activated protein kinase (MAP) and NF-K8 (a 
transcription factor). 
Tumour necrosis factor-a has undergone several clinical trials, but L T 
has not been investigated as a therapeutic agent. After i.v. bolus 
injection the half-life of TNFa was only 15-30min, and circulating levels 
.. 
were only seen with doses above 150Jlg/ml (Asher et al., 1987). 
Continuous infusion protocols produced very low but measurable 
Circulating levels of TNFa. Little clinical benefit was observed, possibly 
because low doses of cytokine were used to treat patients with advanced 
cancer, who had already undergone extensive chemotherapy. 
Administration of recombinant TNFa directly into the tumour was of 
greater clinical benefit. In one such trial, 10 of 22 treated patients 
developed partial responses (greater than 50%) reduction in tumour size) 
to therapy (Taguchi, 1987). This is in agreement with experiments in 
which TNFa was injected into mice bearing human tumour xenografts 
(8alkwill et a/., 1987). 
1.2.5.3 Interferons 
The term interferon was first used by Isaacs and Lindenmann in 1957 to 
describe certain proteins produced by vertebrate cells in response to 
viral infection, which were able to induce resistance in cells of the same 
species to a wide range of viruses. It was subsequently found that these 
molecules could inhibit the growth of experimental tumours, and purified 
extracts of cellular supernatants were injected into cancer patients, with 
some therapeutic success (Goldstein and Laszlo, 1986). 
The interferons are subdivided into 2 main groups; the type I interferons 
which include interferon-a (IFNa), interferon-p (IFNP), and type II 
interferons or Interferon-y (IFNy). Other Interferon subtypes have 
recently been reported (Li and Roberts, 1994; Charlier et a/., 1993). 
Interferon-a and -p are produced by leucocytes and fibroblasts 
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respectively in response to viral infections, whereas IFNy is produced by 
antigen- or mitogen-activated T -lymphocytes. The interferons exhibit a 
range of biological activities, some of which are listed in table 4. 
Interferon Type Biological Activity 
.. 
IFNa, IFNP, IFNi' Enhance NK cell activity 
IFNi' Induce or enhance MHC Class II expression 
IFNa, IFNP, IFN-y Induce or enhance MHC Class I expression 
IFNa, IFNP, IFN-y Protection of cells from viruses and parasites 
IFN-y Induction of cytokine secretion (IFNs, TNFs, IL-1, CSFs*) 
IFNi' (+IL-2) Enhance B-cell proliferation and IgG production 
IFNa, IFNP, IFN-y Inhibit normal and transformed cell growth 
IFNa,IFN-y Influence Cellular Differentiation 
. . TABLE 1.4. Biological Functions of the Interferons. *CSFs - Colony Stimulating 
Factors 
Reviewed by Balkwill, 1989 
The IFNa family consists of 23 genes coding for at least 15 proteins of 
molecular mass 18- to 20-kDa, which have a high degree (-90%) of 
sequence homology. It is not known why so many similar proteins are 
produced, all of which seem to exert a similar range of biological 
activities. There are 2 main classes of a-interferons. Class I IFNas are 
composed of 165-166 amino acid residues and are non-glycosylated, 
whereas class II IFNas have 172 amino acids and are glycosylated 
(Capon et aI., 1985). Interferon-a has been tested extensively in clinical 
trials, in which thousands of cancer patients have been treated (8alkwill 
and Smyth, 1987; Spiegel et aI., 1987), with encouraging results on 
some tumour types. Among those cancers which responded well to 
treatment were hairy cell leukaemia, chronic myelogenic leukaemia and 
low grade lymphomas, in which complete remissions were often 
observed (Goldstein and Lazlo, 1986; Talpaz et aI., 1987). In contrast, 
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melanoma, renal cell carcinoma and breast cancers responded poorly to 
IFNa. 
Interferon-~ is a glycoprotein of Mr 23-kDa which, like IFNa, is coded for 
on chromosome 9. Fewer clinical trials have been performed using this 
cytokine than with IFNa, but some remissions have been reported. In 
one study, 2 out of 18 patients with renal cell carcinoma underwent 
partial remissions (Rinehart et al., 1986). The best response rate to IFN~ 
" treatment was obtained in a study of 6 patients with adult T-cell 
leukaemia, in which 3 partial remissions were observed (Tamura et aI., 
1987). 
Interferon-y is a glycosylated protein of Mr 20-kDa which is coded for on 
chromosome 12. It has no sequence homology to the other IFNs. More 
than a thousand cancer patients have been treated with IFNy in phase I 
(Kurzrock et aI., 1986; Vadhan-Raj et aI., 1986) and phase II (Kurzrock et 
aI., 1987; Tamura et al., 1987) clinical trials. The results of these studies 
suggested that IFNy had some antitumour activity, but was not as 
effective as IFNa. As a therapeutic agent, IFNy showed a similar pattern 
of clinical responses IFNa (e.g., chronic myelogenic leukaemia, renal 
cell carcinoma). In contrast to IFNa and IFN~, IFNy induces upregulation 
of class 1/ MHC molecules on target cells, activate immune cells, and 
stimulate the release of other immunomodulatory and cytotoxic effector 
cytokines from macrophages, NK cells and T-Cells (Table 3). It has been 
proposed that IFNy functions mainly through its effect on immune cells, 
rather than by direct action on tumour cells (Aulitzky et a/. , 1987). 
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1.2.5.4 Interleukin-1 
There are currently two proteins in the interleukin-1 (IL-1) family, IL-1a 
and IL-1 p, which consist of 271 and 269 amino acid precursors and are 
processed into 159 and 153 amino acid proteins (17.5-kDa) respectively 
(March et a/., 1985). There is only 26% amino acid homology between 
these molecules, but Interleukin-1 p also has some sequence homology 
with both basic and acidic forms of fibroblast growth factor (Dinarello, 
~ 
1986). Many biological activities previously thought to be controlled by 
discrete factors are now attributed to IL-1. These include endogenous 
pyrogen, certain 8-cell and T -lymphocyte activating factors, catabolin 
(which catalyses the breakdown of collagen) and an osteoclast activating 
factor. Interleukin-1 has multiple biological activities, many of which 
overlap with those of TNFa and L T, even though the only similarity 
between these molecules is the lack of a hydrophobic signal peptide (the 
presence of which is common to many other secreted proteins). Almost 
every cell type in the body is capable of IL-1 synthesis, induced by 
antigen, toxins, injury, inflammatory reactions and other cytokines 
(mainly IFNs and TNFs). In turn, IL-1 can induce the production of other 
cytokines from cells (including IL-1 itself from particular cell types i.e. 
auto-stimulation), and this pattern of induction is the same as for TNF 
(i.e., IFNa, IFNP, IL-6 and the colony stimulating factors). Another 
similarity between IL-1 and TNF is the ability to be mitogenic for some 
cells (Lachman et a/., 1987), whilst being cytostatic or cytotoxic for 
others, although these cytokines do not necessarily have the same 
actions on a particular cell type. Several tumour cell lines have been 
reported to synthesise IL-1 in vitro (Griffin et aI., 1987), and it acts as an 
autocrine growth factor on some leukaemia cell lines (Sakai et aI., 1987). 
An inhibitor of IL-1, termed IL-1 receptor antagonist (IL-1 RA), has been 
cloned (Hannum et a/., 1990). It has an Mr of 18-kDa, and binds to the 
IL-1 receptor with a similar affinity to IL-1, but has no IL-1 activity. The 
inhibitor has a sequence homology of 19% and 26% for IL-1a and IL-1P 
respectively, and appears to be produced by the same cells which 
produce the active cytokines. 
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IL-1a and IL-1 f3 exert their biological effects by binding to two distinct IL-
1 receptors. Both receptors belong to the Ig superfamily of receptors. 
The type I receptor (IL-1 RI) is an 80-kDa protein, possessing three 
extracellular Ig-like domains, a short transmembrane and a relatively 
large (215 amino acids) cytoplasmic domain (Tate et aI., 1992). The 
second IL-1 binding protein, type II IL-1 receptor (IL-1 RII), is also a 
member of the Ig superfamily, and, like the type I receptor, possesses 
.. 
three extracellular Ig-like domains and a short transmembrane domain. 
Unlike the type I receptor, it has a short cytoplasmic domain of 29 amino 
acids (MacMahan et aI., 1991), and is unable to transduce signals. The 
two receptors bind to IL-1a, IL-1 f3 and IL-1 ra with different affinities. The 
extracellular domain of IL-1 RII is released in soluble form at sites of local 
inflammation and into the serum during systemic inflammation. This 
soluble form of IL-1 RII binds IL-1 f3 more strongly than to IL-1 a or IL-1 RA, 
and is possibly an endogenous inhibitor of IL-1 f3 at inflammatory sites. 
In animal models, IL-1 seems to be less active than the tumour necrosis 
factors. At high doses, it failed to cause haemorrhagic necrosis in the 
TNFa sensitive Meth A sarcoma. (Palladino et a/., 1987). However, when 
given intramuscularly every 3 days to mice bearing Meth A sarcoma, 
complete responses were observed in 86%) of cases, and this effect was 
further augmented by treatment with indomethacin (Nakata et aI., 1988). 
Indomethacin also augmented 816 melanoma cell, adenocarcinoma cell, 
and lung metastases of the Lewis lung tumour cell killing by IL-1a. No 
clinical trials using ether IL-1a or IL-1f3 have yet been undertaken. 
1.2.5.5 Interleukin-2 
Human IL-2 (previously known as T-cell growth factor, TCGF) is a 15-
kDa (133 amino acids) glycosylated protein which is structurally 
unrelated to the interferons, tumour necrosis factor or other interleukin 
families of cytokines. The IL-2 gene is on the short arm of chromosome 4 
and the protein is produced as a 153 amino acid precursor which is 
subsequently processed to the mature form containing 133 amino acids. 
There is a disulphide bond between amino acids 58 and 105, which is 
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required for the activity of the molecule. Although carbohydrate is 
present on the IL-2 molecule, it does not seem to be involved in its 
biological function (Robb, 1984). 
Interleukin-2 is only produced by activated T -cells and functions 
primarily in the generation of cell proliferation and induction of cytotoxic 
activity in activated T-cells (CD4+, CD8+ and y8T-ceII s), macrophages 
and NK cells. T-cells which have not been activated by antigen (or 
.. 
mitogenic signals such as IL-1, IL-6, phytohaemagglutinin (PHA), 
Concanavalin-A (Con-A), anti-CD3) and a co-stimulatory signal such as 
CD28 binding to it's ligand (b7) do not proliferate in response to IL-2, but 
cytotoxic activity can still be induced (LAK activity) in these cells. 
There are three proteins which serve as receptors for IL-2, the a-chain 
(p55, CD25; Smith, 1988), the J3-chain (p75; Nakarai et a/., 1994), and 
the y-chain (64kDa; Nakarai et al., 1994). These bind to IL-2 with 
relatively low affinity, but they can combine together to form high affinity 
IL-2 receptors (Robb et aI., 1987; Nakamura et aI., 1993). Intermediate 
affinity receptors are also formed by combination of the J3- and y-chains. 
High affinity IL-2 receptors are generally expressed by activated T-cells 
and 8-cells (IL-2 induces proliferation and antibody production by 
antigen stimulated B-cells), but low affinity receptors (either a- or J3-
chains) have been reported on NK cells (J3-chain only), oligodendrocytes 
(Saneto, 1986) and some tumour cell lines (Rimoldi et aI., 1993). 
Unstimulated blood monocytes express IL-2 receptors upon activation by 
IFNy. 
In experimental animal models, high dose IL-2 therapy has been 
reported to induce marked regression of pulmonary metastases and 
subcutaneously inoculated tumours (Rosenberg et aI., 1985): an effect 
that was thought to arise from the induction of LAK cell activity. Based on 
these encouraging results, clinical trials were undertaken using high 
dose IL-2 on patients with various advanced cancers. However, the 
toxicity of IL-2 in man was considerably greater than that observed in 
any of the animal models, and treatment with this cytokine was often 
performed in hospital intensive care units. The high toxicity of IL-2 often 
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required a reduction in dose, and hence efficacy of treatment, and 
patients had to be carefully selected for their tolerance to IL-2, which 
resulted in a decrease in the potential usefulness of IL-2 therapy as a 
general treatment for terminal cancers. There are many toxic side effects 
of IL-2 therapy, the most common of which are fevers, chills gastro-
intestinal problems, and reversible hepatic dysfunction characterised by 
hyperbilirubinaemia (Rosenberg et a/., 1987; Thompson et a/., 1987). In 
addition, there is an increase in vascular permeability and a decrease in 
systemic vascular resistance, resulting in hypotension that requires fluid 
replacement and vasopressor treatment. Associated with this , a 
common effect of IL-2 therapy is an increase in body weight of up to 10% 
during a single treatment course (Lotze et aI., 1986) 
Since the generation of LAK cells was the most probable mechanism by 
which IL-2 induced it's anti-tumour activity, new protocols were devised 
whereby leucocytes were removed from the patients, stimulated with 
very high doses of IL-2, and reinjected into the patients, together with 
much lower maintenance doses of IL-2 (Rosenberg et aI., 1987). The 
following section describes the clinical results obtained using IL-2/LAK 
cell therapy. 
1.2.6 Adoptive Immunotherapy (IL-21LAK Cell Therapy) 
In recent years several new approaches to the treatment of cancer have 
been proposed, and one of these, adoptive immunotherapy has been 
studied extensively in clinical trials over the past decade. Several types 
of malignancy responded to this treatment, including non-Hodgkin's 
lymphoma and colon cancer, but malignant melanoma and renal cell 
carcinoma were more responsive to IL-2/LAK cell therapy than other 
cancers. In some clinical trials approximately 25% of patients responded 
to treatment, with some partial, (reduction in tumour mass of >50%) but 
few complete remissions (Rosenberg et aI., 1989; Parkinson et aI., 
1991). Other trials however, reported lower response rates of between 0-
200/0 combined complete and partial responses for melanoma and renal 
cell carcinoma (Dutcher et aI., 1991; Abrams et aI., 1990). Adoptive 
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immunotherapy is still a treatment undergoing development and is only 
used on patients who are refractory to all conventional treatments, and in 
whom the prognosis is very poor. Recent research suggests that immune 
cell interaction with tumour cells is improved when the tumour load is 
small (Ingram et al., 1990). Immunotherapy may, therefore, be more 
beneficial to patients who have undergone surgery to reduce their 
tumour load, or in patients who have been recently diagnosed with early 
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tumours. In addition, the efficacy of adoptive immunotherapy has been 
reported to be enhanced by concomitant treatment with 
chemotherapeutic drugs such as cyclophosphamide (Mitchell, 1992). 
Adoptive immunotherapy initially involves the injection of moderate 
doses of IL-2 into cancer patients to boost leucocyte numbers. 
Mononuclear cells are then leucopheresed from the patient, stimulated in 
vitro with IL-2 for 2-7 days, and reinjected into the patient's circulation, 
where they must (1.) detect a tumour recognition signal, (2.) bind to and 
diapedese across the endothelium adjacent to the tumour, (3.) infiltrate 
the tumour and (4.) adhere to and kill its cells. These stages represent 
several distinct environments with which activated leucocytes must 
interact successfully in order to bring about tumour cell destruction. 
Following continuous i.v. infusion of IL-2 (prior to LAK cell therapy) into 
cancer patients, increased tumouricidal activity, in vitro, by peripheral 
blood leucocytes has been reported (Thompson et aI., 1987). In most of 
the early studies this increased cytotoxic activity was measured against 
an NK sensitive cell line (typically K562) , an NK resistant cell line 
(typically Daudi or Raji), and rarely against a cell line of the same type 
as that of the patient. Later trials included a wider variety of more 
relevant cell lines as target cells, sometimes including cells grown from 
the patients own tumour. Furthermore, high levels of cytotoxicity were 
still observed in vitro when LAK cells were reintroduced into the patients, 
together with low doses of IL-2. When treatment was discontinued, LAK 
cell activity (measured by killing of Daudi cells) decreased rapidly. 
Unfortunately, the increased killing observed in vitro was rarely 
associated with improved clinical benefit. 
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1.3.0 Haemostasis, Immunity and Cancer 
1.3.1 Background 
A relationship between cancer and abnormalities of the coagulation 
system has been recognised for over 100 years. In 1865, Armand 
Trousseau noticed that deep-vein thrombosis of the extremities often 
accompanied visceral cancer and concluded that {(spontaneous 
.. 
coagulation is common in cancerous patients because of a special crasis 
of the blood, which irrespective of inflammation, favours intra-venous 
coagulation" (Trousseau's sign). Another of his observations, later 
restated by Irving Wright in 1952, was that thromboembolic disease 
(usually of unknown aetiology) refractory to anti-coagulant therapy, was 
an early detectable sign of an underlying cancer, which could precede 
the onset of observable cancer by months or years (Wright, 1952). 
Whether patients presenting with idiopathic venous thrombosis should 
be rigorously tested for the presence of cancer is still a subject of debate 
(Luzatto and Schafer, 1990; Levine and Hirsh, 1990). However, there is 
growing evidence to support Wright's observations. In a recent study 
250 patients with no known cancer, who presented with a first episode of 
deep-vein thrombosis of the lower extremity, were followed up for 2 
years to determine if any cancer was evident. There was a statistically 
significant association between idiopathic venous thrombosis and the 
subsequent development of clinically overt cancer, especially in patients 
with recurrent thromboembolism (Prandoni et aI., 1992). Other studies 
have also shown similar results with up to 23% incidence of cancer 
during 2 year follow-up periods following idiopathic deep-vein thrombosis 
(Monreal et aI., 1991; Aderka et aI., 1986). 
Although idiopathic venous thrombosis may be an early diagnostic sign 
for the presence of undetectable cancer, patients with established 
cancer may suffer from a wide variety of haemostatic disorders, ranging 
from thromboembolic episodes to haemorrhagic disease. Haemostatic 
abnormalities in cancer include thromboembolic disease, abnormal 
coagulation, overcompensated intravascular coagulation with fibrinolysis 
34 
(ICF), disseminated intravascular coagulation (OIC), qualitative and/or 
quantitative platelet defects, and interference of malignant paraproteins 
with coagulation factors. Generalised bleeding, although less common 
than thrombosis, may also occur in cancer. This usually happens in the 
later stages of cancer when tumour cells have extensively invaded 
tissues which are responsible for the production of elements of the 
haemostatic system. These include tumour invasion of the bone marrow, 
resulting in reduced platelet numbers; and cancer (or cancer therapy) 
induced liver damage, causing decreased levels of circulating 
coagulation factors. These problems are also common side effects of 
radiation treatment and chemotherapy. Haemostatic abnormalities 
account for the second highest death rate among cancer patients 
(Ambrus et al., 1975, Levine and Hirsh, 1990). 
1.3.2 Laboratory Investigation of Coagulation Abnormalities in 
Cancer 
Although many cancer patients exhibit clinically significant haemostatic 
abnormalities, about 50% of all patients (>90% with metastases) have 
abnormal laboratory coagulation parameters (Luzzatto and Schafer, 
1990). The most commonly reported abnormalities are elevated 
fibrinogen and fibrinopeptide A (FPA) levels, raised platelet count and 
prolonged prothrombin time. One study reported up to 27% of patients 
with cancer were thrombocytopaenic (Kies et aI., 1980), whereas others 
have reported thrombocytosis in as many as 60% of cancer patients 
studied (Davis et al. 1969; Hagedorn et aI., 1974). A more recent study 
of 431 cancer patients, prior to their entry into an anticoagulant trial, 
again demonstrated increased levels of plasma FPA, fibrinogen and 
platelets, together with a steady increase in fibrinogen and platelet count 
prior to death (Edwards et aI., 1987). Levels of FPA also correlated with 
the progression of disease, but other coagulation parameters such as 
PT APTT FOPs or EL T showed no consistent abnormalities during this , , 
study. In addition, these workers previously demonstrated that certain 
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forms of chemotherapy and radiotherapy also caused increased levels of 
FPA. 
Disseminated intravascular coagulation may be subdivided into three 
main categories (Owen and Bowie, 1974). If the coagulation system is 
significantly activated, coagulation factors and platelets will be depleted, 
with a resultant increase in fibrinolysis, this is termed uncompensated 
DIC. When activation of coagulation is less overt, clotting factors and 
platelets are replaced at the same rate as their consumption, resulting in 
compensated DIC. However, these elements may be replaced at a faster 
rate than their consumption, and elevated levels of fibrinogen, other 
clotting factors and platelets are seen. Fibrinopeptide-A levels are also 
be increased, indicating that the presence of an underlying 
coagulopathy. This form of overcompensated DIG is, thus, a possible 
explanation of the results obtained in the studies mentioned above. 
1.3.3 Extravascular Coagulation and Cancer 
Although the subject of controversy for many years, it is currently 
accepted that fibrin is present in the majority of solid tumours (Dvorak et 
aI, 1984; Brown et aI., 1988a). The relative distribution and amount of 
fibrin varies both between tumour types and between similar tumours in 
different patients, but is characteristic for individual human tumours and 
their metastases, as well as murine tumours transplanted several times 
(Brown et aI., 1988b). However, the distribution of fibrin within tumours 
does not correlate with tumour progression (Harris et aI., 1982). For 
example, in carcinomas, fibrin is generally present on the periphery of 
the tumour and surrounding tumour cell clusters but not in older areas of 
tumour where collagenous connective tissue has been laid down 
(Dvorak et aI., 1981). In contrast, fibrin deposition within lymphomas is 
generally around individual tumour cells as well as in areas of tumour 
sclerosis (Harris et aI., 1982). 
Most tumours (with the exception of hepatomas) do not synthesise 
fibrinogen, so tumour fibrin must therefore be derived from plasma 
fibrinogen. Extravasation of fibrinogen (and other plasma proteins) is 
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very slow into normal tissues (in the absence of inflammation or delayed 
(type IV) hypersensitivity reactions, in which leucocyte mediated fibrin 
deposition is a normal process of wound healing), but is considerably 
greater in tumours implying that the tumour capillary endothelium is more 
permeable to plasma proteins than normal endothelium. Tumour cells 
are able to increase vascular permeability in several ways (e.g., 
stimulation of mast cells adjacent to the tumour to produce histamine 
(Tanooka et aI., 1982), induction of a cellular immune response (Dvorak 
et aI., 1980) kinin generation (Matsumura et aI., 1988) and the 
production of vascular permeability factor(s)). The most potent of these 
is vascular permeability factor (VPF, Dvorak et aI., 1992), which is a 
polypeptide (Mr 34- to 43-kDa), and increases vascular permeability in 
skin at concentrations of as low as 1 x 10-13 M (50,000 times more active 
than histamine). Vascular permeability factor is produced by many 
tumour cell types. It's mechanism of action is not known, but it increases 
intracellular calcium levels (an indication of cellular activation) in human 
endothelial cells (Ferrara et aI., 1992). 
1.3.4 Procoagulant Activities of Tumour Cells 
Tumour cells have been reported to express a number of procoagulant 
activities. O'Meara in 1958 observed that malignant tissue was able to 
shorten the clotting time of recalcified plasma more than most normal 
tissues. Tissue factor (TF, tissue thromboplastin), is a non-protease 
membrane protein which enhances the ability of factor VII to activate 
factor X. It is present in most normal tissues, and was initially shown to 
be expressed by leukaemic cells (Gralnick and Tan, 1974), gastric 
carcinomas (Sakuragawa et aI., 1977) and adenocarcinomas (Dvorak et 
aI., 1983). A wide range of tumour cells are now known to express tissue 
factor 
Another procoagulant factor produced by tumour cells was first detected 
by Gordon et aI, 1975, termed cancer procoagulant (CP). Unlike TF, CP 
did not require the presence of factor VII for its activity, but activated 
factor X directly. Cancer procoagulant was characterised in 1985 as a 
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68-kDa protein with cysteine protease activity (Falanga and Gordon, 
1985), and has since been found in a variety of human and animal 
tumours. It has an amino acid structure different from that of other 
cysteine proteases such as cathepsin B, and may be a useful marker in 
the detection of human malignancy. Although CP induces fibrin formation 
in solid tumours, other evidence suggests that the majority of cancer 
procoagulant activity generated by tumour cells in vitro, is attributable to 
TF activity (Edwards et al., 1981). 
Prothrombin conversion to thrombin is mediated by the association of 
prothrombin, FVa and FXa (in the presence of calcium ions) on a 
suitable phospholipid surface (the prothrombinase complex). In normal 
blood coagulation, platelet membranes generally provide the 
phospholipid component of the prothrombinase complex, but this activity 
has also been reported for other normal cells such as leucocytes and 
endothelial cells. Assembly of the prothrombinase complex on tumour 
cells was first described on a guinea-pig hepatocarcinoma cell line (Van 
deWater et aI., 1985) and later on human tumour cells. Clot formation 
induced by the release of thrombin-like enzymes has been reported in 
patients with pancreatic cancer, but this was attributed to the release of 
trypsin into the blood stream by the pancreas (Semerano and Donati, 
1981 ). 
The procoagulant activities of tumour cells are predominantly exhibited 
via the extrinsic or the common pathway of coagulation. However, direct 
activation of factors XII and XI (the intrinsic pathway) by the abnormal 
vasculature of some tumours has been reported (Semerano and Donati, 
1981). In this case activation of factor X is initiated by factor Villa and 
requires the presence of calcium ions and platelet phospholipid. 
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1.3.5 Procoagulant Activities (PCA) of Leucocytes in Cancer 
Monocytes and to some extent lymphocytes and endothelial cells are 
responsible for extravascular coagulation in a wide range of 
inflammatory conditions. These reactions may be specific, as in delayed-
type-hypersensitivity where activated T -cells induce monocyte 
procoagulant activity, mostly via TF expression, (Edwards and Rickles, 
1980), or non-specific, as in activation of monocytes by LPS. In cancer, 
tumour infiltrating leucocytes contribute procoagulant activity in addition 
to that produced by tumour cells and their endothelium. Monocytes also 
synthesise several molecules with direct procoagulant activity, such as 
TF, Factor V, Factor VII, Factor XIII (McGee et aI., 1990; Rothberger et 
aI., 1984; Weisberg et aI., 1987), and high affinity receptors for Factor X 
/Xa and fibrinogen via Mac1 (CD11 b/18; Sherman and Lee, 1977). In 
addition, monocytes secrete cytokines, such as IL-1, TNFa and IFNy, 
which upregulate the procoagulant activities of monocytes, tumour cells 
and endothelial cells (Moon and Geczy, 1988; Carlsen et aI., 1988; 
Nawroth and Stern, 1986). Monocyte procoagulant-inducing factor 
(MPIF) is another cytokine that is chemotactic for monocytes (Gregory et 
aI., 1986). Activated T -cells could induce monocyte procoagulant activity 
in the tumour either by releasing cytokines (e.g., IFNy and TNFa ) which 
activate monocytes, or via antigen presentation. 
Monocytes and NK cells are also been implicated in the generation of 
blood clotting abnormalities in cancer patients. Mononuclear cells 
isolated from cancer patients exhibited greater procoagulant activity than 
mononuclear cells from normal donors (Edwards and Rickles. 1980). In a 
murine tumour model macrophages derived from tumours which were 
poorly immunogenic or metastatic, exhibited relatively low PCA, 
comparable to the levels found in peritoneal exudate macrophages from 
normal mice. Macrophages derived from the MSV sarcoma (which is a 
highly immunogenic tumour), however, were strongly procoagulant (and 
tumouricidal) (Guarini et aI., 1984). 
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1.3.6 Interactions of Tumour Cells with Platelets 
Platelets are rarely present within the stroma of solid tumours. The main 
platelet-tumour cell interactions are believed to occur within the 
vasculature during the process of tumour metastasis. Some tumour cells 
and membrane bound vesicles shed from them activate and aggregate 
platelets directly, whereas others neoplastic cells only cause 
aggregation and secretion by platelets previously activated with ADP or 
serotonin (Paschen et a/. , 1979). It is not clear how tumour cells activate 
platelets, but it has been reported that close cell-cell contact is required 
together with the release of tumour products such as ADP (Gasic et aI, 
1980), or cathepsin B (Sloane, 1981 ). In addition, release of 
procoagulants such as TF from circulating tumour cells may cause 
thrombin generation, and hence platelet activation. 
On entering the circulation, tumour cells adhere to platelets by 
mechanisms which are thought to involve the tumour cell cytoskeleton, 
integrin binding, large molecular weight glycoproteins and products of 
the lipoxygenase system (Chopra et a/. , 1988). Several platelets are 
often able to bind to one tumour cell forming clusters which travel 
through the blood until the platelets adhere to damaged endothelium. 
PlateleUtumour cell clusters adhere weakly to intact endothelium but 
very strongly to damaged endothelium, (Mehta, 1984). After adherence 
to damaged endothelium, the clusters interact with the subendothelial 
layers and fibrin deposition is stimulated. The tumour cells are then able 
to migrate into the distant tissue and form secondary tumours. In the 
absence of disrupted endothelium the cell aggregates continue moving 
in the circulation until they block a small capillary in a distant organ, 
resulting in plateleUtumour cell induced endothelial damage, and 
subsequent tumour cell extravasation (Warren, 1981). In either case it 
would appear that the adherence of platelets to tumour cells promotes 
metastasis (Mehta, 1984; see section on coagulation therapy of cancer). 
In addition, the attachment of platelets to tumour cells may physically 
inhibit immune cytotoxicity in the circulation, again increasing the 
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likelihood of successful metastatic spread. A number of platelet products 
have been implicated in metastatic spread, such as serotonin (increases 
vascular permeability), the a-granule adhesive proteins fibronectin, 
thrombospondin, von Willebrand factor and endoglucosidases which 
degrade heparan sulphate. Similar molecules are produced by some 
tumours and break down the subendothelial matrix glycosaminoglycans 
(Wasteson et aI., 1977). 
Platelets have been reported to be directly cytotoxic for tumour cells 
after 18h in culture (Ibele et al., 1985, Sagawa. et aI., 1990). In vivo, 
however, it is likely that tumour cell extravasation predominates over the 
slower process of platelet cytotoxicity (Crissman et aI., 1988). 
Tumour metastasis is inhibited by treatment of tumour bearing animals 
with drugs which reduce platelet aggregation or activation, such as 
aspirin (Gatspar, 1970), dipyridamole (a platelet aggregation inhibitor; 
Gatspar et aI., 1984), and prostacyclin (PGI2; Honn et al., 1981). The 
calcium channel blockers nimodipine and nifedipine reduce pulmonary 
metastasis in experimental animals, possibly by inhibition of tumour-
platelet-endothelial cell interactions (Onoda et aI., 1984). 
Thrombocytopaenia induced by neuraminidase (which removes 
negatively charged sialic acid residues from cell surface carbohydrates), 
or anti-platelet antibodies, also results in a marked reduction in 
secondary tumour production in animal models (Gasic et al., 1984). 
1.3.7 Anticoagulation Therapy of Cancer 
The function of fibrin in the tumour is unclear, but some reports suggest 
that fibrin deposits can promote tumour growth and neovascularisation of 
growing tumours, protect tumours from immune or chemotherapeutic 
attack and aid tumour cell adhesion to endothelial cells during , 
metastasis (Donati and Poggi, 1980; Dvorak et aI., 1981; Gralnick and 
Tan, 1981; Gorelick et al., 1984). Alternatively, fibrin deposition around 
solid tumours may protect the host from tumour cell invasion by blocking 
their entrance into the circulation (Colucci et aI., 1981). 
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Few clinical trials of anti-coagulation therapy of cancer have been 
undertaken. Most experiments were performed in animal models to 
determine the effects of anticoagulants on metastatic tumour 
progression. Early studies using isotope labelled tumour cells showed 
that tumour cell deposition occurred irrespective of whether the animals 
were anticoagulated, but that subsequent metastatic growth was 
decreased by anticoagulant therapy, implying a role for fibrin in 
metastatic tumour growth (Fisher and Fisher, 1967). 
Warfarin reduces metastasis in animals (McCulloch and George, 1987), 
and Zacharski and co-workers (1984) have undertaken clinical trials 
using warfarin treatment of patients with head and neck, lung, colon and 
prostate cancer. A significant survival advantage was seen only with 
small cell carcinoma of the lung (SCCL), and this finding was later 
confirmed by others (Chahinian et a/., 1989). The mechanism of warfarin 
action in SCCL may not be entirely due to it's anticoagulant activity. 
Warfarin also affects fibrinolysis by interfering with vitamin K-dependent 
post-translational carboxylation of glutamic acid residues on Protein C 
(activated protein C neutralises factor V and factor VIII, thereby inducing 
fibrinolysis) and other biologically active proteins. Warfarins have also 
been reported to cause a decrease in tumour cell adherence to 
endothelial cells (Orme and Ketchum, 1967), and to inhibit primary 
experimental tumour growth and metastasis (Hilgard et a/., 1977), and 
other biological activities, any of which could also be involved in the 
reduction of metastatic tumour spread (Zacharski et a/1984). 
The efficacy of heparin treatment in metastatic inhibition in animal 
models was variable, but was consistently less effective than warfarin. In 
some cases an increase in tumour growth was observed (Chan and 
Pollard, 1980). The heparins comprise a large range of negatively 
charged glycosaminoglycans which have many other biological activities 
in addition to their anticoagulant properties, such as interference with 
lymphocyte recirculation and regulation of smooth muscle growth. 
Significant reduction of metastatic tumour growth has also been 
observed using a number of other anticoagulants such as salivary gland 
extracts from Haementeria leeches, and coumarin derivatives (Gasic et 
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al., 1983). Desulphatohirudin, a low molecular weight protease 
(thrombin) inhibitor, normally present in the peripharangeal glands of 
medicinal leeches inhibits the production of lung metastases of 816 
murine melanoma (Esumi et aI., 1991). 
Anticoagulant therapy has been combined with chemotherapy with some 
success. Significant reduction in metastasis was observed using 
combinations of warfarin and adriamycin or warfarin and 5-fluorouracil 
(5FU) or cyclophosphamide in the presence of bleomycin (Hilgard et aI, 
1977), compared to each treatment alone Warfarin may interfere with 
5FU degradation, thus enhancing the antitumour activity of the drug 
(Kirsch et aI., 1969). 
1.3.8 Fibrinolytic Activities of Tumour Cells and Leukocytes 
Tumour cells produce a number of proteolytic enzymes which degrade 
various components of their stroma, including collagen (type I in the 
extracellular matrix and type IV in the basement membrane), laminin, 
elastin, and fibrin. Some enzymes (collagenases, cathepsins and 
elastase) have a direct activity on tumour associated fibrin, but in the 
majority of cancers, tumour cells produce plasminogen activators (PA). 
These activate plasminogen (extravasated together with fibrinogen from 
the plasma) to plasmin which in turn degrades fibrin, thus allowing 
tumour cell motility though the extracellular matrix. There are three main 
PA produced by tumour cells, but the urokinase type plasminogen 
activator (uPA) which has several forms of 33, 55 and 100-kOa MW 
(Evers, 1982) is the most commonly expressed form. The tissue type 
plasminogen activators (tPA, 70 and 100-kOa, Rijken and Collen, 1981) 
and another high molecular weight PA are also produced by some 
tumours (Vetterlein et a/. , 1979). The plasminogen activators may also 
promote tumour growth and metastasis, by the induction of 
morphological changes associated with tumour promoter action in virally 
transformed chicken fibroblasts (O'Oonnelli-Tormey and Quigley, 1981). 
The production of PA by tumour cells does not seem to correlate with 
metastatic potential. A possible explanation for this is that fibrinolysis 
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enhances tumour cell release into the vasculature from established 
tumours, but also inhibits their adhesion (via platelets and fibrin 
deposition) to endothelial cells, thus preventing tumour cells from leaving 
the blood stream (Donati et a/., 1981). This hypothesis is supported by 
data from experimental animal models. Treatment of animals with anti-
fibrinolytic agents such as epsilon amino caproic acid (eACA) or 
tranexamic acid increased the number of metastases when tumour cells 
were injected intravenously suggesting that fibrin was important in 
tumour cell extravasation. In contrast, a decrease in metastasis was 
seen when the same drugs were given to animals with transplanted 
primary tumours (i.e., the presence of extravascular fibrin prevented 
tumour cell migration into the circulation). In one clinical study, a 
combination of tranexamic acid with cytostatic treatment and radiation 
was claimed to be beneficial (Astedt et a/., 1977). 
Unlike tPA, uPA is not dependent on the presence of fibrin for its ability 
to activate plasminogen, thus providing the tumour cells with the ability 
to generate plasmin whether in the presence or absence of fibrin. This is 
important since plasmin activates procollagenases (Paranjpe et a/., 
1980) such as type IV procollagenase which breaks down Type IV 
collagen in the basement membrane, and also laminin, another 
extracellular matrix component (Liotta et a/., 1981). Plasminogen 
activator activity has also been implicated in several other normal 
physiological processes such as ovulation and spermatogenesis, 
embryonic development, prohormone processing and keratinocyte 
differentiation (Saksela, 1987). 
Macrophages, B-cells, thymocytes and large granular lymphocytes (NK 
cells) also synthesise PA (Chapman et a/., 1979, Goldfarb et a/., 1984). 
T -cells are not thought to produce plasminogen activator activity 
(Maillard and Favreau, 1981). Tumour infiltrating macrophages are 
therefore able to contribute to fibrin degradation in the tumour matrix. 
This may allow cytotoxicity of neoplastic cells by macrophages and T-
cells and act as a host protection mechanism. 
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1.4 Aims of the Project 
Non-specific immunotherapy of cancer may be subdivided into several 
treatment regimes. These are: (1.) infusion of a single cytokine; (2.) 
infusion of a combination of two or more cytokines; (3.) combination 
cytokine therapy and chemotherapy and; (4.) adoptive immunotherapy 
with LAK cells alone or combined with maintenance doses of cytokine 
(usually IL-2). The reaction of the host immune cells, cytokine network, 
vascular system, tumour cells and tumour stroma to these therapies is 
highly complex. The main aim of this project, therefore, was to isolate in 
vitro the interactions between these forms of treatment, and 
representative cellular or stromal components present within the cancer 
patient, in order to identify possible synergistic interactions or inhibitory 
factors involved in the process of tumour cell destruction. To this end, 
the project was subdivided into several major objectives. These were:-
1. To investigate the interactions of several of the major cytokines 
(TNFa, L T, IFNy IL-1 ~ and IL-2) used in cancer therapy with a range of 
tumour cell lines in vitro, in order to assess their direct cytotoxic or 
growth promoting activities. 
2. To study the effect of combinations of cytokines and cytotoxic drugs 
(Act-D and cycloheximide) on their ability to kill tumour cells, and to 
identify any synergistic or inhibitory interactions which may arise. 
3. To examine the cytotoxic activities of unstimulated and cytokine 
activated peripheral blood leucocytes (lymphocytes and monocytes) for 
untreated or cytokine and! or cytotoxic drug pre-treated tumour cells, and 
to investigate the mechanism of these interactions. 
4. To determine the cytotoxicity of IL-2 activated leucocytes (LAK cells) 
against autologous lymphocytes and monocytes, and against human 
umbilical vein endothelial cells or fibroblasts. 
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5. To investigate the effect of components of the coagulation system on 
LAK cell cytotoxicity for tumour cells, and to identify any factors which 
may augment or inhibit cytotoxicity. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Preparation and Culture of Tumour and Normal Cells 
2.1.1 Adherent Tumour Cell Lines 
Four human melanoma cell lines (A375, DX3, SK23 and L T5.1) were 
provided by Dr Ian Hart (ICRF, Lincoln's Inn Fields, London). The 
promonocyte cell line U937 was supplied by Dr N. Hogg (ICRF, Lincoln's 
Inn Fields, London) and the K562 (Erythroblastoma) and Daudi (EBV 
transformed B cells) cell lines were already established in the 
Immunology Department at St Thomas' Hospital. 
2.1.2 Tissue Culture of Adherent Tumour Cell Lines 
The four adherent melanoma cell lines were kept in continuous cell 
culture in 75cm2 tissue culture flasks (Costar Ltd., Berks., U.K.). On 
reaching confluence, cells were detached from plastic by incubation for 
2-3 min with 3ml trypsin (0.5g/l) and EDTA (0.2g/l) in Ca2+, Mg2+ free 
HBSS (Life Technologies, Renfrewshire, Scotland). After centrifugation 
at 200g for 10min the supernatant was removed and 5ml RPMIIFCS 
(appendix III) was added to the cells. A 1 ml aliquot of cells was added to 
each of five 75cm2 tissue culture flasks and the total volume in each 
flask adjusted to 35ml with RPMI/FCS. The flasks were then returned to 
the incubator until required for experiment or until they reached 
confluence. 
In some experiments, A375 cells were required to be grown to 
confluence in the wells of 96 well microtitre plates. They were detached 
from culture flasks and washed, as described above. The final cell pellet 
was reconstituted to 20ml with RPMIIFCS and 100j.l1 added to all wells of 
one or two 96 well microtitre plates and incubated at 37°C for 24-48h, 
until the cells had reached confluence. 
47 
2.1.3 Tissue Culture of Non-Adherent Tumour Cell Lines 
The non-adherent cell lines (K562, Daudi and U937) were maintained in 
continuous cell culture as 20ml volumes in upright 25cm2 tissue culture 
flasks. Cells were passaged every 2-3 days by resuspension with gentle 
agitation and diluting 1: 1 with fresh RPMIIFCS. The cells were returned 
to the incubator until required for experiments or until further subdivision 
was necessary. 
2.1.4 Cytokine Pre-treatment of A375 Cells 
In some experiments, A375 cells were pre-incubated with cytokines prior to 
their inclusion in the cytotoxicity assay. The supernatant was decanted from 
the cells and the flasks were rinsed twice with warm (37°C) RPM!. Dilutions of 
recombinant IL-2 (500-2000U/ml), TNFa (100-500U/ml) IFNy (100-1 OOOU/ml) 
or a combination of two of these cytokines were prepared in 10ml of 
RPMIIFCS, and added to the flasks for 3-72h. In all experiments, control A375 
cells were incubated in 10ml of RPMIIFCS alone for an equivalent time to 
those flasks containing cytokine dilutions. 
2.1.5 Pre-treatment of Tumour Cells with Protein Synthesis 
Inhibitors 
Culture flasks containing fresh or cytokine pre-treated adherent tumour 
cells were rinsed twice with RPMI, and 10ml of RPMIIFCS alone or 
containing either actinomycin-D (0.0001-1Ilg/ml; Sigma, Dorset, U.K.) or 
cycloheximide (0.01-1 Ollg/ml; Sigma, Dorset, U.K.) added to appropriate 
flasks for 3h. The cells were then detached from the flasks using 
Trypsin/EDTA (section 2.1.2), and a cell count and viability performed 
(section 2.1.15), prior to their use in cytotoxicity experiments. 
Flasks containing K562 cells (non-adherent) were decanted into 30ml 
universal containers and centrifuged at 200g for 10min. The supernatant 
was discarded and the cells resuspended in 1-2ml of RPMIIFCS. A cell 
count and viability was performed, and aliquots containing 1 x1 07 cells 
were again centrifuged and the pellets resuspended in 10ml RPMIIFCS 
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alone or RPMIIFCS containing actinomycin-D (0.1Ilg/ml ), and incubated 
for 3h at 37°C. The cells were washed twice in RPMIIFCS prior to their 
inclusion in cytotoxicity experiments. 
2.1.6 Peripheral Blood Collection 
Peripheral venous blood (50-100ml) was withdrawn from normal healthy 
donors into 60ml syringes containing 10U/ml preservative free heparin 
(Leo Laboratories, Princes Risborough). The syringe was inverted 
several times to mix the blood and anticoagulant, and decanted into a 
100ml glass bottle under sterile conditions. 
2.1.7 Preparation of Mononuclear Cells by Lymphoprep Density 
Gradient 
Heparinised blood was diluted 1:1 with warm (room temperature) RPMI, 
and 15ml layered over 8ml Lymphoprep (Nycomed (U.K.), Sheldon, 
Birmingham) in plastic universal containers. These discontinuous density 
gradients were centrifuged for 25min at 450g and the mononuclear cell 
interface removed using a sterile plastic pasteur pipette. The cells were 
washed three times by resuspension and recentrifugation at 200g for 
10min in RPMIIFCS so as to remove platelets. The final cell pellet was 
resuspended in 2-5ml RPMI/FCS (or 2-5ml RPMI for coagulation 
experiments; section 2.2.6) and a cell count and viability performed as 
described in sections 2.1.15. 
2.1.8 Monocyte Purification by Nycodenz Monocytes Density 
Gradient 
For this procedure human peripheral blood (9 parts) was collected into 
glass tubes containing 1 part 2.7%> (w/v) EDTA (pH 7.4). Blood (3ml) was 
then layered onto 3ml Nycodenz Monocytes in a 12ml tube and 
centrifuged at 600g for 15min. After centrifugation the clear plasma was 
removed until 3-4mm remained above the interface. The remaining 
plasma together with approximately half of the separation medium was 
collected and washed three times in calcium- and magnesium-free buffer 
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containing RPMIIAB (appendix III) serum. The purified monocytes were 
resuspended in RPMIIAB and a count and viability performed prior to 
assay. 
2.1.9 Lymphocyte and Monocyte Purification Using Discontinuous 
Percoll Density Gradients 
Percoll (polyvinylpyrollidone coated silica beads (Pharmacia Biosystems Ltd, 
Milton Keynes) was diluted 9 parts to one part medium 199 (Life Technologies, 
Renfrewshire, Scotland) containing phenol red to obtain an isotonic solution 
with a denSity of 1.1294, which will be referred to as 100% percoll. 
Subsequently, 100% percoll was further diluted with RPMI (1x) to 70% (density 
1.09), 60% (density 1.077), 50% (density 1.067), 40% (density 1.056) and 30% 
(density 1.043), in aliquots of 2mllgradient. The 70%, 50% and 30% aliquots 
were slightly acidified by the addition of a drop of 0.1 molll HCI to help in the 
identification of the interfaces between the percoll fractions. Two millilitres of 
100% percoll were placed into a 15ml round bottomed Falcon tube (these 
tubes provided a smooth flow of percoll, resulting in cleaner interfaces 
between percoll fractions), and 2ml aliquots of 70%, 60%, 50% and 40% 
percoll were sequentially layered on top using a glass pasteur pipette. 
Mononuclear cells obtained from lymphoprep density gradients (section 2.1.7; 
not more than 5 x 107 cells/gradient) were pelleted by centrifugation and 
resuspended in 2ml of 30% percoll. The cell suspension was layered onto the 
top of the percoll gradient and the tube centrifuged at 450g for 25min. Cells 
were removed from the gradient interfaces using a pasteur pipette, and 
washed twice in RPMI to remove any remaining percoll. 
2.1.10 Lymphocyte and Monocyte Purification by Plastic Adherence 
Mononuclear cells obtained from the lymphoprep density gradient 
(section 2.1.7) were adjusted to 2 x 106 cells/ml, and aliquots of 5 x 107 
cells added to 75cm2 tissue culture flasks. The flasks were incubated at 
37°C, in 5% CO2, for 1 h in order to allow monocyte adherence to the 
plastic. The non-adherent cells (lymphocytes) were decanted into 
universal containers and washed twice with RPMI. A cell count (section 
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2.1.15) was performed on the final cell suspension and cytocentrifuge 
preparations were made for analysis of cell purity. Cell purity was 
determined by differential counting of lymphocytes and monocytes using 
May-Grunwald/Giemsa stain. The flasks containing the remaining 
adherent cells (monocytes) were rinsed twice with RPMI and 10ml of 
3mmollL EDTA in RPMIIFCS was added. The flasks were incubated at 
37°C for 12min, or until the cells had detached from the plastic 
(determined by observation under an inverted microscope). The cells 
were removed from the flasks using a 5ml pipette, transferred into 
universal containers, and washed three times in RPMIIFCS to remove 
any residual EDTA. A cell count (section 2.1.15) was performed on the 
final cell suspension and cytocentrifuge preparations were made for 
determination of cell purity. It was important that the monocytes were 
used in experiments immediately to avoid re-adherence to the plastic, 
which would result in a decreased cell yield. 
2.1.11 Choice of Purification Technique for Monocytes and Lymphocytes 
In order to obtain highly purified preparations of lymphocytes and 
monocytes from peripheral blood, several separation techniques were 
tested for their yield and purity of these cells. Two established methods 
were used to separate lymphocytes and monocytes from a mononuclear 
cell population obtained from Iymphoprep density gradients (section 
2.1.7): discontinuous density gradient separation using percoll (section 
2.1.9; Brandslund et a/., 1982), and adherence of monocytes to serum 
coated plastic, and subsequent elution using EDTA (section 2.1.10). In 
addition, monocytes alone were purified from whole blood using a 
Nycodenz density gradient (section 2.1.8.; Boyum, 1983). Cell purities 
were measured on cytocentrifuge preparations stained for either non-
specific esterase (monocytes positive; Tucker et al., 1977) or May-
Grunwald Giemsa stain (morphological identification of lymphocytes and 
monocytes) The cell yield was represented as the number of cells (X106) 
derived from 5Cml of whole blood. 
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FIGURE 2.1. Isolation of monocytes by three techniques. Means and SEMs from 
5 (Nycodenz), 6 (Percoll) or 8 (Adherence/EDTA) experiments, showing the purity 
(figure 2.1a) and yield of monocytes from 60ml peripheral blood. Monocyte purity 
by adherence was significantly greater (p<O.05) than either of the other 
separation methods, by MWU. The monocyte yield from plastic adherence was 
significantly greater (p<O.05) than that from Nycodenz, but not from Percoll 
(p>O.05). 
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Figures 2.1 a and 2.1 b show the purity and yield respectively of 
monocytes using Nycodenz Monocytes, Percoll or adherence/EDT A. The 
purity of monocytes obtained from Nycodenz gradients was highly 
variable (72 +/- 7%, n=5), and the final yield of monocytes was very low 
(1 +/- 0.4 x106 cells, n=5). For these reasons Nycodenz was not used in 
further experiments. 
Monocyte separation using Percoll resulted an equivalent purity (71 +/-
50/0, n=5; p>0.05), but a significantly greater yield (7 +/- 3%, n=5; 
p<0.05), than Nycodenz (13 +/- 8 x106 cells, n=5). Highly purified 
lymphocytes were present at both the 50-60% (96 +/- 3%, n=5) and 60-
70% (94 +/- 2%, n=5) percoll interfaces, although the majority of cells 
were found at the 50-60% interface (27 +/- 7 x106 cells, n=5). Two 
problems were found using percoll as a separation medium. Firstly, 
contamination of the final monocyte population with approximately 30% 
lymphocytes made it impossible to determine the contribution of 
monocytes to tumour cell cytotoxicity. Secondly, the lymphocyte 
population was split into three strata (the monocyte layer (40-50%), and 
two lymphocyte layers (50-60% and 60-70%), each of which was 
unrepresentative of the donor whole blood lymphocyte population. Since 
these could not be completely reconstituted due to the presence of 
monocytes in the 40-50% layer, percoll was rejected as a separation 
technique in this study. 
Adherence/EDT A treatment produced a very high purity of monocytes 
(92 +/- 5%, n=8) which was significantly greater (p<0.05) than that 
obtained using either Nycodenz or Percoll separation. Monocyte yield (9 
+/- 2 x106 cells). from adherence/EDTA was similar (p>0.05) to that of 
Percoll, but significantly greater (p<0.05) than Nycodenz. The non-
adherent fraction contained 92 +/- 1 % (n=8) lymphocytes with a mean 
yield of 38 +/- 6 x1 06 cells (n=8; Figures 2.2a and 2.2b), and purity of 92 
+/- 1 % (n=8), which were not significantly different (p>0.05) from the 
values seen for Percoll. Adherence/EDTA was, therefore, chosen as the 
method for lymphocyte and monocyte purification in this study. 
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FIGURE 2.2. Isolation of lymphocytes by two techniques. Means and SEMs from 
6 (Percoll 50-60% interface) or 8 (Adherence/EDTA) experiments. Mononuclear 
cells from 60ml blood were either layered onto percoll gradients or fractionated 
into lymphocytes and monocytes by plastic adherence. Lymphocyte purities and 
yields were not significantly different (p>0.05) by either method, as determined 
by MWU. 
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2.1.12 Purification of Lymphocyte Subsets by Cell Sorting 
Peripheral blood mononuclear cells prepared as described in section 
2.1.7, were incubated for 18h in 75cm2 tissue culture flasks at a density 
106/ml in RPMI/FCS. The cells were washed once in azide free flow 
cytometry sheath fluid (Facsflow; Becton-Dickinson Immunocytometry 
Systems, Oxford, U.K.) and the cell concentration adjusted to 5 x 106/ml 
in HBSS. The cell preparation was incubated with 2.5J-l1 of FITC labelled 
anti-CD8 monoclonal antibody per 100J-l1 cells for 20min at room 
temperature, and washed twice in HBSS. An aliquot (100J-l1) of 
unlabelled lymphocytes was also labelled with 2.5J-l1 isotype IgG1 FITC 
control, incubated for 20min, and washed twice in HBSS. All cell 
preparations were resuspended in 400J-l1 HBSS per 100J-l1 cells. The cells 
were then passed through the cell sorter according to the following 
procedure. 
After preparation of the FACStar plus for sterile sorting, the isotype 
control labelled cells were passed through the flow cytometer to 
determine the negative to positive delineator for FITC. A "sort gate" was 
placed around the unlabelled cells, which resulted in the collection of 
lymphocytes depleted of CD8+ cells. Approximately 5-10 x 106 cells were 
collected for inclusion in the cytotoxicity assay. In all experiments 
depletion of CD8+ cells was >95%. 
Three experiments were performed to determine if the passage of the 
cells through the cell sorter alone had any effect on subsequent 
lymphocyte activity (figure 2.3). Unlabelled lymphocytes were passed 
through the cell sorter and their cytotoxicity compared with that of fresh 
matched lymphocytes (i.e. cells which had not been passed through the 
cell sorter) which were added directly onto the target cells (untreated 
A375 melanoma cells). The assay was set up according to the method 
described in section 2.2. Figure 2.3 shows that passage through the cell 
sorter did not significantly affect lymphocyte killing of A375 cells (p>O.05 
by MWU and PIT). 
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Figure 2.3. Effect of cell sorting on the cytotoxicity of lymphocytes against A375 
cells. Freshly isolated lymphocytes were split into 2 aliquots. One aliquot was 
incubated at 37°C (untreated) and the other passed through the cell sorter. 
Lymphocytes were added to A375 cells at an effector:target cell ratio of 50:1 for 
18h at 37°C. The results are expressed as the mean and SEM from 3 such 
experiments. No significant effect (p>0.05) on lymphocyte cytotoxicity was 
observed by passage of lymphocytes through the cell sorter, as detennined by 
MWU and PTT. 
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2.1.13 Preparation of LAK and Control Cells 
Non-adherent lymphocytes derived from 60ml of blood were divided into 
two aliquots containing equal numbers of cells. The cells were 
centrifuged and the pellets resuspended to 2 x 106 cells/ml in either 
RPMIIFCS (control cells) or RPMIIFCS containing graded concentrations 
of IL-2 (LAK cells). Lymphocytes were incubated at 37°C upright in 
25cm2 (not more than 25mllflask) tissue culture flasks for 4h to 7d, 
decanted into universal containers, washed three times in RPMI to 
remove any residual IL-2, and a cell count and viability assessment 
(sections 2.1.15) performed prior to their inclusion in cytotoxicity 
experiments. 
2.1.14 Isolation and Growth of Endothelial Cells and Fibroblasts 
Human umbilical cords were collected into physiological saline by staff in 
the St. Thomas' Hospital delivery suite and stored at 4°C for up to 16h. 
In the laboratory, the cords were cut into 1 0-15cm lengths, and one vein 
of each cut piece cannulated using 16 gauge stainless steel cannulae. 
The veins were flushed through with 10ml RPMI to remove any blood, 
and then filled with 10ml RPMI containing 300U/ml type IV collagenase 
(Sigma, Dorset, U. K.). After 10min incubation at 37°C the collagenase 
solution containing endothelial cells was removed into universal 
containers. RPMI (30ml total volume) that was flushed though each vein 
to remove any remaining endothelial cells was also collected. The cell 
suspensions were centrifuged at 200g for 10min, and the pellets 
resuspended in 20ml of RPMIIFCS. An aliquot of cells was examined 
under the microscope to check for the presence of endothelial cells. The 
cell suspension was then placed in 25cm2 tissue culture flasks and 
incubated at 37°C. After 6-18h the flasks were examined for adherent 
cells. The culture medium was changed every 2 days until the cells had 
formed a confluent monolayer. On attaining confluence, the cells were 
detached by the addition of 2ml trypsin/EDTA solution (as used for the 
detachment of tumour cells; section 2.1.2) followed by gentle swirling of 
57 
the flask. Using an inverted microscope cell detachment was seen as 
sheets of endothelial in suspension. Twenty millilitres of RPMIIFCS were 
then added to each flask and repeatedly pipetted in and out of the flask 
to break up the cell monolayers. The cells were either decanted into 2 
fresh flasks (1 Oml each) together with 10ml RPMI/FCS for further growth, 
or 200lli aliquots pipetted into flat bottomed 96 well microtitre plates 
(Costar Ltd., Berks., U.K.) for use in the cytotoxicity assays. Plates were 
regularly checked for cell attachment and growth, and were introduced 
into cytotoxicity experiments on reaching confluence. 
The concentration and incubation time of collagenase in the umbilical 
veins was critical. Increasing either or both of these factors resulted in 
fibroblast detachment from the vessel walls, which subsequently overran 
and replaced the endothelial cells in culture. In this study, fibroblast 
cultures were treated in the same way as the endothelial cultures for 
inclusion in the cytotoxicity assay. 
2.1.15 Assessment of Cell Numbers and Cell Viability 
Tumour, leucocyte or normal cell numbers or viability were determined 
by the addition of 20111 of cell suspension to 180111 of either crystal violet 
solution (0.1 % w/v crystal violet (Merck Ltd, Lutterworth, Leics.) in a 
solution of 3% acetic acid (v/v) in distilled water, or (0.5%) w/v of the vital 
stain trypan blue (Merck Ltd., Lutterworth, Leics.) respectively. The cell 
suspensions were placed in an Improved Neubauer haemocytometer 
chamber. The number of cells occupying the central and four peripheral 
large fields was counted and divided by 50. This represented the 
concentration of cells in 106cells/ml. 
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2.2 Cytotoxicity Assays 
2.2.1 Cytotoxicity of Tumour Cells 
Cytotoxicity of tumour cells was determined using a standard Na51 Cr04 
(Amersham International PLC, Aylesbury, Bucks) release assay. All 
assays were performed in triplicate. Target cells (fresh tumour cells; 
sections 2.1.2 and 2.1.3) or cytokine (section 2.1.4) and/or Act-O 
pretreated tumour cells (section 2.1.5) were washed once in RPMI to 
remove any FCS, the supernatant discarded and 150~Ci of added to the 
pellet and mixed. The cells were then incubated at 37°C for 45min. After 
this period, the cells were washed twice with RPMI/FCS (to remove any 
free Na51 Cr04), followed by a single wash in RPMI. The final pellet was 
resuspended in 1 ml RPMI and a cell count and viability (section 2.1.15) 
performed. The cell concentration was adjusted to 1 x 105/ml or 2 x 
105/ml and 1 OO~I or 50~1 respectively added to the appropriate wells of a 
96 well round bottomed microtitre plate. The ratio of effector molecules 
and cells varied according to experimental design. The details of 
preparation and addition of these effectors to the tumour cells are 
outlined in the following subsections. 
2.2.2 Cytotoxicity Mediated by Soluble Effector Molecules and Cytokines 
In experiments investigating the cytotoxic activity of various factors (e.g. 
cytokines, LPS ; see chapter 4), serial dilutions (usually 6) were made 
from the stock solutions (appendix IV) in RPMIIAB or RPMIIFCS 
(depending on the experiment) and 1 OO~I added to tumour cells in the 
microtitre plate. 
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2.2.3 Inhibition of Cytokine Cytotoxicity by Monoclonal Antibodies 
In these experiments, tumour cells were initially diluted in RPMI to four 
times the final dilution required and SOIlI added to each of the assay 
wells. Monoclonal antibodies to cytokines (TNFa and L T) were diluted to 
four times the required final concentration in RPMI, and SOIlI added to 
relevant wells in the microtitre plate. Cytokines were prepared and 
added to the wells as in the previous section. 
2.2.4 Cytotoxicity Mediated by Effector Cells 
To investigate the cellular cytotoxicity of tumour cells, effector cells 
(control, LAK, monocytes) were adjusted to S x 106 cells/ml in RPMIIAB 
or RPMIIFCS (depending on the experiment), and S serial two-fold 
dilutions prepared. Effector cells (100IlI) were then added to the 
appropriate wells containing tumour cells. 
Spontaneous and total Na51 Cr04 release were determined by adding 
100lli RPMIIAB (FCS) and 100lli 6% sodium dodecyl sulphate (SOS) 
respectively to wells (in triplicate) containing only tumour cells. 
Spontaneous counts were thus a measure of non-specific Na51 Cr04 
release from the target cells, and total counts represented the total 
amount of radioactivity in 100lli of target cells. 
2.2.5 Inhibition of Cellular Cytotoxicity by Monoclonal Antibodies 
Tumour cells were initially diluted in RPMI to four times the final dilution 
required and SOIlI added to each of the assay wells. Monoclonal 
antibodies to cytotoxic effector molecules (TNFa or L T; appendix IV) 
were diluted to four times the required final concentration in RPMI, and 
SOml added to relevant wells in the microtitre plate. Lymphocytes or LAK 
cells were prepared and added to the wells as described in section 
2.2.4. 
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2.2.6 Inhibition of Cellular Cytotoxicity by Coagulation Factors and Their 
Inhibitors 
In experiments investigating the inhibition of cytotoxicity by plasma 
(chapter 5) the following modifications were made to the cytotoxicity 
assay. Target cells (A375) were adjusted to 2 x 105/ml and 50~1 added to 
relevant wells. Plasma/serum (normal or coagulation factor deficient) 
were diluted to twice the final concentration required and 1 OO~I added to 
relevant wells. The coagulation factor deficient plasmas (factor-V; factor-
VII, factor-VIII, factor-IX, factor-X), were obtained from Sigma Chemical 
Co. Ltd., Dorset, U.K.; and factor XIII deficient plasma was obtained from 
a patient with hereditary severe factor XIII deficiency, who had been 
referred to the Haemophilia Centre by Dr Osier at Bournemouth General 
Hospital. Effector cells were adjusted to 1 x1 07/ml and 50~1 added to 
relevant wells. Additional constituents of the assay such as graded 
concentrations of eACA or Gly-Pro-Arg-Pro (Sigma Chemical Co., Ltd., 
Dorset, U.K.) were included in the serum/plasma dilution. In some 
experiments effector or target cells were mixed with serum/plasma 
dilutions and incubated for 30min prior to addition of the other cellular 
component(s). Total counts were measured as described above, but 
spontaneous counts were determined by the addition of 1 OO~I of the 
relevant plasma/serum dilution and 50~1 RPMI to the tumour cells. After 
addition of both target cells and effector (cells or soluble factors and/or 
inhibitors), the plates were incubated at 37°C for 4-18h, depending on 
the experiment. At the end of the incubation, the supernatants were 
harvested from the wells using a filter based supernatant collection 
system (Skatron Ltd) (In experiments investigating the inhibition of 
cytotoxicity by plasma, almost all of the supernatant could be collected 
from the wells using this harvesting system, even when clots were 
present). The tubes were then counted on a gamma spectrometer 
(Wallac (U.K.) Ltd.,Crownhill, Milton Keynes; model number 1282). The 
mean values from the triplicate counts was calculated. 
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Results were expressed as:-
x100% 
cpm(test) - cpm(spontaneous) 
cpm(total) - cpm(spontaneous) 
2.2.7 Cytotoxicity by Soluble Factors from Effector Cells. 
To investigate whether cell-cell contact was necessary for cellular 
cytotoxicity to occur, effector cells were physically separated from target 
cells in the culture wells by polycarbonate culture well inserts, which 
were porous to soluble molecules, but would not allow the passage of 
cells. Cytotoxicity observed under these conditions was compared with 
that in which the membranes were absent. 
Culture well inserts are only available for 24 well and larger tissue 
culture plates. The microcytotoxicity assay described in section 2.2 was 
therefore scaled up from a total final volume of 200111 using 96 well 
plates to 2ml in 24 well plates (Costar Ltd., Berks., U.K.). A375 cells 
were detached from plastic and labelled with Na51 Cr04 (Section 2.2.1), 
and assessed for cell number and viability (section 2.115). The cell 
concentration was adjusted to 1 x 105cells/ml in 10%FCS and 1 ml added 
to the relevant wells of a 24 well microtitre plate. 
Control and LAK cells were prepared as described in section 2.1.13, and 
adjusted to 5 x 106cells/ml in RPMIIFCS. The effector cells (1 ml) were 
either added to wells containing tumour cells alone (thus mixing effector 
and target cells), or to the inside of polycarbonate membranes (0.811 
pore size, Nunc, Life Technologies, Renfrewshire, Scotland) which had 
been inserted above the tumour cells in the wells, thus preventing cell-
cell contact. The volume of target cells (1 ml) ensured that the 
polycarbonate inserts were surrounded by culture medium, in order to 
allow the passage of soluble molecules across the membranes. 
Spontaneous and total counts were determined by the addition of 1 ml 
RPMIIFCS or 1 ml 6% SOS respectively to the tumour cells. The plates 
were incubated at 37°C for 18h and the polycarbonate membranes 
removed. The plates were then centrifuged at 400g for 5min in a Jouan 
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CR422 centrifuge (with swingout adaptors for microtitre plates), and 
0.5ml of supernatant transferred to LP2 tubes (Luckham Ltd, Burgess 
Hill, Sussex). The radioactivity was counted, and the results calculated 
as described in the previous section. 
2.2.8 Control and LAK Cell Cytotoxicity of Autologous Leucocytes 
Lymphocytes were purified from 60ml heparinised blood (section 2.1.6) 
as described in section 2.1.10, and control and LAK cells prepared 
(section 2.1.13). After 48h the control and LAK cells were washed three 
times in RPMI/FCS to remove any residual IL-2, and a differential cell 
count and cell viability determined (section 2.1.15). The effector cell 
concentration was adjusted to 5 x 106/ml and added to the relevant wells 
of a microtitre plate together with target cells where appropriate. 
After the 48h incubation required for the preparation of control and LAK 
cells, a second blood sample (30ml) was collected from the same donor 
and lymphocytes and monocytes prepared (section 2.1.10). An aliquot of 
cells (3-5x106 cells depending on cell yield) was centrifuged at 200g for 
10min, resuspended in its own volume, 1 OO~Ci Na51 Cr04 added and the 
cells incubated for 45min at 37°C. After this time the cells were washed 
twice in RPMIIFCS and a differential cell count and viability test (section 
2.1.15) performed. The cell concentrations were adjusted to 1 x1 05 
cells/ml and 1 OO~I added to the relevant wells of the microtitre plate. 
Total and spontaneous counts were determined as described for tumour 
cells in section 2.2.4. 
2.2.9 Control and LAK Cell Cytotoxicity of Endothelial Cells and 
Fibroblasts 
Microtitre plates containing confluent endothelial cells or fibroblasts were 
washed twice with RPMI and 1 OO~I of RPMI added to all cells except 1 
row of cells to which was added trypsin/EDTA for 5 min. The 12 wells 
containing trypsin/EDTA treated cells were gently pipetted repeatedly 
several times using a plastic pasteur pipette to dislodge any remaining 
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adherent cells and their contents pooled into a 7ml plastic bijou bottle. 
The cells were counted using crystal violet (section 2.1.15), and the 
mean concentration of cells/well calculated. The RPMI in the plate was 
decanted and 100J,.l1 of RPMI containing 2J,.lCi Na51 Cr04 added to each 
well and incubated for 45 min at 37°C. The cells were washed twice in 
RPMI/FCS and 200J,.l1 of RPMIIFCS containing either control or LAK cells 
were added to appropriate wells. The highest density of control or LAK 
cells was adjusted to 50 times the mean concentration of target cells, 
and doubling dilutions were made from this preparation. To six wells 
were added 200J,.l1 10% FCS which acted as a medium control, and 200 J,.l I 
6% SOS were also added to 6 wells, from which the total radioactivity 
present in each well was determined. After 1, 2, 4 or 18h incubation at 
37°C the supernatants from individual wells were collected onto 
absorbant filters using the Skatron Macrowell™ harvesting system 
(Skatron Ltd., Newmarket, Suffolk), and the radioactivity counted on a 
gamma spectrometer. Results were calculated according to the formula 
described in section 2.2.6 
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2.3 Coagulation Assays and Preparative Techniques 
2.3.1 Preparation of Normal Plasma and Serum 
Sixty millilitres of venous blood was obtained from normal healthy 
donors, of which 30ml was placed into 6 vacutainer tubes containing 
sodium citrate (9 parts blood to 1 part 0.109M trisodium citrate) for 
plasma, and 30ml placed in 3 glass vacutainer tubes for serum. All tubes 
were centrifuged at 600g for 15min and the serum or plasma removed 
into separate 30ml universal containers, which were re-centrifuged at 
600g for 15min. Serum and plasma were then divided into 1 ml aliquots in 
7ml plastic bijou bottles and stored at -70°C. For use, vials of plasma 
were removed from the freezer, together with vials containing donor 
matched serum. These were thawed at 37°C in a water bath in order to 
minimise cryoprecipitate formation. 
2.3.2 Preparation of Aluminium Hydroxide Adsorbed Plasma 
A stock solution of Aluminium Hydroxide was prepared by adding 3g 
AI(OHh to 4ml distilled water in a universal container. The resulting 
saturated solution of aluminium hydroxide (1 part) was added to fresh 
° citrated plasma (5 parts), and the mixture incubated for 3min at 37 C. 
The mixture was centrifuged at 600g for 10min and the supernatant 
(aluminium hydroxide adsorbed plasma) was removed for use in the 
cytotoxicity assay. 
2.3.3 Preparation of Plasminogen Depleted Plasma 
Plasminogen depleted plasma had already been prepared in the 
coagulation research unit and was therefore available for use in this 
study. It was prepared by passing whole plasma though a 
chromatography column packed with sepharose 48, to which lysine had 
been covalently coupled (Cuatrecasas, 1980). As a result, plasminogen 
in plasma bound to the lysine groups on the matrix, and the run-through 
volume of the column contained plasma which had been depleted of 
plasminogen (as previously assessed by ELISA). 
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2.3.4 Visual Assessment of Clot Formation 
Coagulation induced in normal and coagulation factor deficient plasmas 
(V, VII, VIII, IX and X) in the presence of RPMI, control cells, LAK cells, 
A375 cells, control + A375 cells and LAK + A375 cells was observed in 
24 well tissue culture plates. The final leucocyte and tumour cell 
concentrations (and thus the effector:target cell ratio of 50: 1) were the 
same as those used in the cytotoxicity assay (section 2.2.1). Control and 
LAK cells were adjusted to 1 x1 06ceII s/m I (when added to the plate in the 
absence of A375 cells) or 2x106/ml (when added to the plate with A375 
cells) and 1 ml or 0.5ml respectively added to relevant wells of a 24 well 
tissue culture plate. The A375 cell concentration was adjusted to 1 
x105cells/ml (in the absence of effector cells) or 2 x 105/ml (in the 
presence effector cells) and 1 ml or 0.5ml respectively added to the wells. 
Plasma was diluted 1:9 with RPMI and 1 ml added to the relevant wells. 
All assays were performed in triplicate. Where multiple time pOints were 
required, plates were set up in parallel (one for each time point). The 
plates were incubated at 37°C for 0,1,2 or 4h, and were visually 
examined for clot formation. A score from - to +++ was assigned to each 
well, depending on the solidity of the clot. A score of: (-) indicated no 
observable clot formation; (+) - partial clotting, resulting in increased 
viscosity of the cell suspension; (++) - a solid clot which disintegrated on 
agitation; (+++) - a solid clot which was not dispersed by agitation. 
Supernatants (0.5ml) were taken from each well and snap frozen at -
70°C in cryovials (Costar Ltd., Berks., U.K.) for later analysiS of thrombin 
and D-dimer production. 
2.3.5 Chromogenic Determination of Thrombin Generation 
Supernatants from experiments described in section 2.3.4 were thawed and 
50~1 added in triplicate to the relevant wells of a 96 well microtitre plate. To 
this was added 50~1 of diluent buffer from a commercial thrombin test kit 
(Quadratech Ltd, Epsom, Surrey.), together with 100~1 of S2238 thrombin 
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specific chromogenic substrate. The plate was incubated for 4h at 37°C and 
the reaction was stopped by the addition of 100lli of 50% acetic acid (B. D. H. 
Laboratory Supplies, Lutterworth, Leics.) in distilled water. The absorbance 
values were read at 405nm on a microtitre plate reader. Results were 
expressed as the mean absorbance (from the triplicates) for each sample. 
2.3.6 Chromogenic Determination of Factor X Activation by A375 Cells 
Lyophilised purified Factor X (Alpha Therapeutic) was reconstituted with 
10ml distilled water, diluted to 1 U/ml (1 U is the amount of Factor X 
present in 1 ml of normal plasma), and 100lli added in quadruplicate both 
to the A375 cells in the wells of a 96 well microtitre plate, and in parallel 
to empty wells of a separate microtitre plate. The plates were incubated 
for 4h at 37°C and 100lli of the chromogenic substrate S2222 (specific 
for Factor Xa; Quadratech Ltd., Epsom, Surrey) was added to each well 
which contained Factor X. After a further incubation at 37°C the plates 
were read at 405nm on a microtitre plate reader. Absorbances in wells 
containing reagents but not A375 cells (blank) were subtracted from 
absorbances obtained from wells which contained cells. 
2.3.7 Chromogenic Determination of Plasmin Activity on A375 Cells 
To confluent A375 cells in a microtitre plate (section 2.1.2) was 
introduced ,in triplicate, 100lli of RPMI or plasminogen depleted plasma 
(section 2.3.3), normal plasma or matched serum which had been diluted 
to 20, 10, 5, 2.5, 1.25 and 0.63% in RPMI. The plate was incubated at 
37°C for 4h, washed three times with RPMI and 100lli of the plasmin 
specific chromogenic substrate S2251 (Quadratech Ltd, Epsom, Surrey: 
S2251 does not show activity with any of the collagenases, elastase or 
cathepsin-G: personal communication from Graham Jones, Quadratech 
Ltd.) added to each well. The plate was incubated at 37°C overnight and 
the absorbance of the wells measured at 405nm in a microtitre plate 
reader 
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2.3.8 Measurement of D-Dimer Production 
Supernatants obtained in experiments described in section 2.3.4 were 
thawed and D-dimer measured using a commercial Enzyme Linked 
Immunosorbant Assay kit (ELISA; Quadratech Ltd., Epsom, Surrey). 
Microplate wells coated with an anti-D-dimer monoclonal antibody were 
incubated with samples or D-dimer standard solutions. During the 
incubation period, D-dimer present in the sample bound to the antibody. 
The wells were then washed with buffer to remove unbound substances , 
and an enzyme labelled anti-D-dimer antibody was added to the wells 
and a further incubation performed. This conjugate bound to the antigen-
antibody complexes which in turn were bound to the plate. The plate was 
again washed to remove excess labelled antibody and the enzyme 
substrate was added for a further incubation period. The absorbance of 
the product in the wells was read in a microtitre plate reader at 450nm. A 
standard curve was obtained by plotting the concentrations of the D-
dimer standard solutions against their absorbance readings. The 
concentration of D-dimer present in the samples was interpolated from 
the standard curve. 
2.3.9 Gel Filtration of Fibrinogen 
One vial of commercial fibrinogen concentrate (Centre de Regionale 
Transfusion de Lille, France. Batch No. 1020030.0) was reconstituted 
with 20ml distilled water according to the manufacturer's instructions. 
The fibrinogen concentration was 18.62mg/ml (as measured by ELISA, 
section 2.3.10). A chromatography column containing sepharose CL-6B 
was equilibrated with RPMI and 12ml fibrinogen concentrate (223.44mg) 
added. The flow rate through the column was adjusted to 60ml/h and 
fractions (10ml) were collected until the absorbance at 280nm had 
returned to baseline values A total of 31 fractions were collected and 
stored at -70cC. The fibrinogen concentration of each fraction was 
determined as described in section 2.3.10. Figure 2.4 shows that the 
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peak fibrinogen concentration in the fractions corresponded to the peak 
absorbance. The original fibrinogen preparation and fractions 13, 14, 15 
and 16 (containing the highest concentrations of fibrinogen) were 
assayed for functional (clottable) fibrinogen by the clinical coagulation 
laboratory. The fibrinogen in the samples was clotted by addition of 
thrombin in 96 well microtitre plates. The plates were centrifuged and a 
protein determination performed on the supernatants. The detection of 
protein in the supernatants suggested the presence of non-clottable 
fibrinogen. Fibrinogen was reported to be >95% clottable by this 
technique, indicating that the fibrinogen retained its biological activity 
after gel filtration. 
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FIGURE 2.4. Absorbance and protein concentration of fractions from gel filtered 
fibrinogen. The absorbance at 2S0nm was measured during gel filtration of 
fibrinogen, until 310ml (31 fractions) had passed through the column. A peak in 
absorbance was observed in fractions 13-16. Fibrinogen concentration 
(measured by ELISA) showed a peak in the same fractions, indicating that the 
absorbance peak corresponded to eluted fibrinogen. The Fibrinogen 
concentrations in these fractions were: fraction 13 (5.032mg/ml); fraction 14 
(11.52mg/ml); fraction 15 (S.S5mg/ml) and; fraction 16 (2.S3mg/ml). 
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2.3.10 Fibrinogen ELISA 
The fibrinogen concentrations of the fractions collected from the gel 
filtration column were measured using an "in-house" ELISA specific for 
fibrinogen. 
Rabbit anti-human fibrinogen polyclonal antibody (Immunotech Ltd.) was 
diluted 1: 1 000 in carbonate-bicarbonate buffer (0.05molll) and aliquots 
(100JlI) added to each well of a 96 well microtitre plate, for 1 h at room 
temperature in a damp chamber. During this period the supernatants 
from the gel filtration column were thawed and the Iyophilised plasma 
standard (NIBSC) and control plasma (Immuno Ltd, Sevenoaks, Kent) 
reconstituted. These were then diluted 1 :8000, 1 :16000, 1 :32000 and 
1 :64000 in 1 mill BBS. After incubation the plate was washed three times 
with BBS, with a 1-2min wait before discarding each wash. The diluted 
standards or test samples, in duplicate, (buffer was added to each well of 
row 1 as a sample blank) were added to the plate, incubated for 1 h at 
room temperature in a damp chamber, and washed three times with 
BBS. Peroxidase conjugated rabbit anti-human fibrinogen was diluted to 
1 :2000 with BBS and 100JlI added to each well of the plate, for a further 
one hour incubation. This was followed by two washes with BBS, one 
wash with citrate buffer, and 100JlI of the substrate added to each well. 
The plate was incubated at room temperature until the absorbance of the 
control at a 1 :8000 dilution reached 0.15 at 492nm. The enzyme reaction 
was stopped by addition of 100JlI 1.0molll sulphuric acid to each well 
and the plate read at 492nm. The relative potencies of the samples were 
calculated using a bioassay computer program (Williams et aI., 1975). 
2.3.11 Phast Gel Electrophoresis of Fibrinogen (Reduced) 
Samples were diluted in reducing buffer (4%) sodium dodecyl sulphate, 
2%) mercaptoethanol, 20°A, glycerol, 0.0082% bromophenol blue, 
0.125molll tris. pH 6.8), heated in a boiling water bath for 10min and 
centrifuged at 12000g for 3min. Parafilm was placed over an 
electrophoresis stencil and pressed to form 8 indentations into which 
small (4JlI) volumes of the samples were placed in positions 2-7. The 
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same volume of the molecular weight marker solution (MW range 14 to 
94-kDa, Pharmacia Biosystems Ltd., Knowhill, Milton Keynes) was 
added to positions 1 and 8. The separation bed of the phast system was 
wetted with water and 200k Phast gels (resolution 2 to 150-kDa, 
Pharmacia Biosystems Ltd, Knowhill, Milton Keynes) placed on the bed 
within the boundaries and any air bubbles removed. SDS buffer strips 
(Pharmacia Biosystems Ltd., Knowhill, Milton Keynes) were inserted into 
the frames and placed in the electrophoresis chamber on either end of 
each gel. The electrodes were lowered onto the buffer strips, and the 
electrophoresis program set to run for 200k gels. Reagents were 
prepared as described in appendix VII and connected to the appropriate 
inlet and outlet ports of the machine. The waste collection bottle was 
connected to port O. A sample applicator with 8 teeth was lowered onto 
the samples and placed in the sample holder. The lid of the phast gel 
electrophoresis unit was then closed and the separation program 
activated. 
After separation, the gels were inserted into the development unit and 
stained with coomassie blue, after which they were dried and scanned 
on a computing densitometer (Molecular Dynamics Ltd., Sevenoaks, 
Kent) to obtain computerised images (figure 2.5). 
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FIGURE 2.5. Phast gel electrophoresis of fibrinogen fractions 13-23. Fibrinogen 
fractions (numbers under lanes) and the unfractionated commercial product (S) 
were diluted in reducing buffer, boiled, centrifuged at 10,000g and applied to the 
gels. Molecular weight markers (M) were added to the first and last lanes of each 
gel. The two gels were run together on the phast system. After staining with 
Coomassie blue, the characteristic 3 bands of reduced fibrinogen were observed 
in the unfractionated material, i.e., the Au (66.5-kDa), B~ (52-kDa) and y (46.5-kDa) 
chains, as well as fractions 13-16 (corresponding to the absorbance and 
fibrinogen ELISA peak), but not in any subsequent fractions. 
In the starting material and fractions 13-16, only the fibrinogen bands were 
present, indicating that these preparations were not contaminated with 
proteinaceous material with an Mr below 100kDa. The molecular weight 
markers in the right hand lane of the first gel gave closer molecular weight 
comparisons for the fibrinogen chains to the published data. 
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2.4 Flow Cytometry 
2.4.1 Detection of Cell Surface Antigens (Direct Labelling) 
Mononuclear cells, lymphocytes, monocytes, LAK cells or tumour cells were 
adjusted to S x 106 cells/ml in Facsflow™ (Becton-Dickinson, San Jose, 
California, USA). Cells were aliquoUed (1 OO~I) into Falcon™ FACS tubes 
(Becton-Dickinson, San Jose, California, USA)., and 20~1 of fluorophore 
labelled (FITC, PE) monoclonal antibody (see individual experiments for 
antibody specificity) or isotype control added, for 20min at room temperature. 
In some experiments, two different antibodies were added to the same tube in 
order to distinguish more than one antigen on the same cell, e.g., monocytes 
were distinguished from lymphocytes in the same cell preparation by addition 
of anti-CD14PE, as well as the antibody of interest (e.g., anti-CD2S). Where 
Becton-Dickinson directly labelled antibodies were used, equivalent volumes 
of antibody and isotype control could be used. For other antibodies the volume 
of isotype control was calculated to achieve an equivalent final 
immunoglobulin concentration to that of the monoclonal antibody. Two 
millilitres of Facsflow were added to each tube and the tubes were centrifuged 
at 400g for Smin. The supernatant was discarded and the cells resuspended in 
400~1 of Facsflow. Cell surface markers were measured on the cells using a 
Becton-Dickinson FACScan and calculated on Lysys II and QuickCal software. 
Ten thousand events were acquired from each tube, and compared with an 
equal number of events acquired from the isotype (negative) control. 
2.4.2 Detection of Cell Surface Antigens (Indirect Labelling) 
The procedure for the labelling of cells with unlabelled primary antibody (e.g., 
anti-human Factor V (Sigma, Dorset, U.K.) was essentially the same as in the 
previous section, with the exception that the volume of isotype control was 
adjusted to equal the concentration of IgG1 in respective tubes. After the initial 
incubation and wash step, S~I of FITC labelled goat anti-mouse Fab" antibody 
were added to the cell pellets (total volume -1 OO~I) and incubated at room 
temperature for 20min. The cells were again washed and resuspended In 
400~1 Facsflow. Cells were counted as described in the previous section. 
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2.4.3 Quantification of Cell Surface Markers 
2.4.3.1 Instrument calibration. 
The fluorescence intensities of QuickCal™ FITC labelled latex beads carrying 
six different known amounts of FITC (Flow Cytometry Standards Corporation 
(FCSC), Leiden, The Netherlands) were measured on a FACScan using the 
same instrument settings as for cellular acquisition. This allowed the 
instrument to be calibrated for FITC. The data was then loaded into the 
QuickCal™ software program which created a Levey-Jennings plot of 
histogram channel number against the known values of molecules of 
equivalent soluble fluorophore (MESF) for FITC. 
2.4.3.2 Fluorochrome to protein (F/P) ratio calculation. 
Goat anti mouse coated latex beads ("Simply Cellular", FCSC, San Juan, 
PR) were incubated with SJ..l1 of relevant FITC labelled monoclonal 
antibody (McAb) at RT for 1Smin. Subsequent analysis of gated singlet 
bead population on FSC Vs SSC dot plot and histogram analysis of the 
FITC peak produced a median channel value for the fluorescent peak for 
the McAb. The MESF values for the McAb were calculated from the 
QuickCal FITC Levey-Jennings plot by loading the median channel 
values into the MESF calculator software programme. Since "Simply 
Cellular" beads have a quoted number of mouse McAb binding sites, the 
F/P Ratio for each McAb was calculated by dividing the MESF values by 
the bead binding site number. Autofluorescence of latex beads was 
subtracted at all times from test MESF values by acquiring certified blank 
latex beads (FCSC, Leiden, The Netherlands;) and calculating the MESF 
value due to latex beads alone. 
2.4.3.3 Determination of Cell Surface Antibody Binding Site Numbers. 
Histogram FL-1 analysis of the cell population produced a median 
channel value for the relevant McAb. This channel value was converted 
to an MESF value via the MESF calculation software, as were cellular 
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autofluorescent median channel values. The mean antibody binding site 
number (MBSN) for the McAb was calculated by first subtracting the 
MESF value of autofluorescent certified blank latex beads from the 
autofluorescence of unlabelled cells. This value was then subtracted 
from the MESF value of labelled cells, thus accounting for any MESF 
values contributed by cellular autofluorescence. Since the F/P ratio is 
known for the McAb, the MBSN could be calculated for antibody binding 
sites on the cell populations. 
2.5 Statistical Methods 
In most of the groups of experiments in this study an insufficient number 
of data points were present to establish whether the data was normally 
distributed. As a result, non-parametric statistical procedures were 
applied to the data to test the null hypotheses that the results to be 
compared originated from the same population, and to determine the 
significance of any deviations observed. Error bars on figures represent 
standard error of the mean (SEM), 
The Mann-Whitney U-test (MWU) was used to test unpaired data, and 
the Wilcoxon signed rank test (WSR) was used to test paired data, when 
the number of observations (n) exceeded 5. When n was less than 5 the 
paired t-test and Mann-Whitney U-tests were used. Probabilities less 
than 0.05 (p<0.05) were considered to be significant. These tests were 
performed using the Unistat statistical software package (Unistat Ltd., 
Maida Vale, London). 
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2.6 Cytotoxicity Assay Development 
2.6.1 Time Course of Spontaneous 51Cr Release from Tumour Cells 
All cells spontaneously release Na51 Cr04 with time after loading. 
Therefore the incubation time for cytotoxicity assays is limited by the rate 
at which radiolabel is lost from the cells. Typically, Na51 Cr04 release 
assays continue up to 24h, after which, for most cell types, the 
spontaneous Na51 Cr04 release becomes too high to give meaningful 
results. The cell lines K562 and Daudi were tested for their spontaneous 
Na51 Cr04 release at 4, 18, 48 and 72h (Figure 2.6). 
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FIGURE 2.6. Time course for spontaneous Na51Cr04 release from K562 and Oaudi 
cells. Tumour cells (K562 and Oaudi) were loaded with excess Na51 Cr04 (150#,Ci / 
5x106 cells for 45min), washed and added to 4 microtitre plates (1 x 104 
cells/well). After incubation for 4, 18, 48 or 72h incubation supernatants were 
removed from the appropriate plate and the radioactivity counted. Three 
experiments were performed, and the means and SEMs are shown. After 4h 30% 
(K562) and 33% (Oaudi) of the Na51 Cr04 was released from the cells and there was 
a time-dependent increase in spontaneous Na51 Cr04 release from the tumour 
cells (p<0.05 by MWU and PTT), reaching 63% (K562) and 73% (Oaudi) after 72h. 
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Figure 2.7 shows that there was a time-dependent increase in the 
spontaneous Na51 Cr04 release from the cells, with a loss of 63% and 
73%) of the total available radioactivity from K562 and Daudi cells 
respectively by 72h. At each time point, the level of Na51 Cr04 released 
was not significantly (p>0.05, Mann-Whitney U-test) different between 
the tumour cell lines. A high level of spontaneous Na51 Cr04 release from 
target cells would result in a decrease in the sensitivity of the assay at 
longer incubation times. 
One of the melanoma cell lines (A375) was also tested for spontaneous 
Na51 Cr04 release at 2, 4, 6 and 18h after loading (Figure 2.8). After 18h, 
spontaneous Na51 Cr04 release was 38%), which was similar to the levels 
observed for K562 (41 0/0) and Daudi (43%») cells at 18h (p>0.05 by 
MWU). 
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FIGURE 2.7. Time course for spontaneous Na51 Cr04 release from A375 cells. After 
detachment from plastic, A375 cells were treated as described in figure 2.7. The means 
and SEMs from 6 experiments are shown After 2h the spontaneous Na51Cr04 release 
was 14%, which rose to 38% after 18h (p<O.05 by WSR). The observed increases in 
spontaneous Na51Cr04 release at 4 and 6h were not significantly different to the value at 
2h (WSR). 
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2.6.2 Cytotoxic Activity of Actinomycin-D on A375 Melanoma Cells 
Actinomycin-D is a cytotoxic drug used in the treatment of various 
malignant diseases including melanoma, and has been extensively 
reported to sensitise tumour cells in vitro to the tumouricidal activity of 
cytokines and leucocytes (Colotta et aI., 1984). A375 cell susceptibility to 
killing by Act-D was investigated at drug concentrations of 0, 0.0001, 
0.001, 0.01, 0.1 and 11lg/ml. Figure 2.8 shows that concentrations of Act-
O above 0.01 mg/ml significantly increased (p<0.05 by Wilcoxon signed 
rank test) Na51 Cr04 release from A375 cells, in a dose dependent 
manner, up to the highest concentration tested (1.0Ilg/ml). In the 
absence of Act-D pre-treatment, spontaneous Na51 Cr04 release was 
34%>, which was similar to the level observed in the previous section 
(38%>, p>0.05 by MWU and WSR) 
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FIGURE 2.8. Actinomycin-O induced Na51Cr04 release from A375 cells. 
Actinomycin-O (0-1.0",g/ml, in triplicate) was added to Na51Cr04 labelled A375 
cells (1 xi 04cells/well) in microtitre plates, incubated for 18h at 37°C, and the 
radioactivity in the supernatants counted. The results shown are means and 
SEMs from 4 such experiments. A dose dependent increase in Na51Cr0 4 release 
was induced by Act-O, to a maximum of 82% (p<0.05 by PTT and MWU) at the 
highest concentration tested. A significant increase (p<0.05) in Na51Cr04 release 
was also observed at 0.1 Jlg/ml. 
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2.6.3 Cytotoxic Activity of Cycloheximide on A375 Melanoma Cells 
Cycloheximide is another protein synthesis inhibitor which acts at a post-
transcriptional level. In 3 experiments the direct cytotoxic activity of 
cycloheximide (0.01, 0.1, 1.0 and 10)J.g/ml) against K562 and A375 cells 
was investigated at 18h in the Na51 Cr04 release assay (section 2.2.1). 
Specific cytotoxicity was not greater than 4% on either cell line at any 
concentration of cycloheximide tested, indicating that the drug was not 
cytotoxic for these cell lines. 
2.6.4 Effect of Target Cell Confluence on Lymphocyte Cytotoxicity 
Actively growing A375 cells reach confluence within 2-3 days after 
subculture (section 2.1.2). Extending the incubation time results in the 
cells growing over each other. At this point there may be changes in the 
expression of various surface markers which could influence 
susceptibility to killing by leucocytes. To determine whether the state of 
confluence affected tumour cell cytotoxicity by lymphocytes, cells which 
had been grown for 24h after subculture (non-confluent) were harvested 
at the same time as cells which had been grown for 72h (confluent) for 
inclusion in the cytotoxicity assay. Figure 2.9 shows the mean 
lymphocyte cytotoxicity (E:T ratio 50: 1) of confluent and non-confluent 
A375 cells obtained from 3 experiments. The state of confluence of the 
cells had no significant effect on lymphocyte killing (figure 2.9). 
Accordingly, all future experiments were performed with 2-3 day cultured 
A375 cells, because of the greater cell yield after this time. 
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FIGURE 2.9. Effect of A375 cell confluence on their susceptibility to killing by 
lymphocytes. A375 cells were harvested from flasks which had been subcultured 24h 
(non-confluent) or 72h (confluent) previously, labelled with Na51Cr04 and 1x104 cells 
added to a microtitre plate, together with 5x105 freshly isolated lymphocytes. The plate 
was incubated for 18h and the radioactivity in the supernatants counted. Cytotoxicity 
was calculated as described in section 2.2. In 3 experiments (means and SEMs are 
shown), lymphocyte cytotoxicity against 24h cultured tumour cells was not 
Significantly different (p>0.05 by MWU and PTT) from that of tumour cells grown for 72h 
prior to inclusion in the cytotoxicity assay. 
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2.6.5 Effect of Serum on Lymphocyte Killing of A375 Cells 
Initial experiments on lymphocyte cytotoxicity of tumour cells were 
performed using 10% human AB serum in RPMI 1640 (RPMI/AB), 
because AB serum is not mitogenic for human mononuclear cells. Foetal 
calf serum (FCS) had been used in previous studies (Lamph et a/., 
1988). Consequently, a comparison of lymphocyte cytotoxicity against 
A375 cells in tissue culture medium containing either RPMIIAB serum or 
RPMIIFCS was performed. In three comparative experiments no 
significant difference in lymphocyte killing was seen using AB serum or 
FCS (Figure 2.10). Subsequent experiments were carried out using 
RPMIIFCS as the tissue culture medium in the cytotoxicity assay. 
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FIGURE 2.10. Comparison of FCS with AS serum on lymphocyte killing of Act-O 
pre-treated A375 cells. Freshly isolated lymphocytes were added to A375 cells 
(effector:target cell ratio 50:1), in the presence of either RPMI/FCS or RPM lIAS, 
and incubated for 18h. The supernatants were harvested, counted and 
cytotoxiCity calculated. In 3 experiments, there was no Significant difference 
(p>0.05 by MWU and PTT) between lymphocyte killing of A375 cells in the 
presence of either serum type. 
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CHAPTER 3 
CYTOTOXICITY OF TUMOUR CELLS BY CYTOKINES AND 
LEUCOCYTES. 
3.0 Introduction 
The interactions between immune cells, cytokines, the extracellular 
matrix, and tumour cells in vivo are highly complex. Leucocytes adhere 
to tumour cells and kill them using a variety of cytolytic mechanisms. 
Among these are production of reactive oxygen metabolites, and 
secretion of pore forming proteins (perforins). Leucocytes also secrete 
cytokines, some of which are directly cytolytic to tumour cells. Other 
cytokines influence tumour growth by their interaction with leucocytes or 
tumour cells to modulate other mechanisms of immune killing. In 
addition, some tumours produce cytokines which either influence 
leucocyte reactions to the tumour or possess an autoregulatory growth 
function. 
Over the past twenty years, several cytokines have been found to be 
therapeutically beneficial when given to tumour bearing animals or 
patients with terminal cancer. These primarily include the interferons 
(Balkwill and Smyth, 1987), tumour necrosis factor-a (Blick et a/., 1987) 
Iymphotoxin (animal experiments; Funahashi et al., 1993); and 
interleukin-1 (animal experiments, Nakata et al., 1988), which also have 
direct anti-tumour activity in vitro. Cytokines such as interleukin-2 and 
the colony stimulating factors, are not directly cytotoxic to tumour cells, 
but act by leucocyte activation or growth promotion, and thus playa 
secondary, but important, role in tumour cell destruction. 
In addition to the multiple biological functions exhibited by most 
cytokines, the presence of more than one cytokine in a cellular 
environment, which would normally be expected in vivo, often results in 
activities not attributable to an individual cytokine. For example, the 
cytotoxiC activity of TNFa was augmented by addition of any of the 
interferons (Sugarman et al., 1985). Negative interactions also occur, 
since IL-1 has been reported to inhibit TNFa cytotoxicity (Holtman and 
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Wallach, 1987). However, IL-1 also synergised with TNFa In the 
elimination of cultured melanoma cells (Ruggerio and Baglioni, 1987), 
demonstrating that the action of the same combination of cytokines can 
vary on different target cell lines. 
Experimental Design 
Seven tumour cell lines were chosen for this study. These included 4 
melanoma cell lines. A375 - an amelanotic melanoma cell line derived 
from metastatic melanoma. DX3 - a second amelanotic metastatic 
melanoma for comparison with A375. L T5.1 - DX3 cells which had been 
passaged through a nude mouse to increase its metastatic activity. SK23 
- a metastatic melanotic melanoma. Also included were the 
erythroblastoma cell line K562 , which is known to be NK sensitive: 
Epstein-Barr virus transformed B-cell line, Daudi, which is resistant to 
NK cells in 4h cytotoxicity assays: and U937, a promonocytic cell line 
which is sensitive to killing by TNFa. 
The aims of this phase of experimentation were firstly to determine the 
cytotoxic activity of several cytokines (IL-1, IL-2, TNFa, L T and IFNy, as 
well as that of purified lymphocytes and monocytes on the seven cell 
lines chosen for study, and secondly to study the role of pre-incubation 
of tumour cells with cytokines and/or cytotoxic drugs on lymphocyte and 
monocyte tumouricidal activity. 
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3.1 Cytokines 
3.1.1 Direct Cytotoxicity of Tumour Cells by Cytokines 
A large number of cytokines which modulate the immune response to 
tumour cells in vivo and in vitro have been reported. Several cytokines 
(TNFa, L T, IL-2, IFNy and IL-1~) were chosen for study, because they 
have been reported to exert a range of direct and modulatory effects, 
alone or in combination, on leucocytes and tumour cells. Additionally, 
most of them have been used clinical trials to investigate their role as 
anti-cancer agents alone or in combination with cytotoxic drugs and/or 
adoptive immunotherapy by leucocytes. 
3.1.2 Tumour Necrosis Factor Alpha (TNFa) 
Tumour necrosis factor-a has been reported to be directly cytotoxic for a 
large variety of tumour cell lines in vitro (Helson et a/. J 1975), although 
many other lines have proved to be resistant to attack by this cytokine. 
The cytotoxic activity of TNFa for the 7 cell lines, and the effect of pre-
treatment of target cells with Act-O on TNFa killing was investigated. 
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Figure 3.1 
Time Course of TNFa Cytotoxicity to A375 
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FIGURE 3.1. Time course of TNFa cytotoxicity against A375 cells +/- Act-D. 
Tumour necrosis factor-a (1000U/ml) was incubated in 4 parallel cultures with 
Na51cr04 labelled A375 cells untreated or pre-incubated for 3h with Act-D 
(0.1 "g/ml). Supernatants were harvested after 2, 4, Sand 18h, their radioactivity 
measured, and specific cytotoxicity calculated. In 3 experiments (means and 
SEMs shown), Act-D pre-treatment of A375 cells resulted in significant (p<0.05 by 
MWU and PTT) TNFa cytotoxicity at Sand 18h. At 18h (but not 2,4 or Sh). Killing 
of Act-D pre-treated A375 cells by TNFa was significantly greater (p<0.05 by MWU 
and PTT) than that of untreated A375 cells. 
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A375 cells were incubated with recombinant TNFa at a concentration of 
1 OOOU/ml for 2, 4, 6 and 18h, in the presence or absence of Act-D 
(0.1 mg/ml) (Figure 3.1). Each experiment was performed in triplicate. In 
3 such time course experiments no significant tumour cell killing was 
seen at incubation times less than 18h, irrespective of whether the target 
cells were untreated or pre-treated with Act-D for 3h, although some 
cytotoxicity (6%; compared with spontaneous Na51 Cr04 release) was 
seen at 6h for Act-D pretreated A375 cells. Cytotoxicity mediated by 
TNFa against Act-D pretreated A375 cells was significantly greater than 
against untreated A375 cells after 18h, indicating that A375 cells were 
sensitised to the action of TNFa (at 1000U/ml) by pre-incubation with 
Act-D. 
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FIGURE 3.2. Dose response of TNF a cytotoxicity against A375 cells. Tumour 
necrosis factor-a (31.25-1000U/ml) was incubated with Na51Cr04 labelled A375 
cells for 18h and cytotoxicity measured. The results shown are means and SEMs 
from 12 experiments. Significant (p<0.05 by PTT and MWU) TNF a cytotoxicity 
against untreated A375 cells was observed at [TNF a] above 62.5U/ml, and at all 
concentrations of TNF a tested against A375 cells pre-treated with Act-D (0.1 "g/ml 
for 3h). Pre-incubation of the tumour cells with Act-D significantly (p<0.05 by 
PTT and MWU) increased TNFa cytotoxicity compared with untreated A375 cells 
at all concentrations of TNFa tested. 
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Figure 3.2 shows the mean dose response curves for TNFa cytotoxicity 
(at concentrations of 31.25, 62.5, 125, 250, 500 and 1000U/ml) for A375 
cells at 18h from 12 experiments. Tumour necrosis factor-a alone 
induced relatively low levels of A375 cell killing at the highest 
concentration tested (i.e. 1000U/ml). Pre-treatment of the target cells 
with Act-O (at 0.1 mg/ml) significantly enhanced TNFa cytotoxicity These 
results show that TNFa was not highly cytotoxic for fresh A375 cells at 
the concentrations used, and that pre-treatment with Act-O caused the 
target cells to become susceptible to killing by this cytokine, although the 
actual levels of cytotoxicity values were still relatively low at 
concentrations up to 1000U/ml. 
In 4 further experiments, inclusion of a monoclonal antibody against 
TNFa significantly inhibited killing of Act-O pretreated A375 cells by 
TNFa at all concentrations tested. These experiments indicate that 
TNFa killing was specific and that the monoclonal antibody was effective 
in blocking the tumouricidal activity of TNFa (Figure 3.3). 
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FIGURE 3.3. Effect of anti-TNFa antibody on TNFa killing of A375 cells. Tumour 
necrosis factor-a (31.25-1000U/ml) cytotoxicity for A375 cells (pre-treated with 
Act-O (O.1I'g/ml)) was measured alone and in the presence of a neutralising 
antibody to TNFa (10l'g/ml). In 4 experiment (means and SEMs are shown), 
cytotoxicity was significantly inhibited in the presence of the antibody at all 
concentrations of TNFa tested (p<O.05 by MWU and PTT; also by WSR and PTT 
for comparison of complete dose response curves). 
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Tumour necrosis factor-a cytotoxicity for three other melanoma cell lines , 
as well as K562 , Daudi and U937 was also measured. Table 3.1 
summarises the maximal TNFa killing (at 1000U/ml) of cell lines 
untreated and pre-incubated with Act-D (O.1Ilg/ml) for 3h prior to addition 
of cytokine. 
Cell Source n Cytotoxicity Cytotoxicity 5 ig n ificance 
Line -ActO (%) +ActO (%) 
A375 Melanoma 12 5 (1) 24 (3) p<0.05 
OX3 Melanoma 3 6 (1) 26 (2) p<0.05 
SK23 Melanoma 3 18 (2) 18 (3) p>O.05 
LT5.1 Melanoma 3 8 (3) 21 (3) p<0.05 
K562 Erythroblast 6 16 (2) 15 (5) p>O.05 
Oaudi EBV, B-Cell 4 17 (4) 15 (4) p>O.05 
U937 Promonocyte 3 23 (5) 52 (7) p<0.05 
. . TABLE 3.1. TNFa klllmg of seven tumour cell lines. Tumour necrosis factor-a 
(1000U/ml) cytotoxicity (after 18h) was assessed against seven tumour cell lines 
untreated or pre-incubated with Act-O (0.1 "g/ml for 3h). n = number of 
experiments, and numbers in brackets are SEMs. TNF a was cytotoxic for all cell 
lines (p<0.05 compared to spontaneous release, by MWU), but SK23, K562, Oaudi 
and U937 cells were more sensitive (p<0.05) to the action of TNFa than the A375, 
OX3 or L TS.1 cell lines. Pre-treatment of the tumour cells with Act-O increased 
TNFa killing of some, but not other, cell lines (see significance column: MWU 
and PTT). 
As with A375 cells, the DX3 and L T5.1 cell lines were relatively 
unresponsive to the action of TNFa alone, but pre-treatment with 
Actinomycin-D enhanced (p<O.05) their susceptibility to killing. While 
SK23 K562 and Daudi cells were more sensitive than A375, DX3 and , 
L T5.1 cells to the action of TNFu, there was no significant increase in 
cytotoxicity following preincubation with Act-D. The promonocyte cell line 
U937 was sensitive to TNFa, untreated, at a comparable level to the 
melanoma lines (A375, DX3 and L T5.1) after pre-treatment with Act-D. In 
contrast to the 3 other TNFa sensitive cell lines (SK23, K562 and 
Daudi), killing of U937 cells by TNFa was more than doubled by pre-
incubation with Act-D. These results show that there is considerable 
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heterogeneity in the susceptibility of the various cell lines to killing by 
TNFa, as well as in their ability to be sensitised by Act-D to the action of 
TNFa. 
Further studies on the direct action of cytokines on tumour cells were 
performed using only the A375 melanoma cell line, because of its 
inducible sensitivity to killing by Act-D, although either DX3 or L T5.1 
cells would have been equally suitable. 
3.1.3 Cytotoxicity of A375 cells by IL-1 {j, IFN-y IL-2 and L T 
Using the same experimental design described for TNFa in the previous 
section, several other cytokines were tested for their direct cytotoxic 
activity against A375 melanoma cells, in order to determine whether they 
are directly involved as leucocyte cytotoxic effector molecules or whether 
they have a secondary role in the induction of other leucocyte cytotoxic 
mechanisms. Incubation of A375 cells with IL-1 ~ (0.001-100U/ml), IFNy 
(0.001-100U/ml), IL-2 (15-500U/ml) or LT (39-1250U/ml) for 2, 4 or 6h 
did not result in any detectable cytotoxicity (p>0.05 compared to 
spontaneous Na51 Cr04 release), but after 18h minimal killing was 
observed with L T at 1250U/ml. Table 3.2 summarises the maximal (at 
the highest dose in each case) killing of A375 cells untreated or pre-
incubated with Act-D by each of the above cytokines after 18h. Pre-
treatment of the tumour cells with Act-D resulted in increased killing by 
IL-1~, IFNyand L T (p<0.05 compared to untreated target cells), but IL-2 
demonstrated no significant (p>0.05 compared to spontaneous Na51 Cr04 
release) cytotoxiC activity on A375 cells before or after pre-treatment 
with Act-D. 
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Cytokine Concentration n Cytotoxicity Cytotoxicity Significance 
-ActO (%) +ActO (%) 
IL-1,s 100U/ml 3 1 (1) 17 (S) p<O.05 
IL-2 SOOU/ml 4 o (0) o (0) p>O.OS 
IFN)' 100U/ml 4 0(0) 13 (S) p<O.05 
LT 12S0U/mi 3 6 (2) !9 (6) p<O.05 
.. TABLE 3.2. Cytokme killing of A375 melanoma cells. Five cytokines were 
assessed for their cytotoxicity against untreated or Act-D pre-treated A375 cells 
after 18h incubation. The number of experiments is shown in the column headed 
n, and numbers in brackets are SEMs. Only Iymphotoxin was cytotoxic for 
untreated A375 cells (p<O.05 compared to spontaneous release by MWU and 
PTT). Actinomycin-D pre-treated A375 cells were sensitive to IL-1 {j and IFN-y 
killing, and L T cytotoxicity was augmented (p<O.05 by MWU and PTT) by this 
treatment. 
The cytokines tested were not highly cytotoxic (i.e., <20% specific 
cytotoxicity) for A375 cells, even after target cell pre-treatment with Act-
D. However, a longer incubation time may have been required for 
maximal cytokine killing to occur. Alternatively, other effects such as 
cytostasis (which cannot be determined using Na51 Cr04 release) could 
have been induced. Further experiments were therefore performed to 
examine the effect of incubation with the cytokines IFNy and IL-2 (which 
representative of cytokines which are directly cytotoxic and which have 
secondary effects on tumour cells) on the number of A375 cells 
recovered from culture after several days in culture. 
3.1.4 Effect of Cytokines on Growth of A375 Cells 
Interferon-y has been reported to be cytotoxic to many tumour cell lines 
in vitro after 24-48h, but the Na51 Cr04 release assay is unsuitable for 
these longer term assays (section 2.7.1). Some melanoma cell lines 
have been reported to express high (p55/p75) and low (p75) affinity IL-2 
receptors (Rimoldi, 1993). The effect of IFNy and IL-2 on A375 cells was 
therefore determined by incubation of tumour cells alone or in the 
presence of various concentrations of IFNy or IL-2 for 48 or 72h 
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In 3 experiments, A375 cells at a single cell density (1 in 5 dilution from 
a confluent 25cm2 tissue culture flask), were incubated in RPMIIFCS 
alone or containing IFNy (250, 500 and 1000U/ml), or IL-2 (250, 500, 
1000 and 2000U/ml of A375 cells for 48h (IFNy) or 72h (IL-2). The cells 
were removed from the flasks and the number of viable cells (trypan blue 
negative) counted. 
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FIGURE 3.4. Effect of IFNI' on A375 cell growth. To each of 4 x 25cm2 tissue 
culture flasks was added 7 .5x1 05 A375 cells alone or containing IFNI' (250, 500 or 
1000U/ml), and incubated for 48h at 37°C. The cells were detached from plastiC 
and a cell count and viability performed. Cell viability was >90% in all cases. The 
means (of viable cells recovered) and SEMs from 3 experiments are shown. In 
the absence if IFNI', A375 cells expanded in number (p<0.05 by MWU and PTT), 
but a progressive decrease in cell yield was observed with increasing IFNI' 
concentration, which was significant (p<0.05 by MWU and PTT) at 500 and 
1000U/ml. 
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A significant decrease in the number of cells recovered from culture was 
observed when target cells were incubated with IFNy at concentrations 
of 500 and 1000U/ml, but not 250U/ml (Figure 3.4). These results 
indicated that high concentrations of IFNy were cytostatic, or cytotoxic, 
for A375 cells in a dose-dependent manner after 48h. This reduction in 
cell yield could be due to the direct cytotoxic action of IFNy or could 
result from natural cell death following IFNy-induced cytostasis. 
In contrast to IFNy, IL-2 induced a dose-dependent increase in the 
number of A375 cells recovered from culture (Figure 3.5), reaching a 
maximum at 1000-2000U/ml. In the absence of IL-2, more cells were 
recovered from culture than in the IFNy experiments. This was most 
likely due to the extra 24h incubation time in the IL-2 experiments which 
gave a greater yield of cells. These results suggest that IL-2 may be a 
growth promoting factor for A375 cells. 
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FIGURE 3.5. Effect of IL-2 on A375 cell growth. Tumour cells (A375; 7.5x105 in 
10ml RPMIIFCS) were added to 5 x 25cm2 tissue culture flasks alone or in the 
presence of IL-2 (250-2000U/ml), and incubated for 72h at 37°C. The cells were 
detached from plastic and a cell count and viability performed. Cell viability was 
>90% in all flasks. The means and SEMs from 3 experiments are shown. Addition 
of IL-2 to the cultures resulted in an increased yield of cells at all concentrations 
(p<0.05 at all pOints compared to no added IL-2, by MWU and PTT). In addition, a 
significant increase in yield was observed between 250 and 500U/ml (p<0.05 by 
MWU and PTT) as well as 500 and 1000U/ml (p<0.05 by MWU and PTT), but not 
between 1000-2000U/ml IL-2 (p>0.05). 
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For IL-2 to promote cell growth it must first bind to one of its receptors. 
Experiments were thus performed to determine whether A375 cells 
expressed p55 (CD25; IL-2 receptor-a.) or p75 (IL-2 receptor-~) IL-2 
receptors (section 2.5.0). Figure 3.6a is a representative histogram 
showing log fluorescence for direct FITC labelled anti-CD25 monoclonal 
antibody on the surface of A375 cells together with the corresponding 
isotype control. 
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FIGURE 3.6. A375 cell surface CD25 and p75 IL-2 receptors. A375 cells were 
labelled with anti-CD25, anti-p75 or isotype control as described in section 2.4. 
Figure 3.6a shows that the histogram for anti-CD25 staining is right shifted 
compared to the isotype control, indicating that A375 cells possess the IL-2 
receptor (a-chain). In contrast, no positive events were detected for the p75 
antigen (figure 3.6b), indicating that A375 cells do not possess the IL-2 receptor 
p-chain. 
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The CD25 histogram is right shifted compared with the control, indicating 
that the p55 molecule was present on these cells. Using the calculations 
described in section 2.5.3, a mean (from 3 experiments) of 11456 (+/_ 
4267) p55 IL-2 receptors was detected on cultured A375 cells. In 
contrast figure 3.6b shows that no events from directly labelled PE anti-
p75 were more fluorescent than the isotype control, indicating the 
absence of p75 on A375 cells. These results show that low affinity IL-2 
receptors are present on A375 cells, and provides further evidence that 
IL-2 is a growth stimulatory molecule for this cell line. 
3.2.0 Lymphocyte Cytotoxicity Against Tumour Cells 
The lymphocyte population from normal donors is comprised of several 
subsets, some of which are spontaneously and non-specifically cytotoxic 
for tumour cells. Examples of these are the NK cells (CD4-, CD8-, CD3-, 
CD16+, CD56+) and the CD16+, CD8+ cytotoxic T-cells. Other cells 
such as cytotoxic T-cells (CD3+, CD8+, CD3+, CD16-) are antigen-
specific and require antigen processing and presentation via the T-cell 
receptor and MHC before they are able to kill a specific cell line, or a 
related group of cell lines. A minority of CD8+ T -cells however, are able 
to kill tumour cells in the absence of specific antigen processing. Most 
tumour infiltrating lymphocytes comprise CD8+ antigen specific cytotoxic 
T-cells, although CD4+ T-cells and NK cells have been detected in some 
tumours. 
Experiments were performed to (1.) evaluate the ability of the whole 
lymphocyte population from normal donors to kill spontaneously the 4 
melanoma cell lines, K562 (NK-sensitive), Daudi (NK-resistant), and the 
promonocyte cell line U937, untreated or pre-incubated with the protein 
synthesis inhibitors Act-D or cycloheximide; (2.) to determine the relative 
contributions of NK cells and cytotoxic T -cells to lymphocyte killing of 
A375 cells by depletion of CD8+ cells from whole lymphocyte 
populations; (3.) to investigate further the mechanisms of lymphocyte 
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killing by incorporating monoclonal blocking antibodies against TNFa 
and L T in the cytotoxicity assay. 
3.2.1 Lymphocyte Cytotoxicity of A375 Melanoma Cells 
Direct lymphocyte cytotoxicity was assessed using non-adherent 
lymphocytes which were >89% pure (section 2.2.10). 
Fresh non-adherent lymphocytes were incubated with A375 cells +/- Act-
O at effector:target ratios of 50: 1 to 1.6: 1 in doubling dilution for 18h at 
37°C (section 2.3.1.3). 
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FIGURE 3.7. Lymphocyte killing of A375 cells. Lymphocytes were incubated for 
18h with Na51Cr04 labelled A375 cells alone or pre-treated with Act-D (0.1 Itg/ml) 
for 3h, and the supernatants harvested and counted. The results shown are 
means and SEMs of specific lymphocyte cytotoxicity from 19 experiments. 
Lymphocytes were cytotoxic for untreated (6%) and Act-D pre-treated A375 cells 
at an effector target ratio (E:T) of 1.6:1 (p<0.05 compared to spontaneous release 
by WSR and PTT), which rose significantly to 15% and 50% (p<0.05 by WSR and 
PTT) respectively at an E:T of 50:1. Pre-treatment with Act-D significantly 
increased lymphocyte killing of A375 cells at all E:T (p<0.05 by WSR and PTT) 
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Figure 3.7 shows that lymphocyte cytotoxicity was effector:target cell 
ratio dependent giving maximal killing at an effector:target cell ratio of 
50: 1. Higher effector: target cell ratios were not used because there 
would be insufficient cells for experiments to be performed , and nutrient 
deprivation would have become a contributory factor to cytotoxicity in 
longer term assays. Actinomycin-D significantly (p<0.05) increased 
lymphocyte tumouricidal activity at all effector:target cell ratios tested. 
The slope of the cytotoxicity curve for untreated A375 cells was lower 
than that for Act-D pre-treated A375 cells, indicating that the mechanism 
of lymphocyte killing may not have been the same in each case. Maximal 
killing of untreated A375 cells by lymphocytes was greater than that 
seen with any of the cytokines alone or in combination, indicating either 
that there are other factors involved in the mechanism of lymphocyte 
killing of A375 cells or that the concentrations of effector cytokines at the 
cell-cell junctions reached levels in excess of those used in this study. 
3.2.2 Time Course for Lymphocyte Killing of Tumour Cells 
Tumour cell lines are extremely heterogeneous in their sensitivity to 
cytotoxic effectors, both in the degree of cytotoxicity generated and the 
incubation time required for maximal killing. For this reason, the time 
course for lymphocyte killing of K562 cells (already known to be 
relatively sensitive to lymphocyte killing after 4h, and A375 cells was 
investigated. 
Figures 3.8 and 3.9 show the maximal lymphocyte cytotoxicity of K562 
and A375 cells respectively (+1- Act-D), after 2, 46 and 18h incubation. 
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FIGURE 3.8 Lymphocytes were incubated with K562 cells at an effector:target 
cell ratio of 50:1. Four plates were set up in para"el, and harvested after 2, 4, 6 or 
18h. The means and SEMS from 3 experiments are shown. Significant 
lymphocyte cytotoxicity of both untreated and Act-O pretreated target cells was 
observed after 2h (compared to spontaneous release; p<0.05 by MWU and PTT) 
which further increased after 4 (killing at 6h was not significantly different from 
that at 4h; p>0.05 by MWU and PTT) and 18h (p<0.05 compared to previous time 
pOint by MWU and PTT). Act-O pretreatment did not significantly affect 
lymphocyte killing of K562 cells at any time point (compared to untreated cells; 
p>0.05 by MWU and PTT). 
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FIGURE 3.9. Time course of lymphocyte killing of A375 cells +/- Act-D. 
Lymphocytes were incubated with A375 cells at an effector:target cell ratio of 
50:1. Four plates were set up in parallel, and harvested after 2, 4, 6 or 18h. The 
means and SEMS from 3 experiments are shown. Significant lymphocyte 
cytotoxicity (p<0.05, compared to spontaneous release by MWU and PTT) of 
untreated A375 cells (8%) was observed after 6h which increased to 25% after 18h 
(p<0.05 compared to 6h by MWU and PTT). Act-D treated A375 cells were 
sensitive to lymphocyte killing after 4h (5%; p<0.05 compared to spontaneous 
release by MWU and PTT), which rose to 36% after 18h (compared to 4 and 6h; 
p<0.05 by MWU and PTT). Act-D pretreatment significantly increased lymphocyte 
cytotoxicity of A375 cells after 18h (p<0.05 by MWU and PTT). 
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Lymphocytes were cytotoxic for K562 cells after 2h, and maximal killing 
was observed after 18h. Actinomycin-O pre-treatment of K562 cells did 
not result in Significantly (p>0.05) increased lymphocyte cytotoxicity at 
any time point. In contrast, A375 cells were insensitive to lymphocyte 
killing at 2 and 4h, but cytotoxicity was observed at 6h (p<0.05 compared 
to spontaneous counts), which increased further after 18h incubation. In 
addition, Act-O Significantly increased lymphocyte killing of A375 cells 
only after 18h incubation (p<0.05). 
3.2.3 Effect of Cycloheximide on Lymphocyte Killing of A375 Cells 
Increased lymphocyte cytotoxicity was not observed when A375 cells 
were pre-incubated for 3h with cycloheximide (a post-transcriptional 
protein synthesis inhibitor) at concentrations of 0.01, 0.1, 1 or 10mg/ml, 
(Figure 3.10), compared with untreated tumour cells. Pre-incubation of 
A375 cells with Act-O as a positive control resulted in increased 
cytotoxicity, as described in the previous sections. 
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FIGURE 3.10. Effect of cycloheximide pre-treatment on lymphocyte killing of 
A375 cells. Lymphocyte cytotoxicity was assessed against A375 cells untreated 
or pre-incubated with Act-D (0.1 #,g/ml) or cycloheximide (eX, 0.01-10#,g/ml), at an 
E:T of 50:1 after 18h incubation. Results are means and SEMs from 3 
experiments. Although Act-D enhanced lymphocyte killing (p<0.05 by MWU and 
PTT), no augmentation was observed by target cell pre-treatment with ex at any 
concentration tested (p>0.05 by MWU and PTT). 
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3.2.4 Subset Depleted Lymphocyte Killing of A375 Cells 
Highly purified subpopulations of lymphocytes for cytotoxicity 
experiments were prepared using a Becton Dickinson Facstar plus cell 
sorter. In order to separate the NK population from the T -cells, non-
adherent lymphocytes (MNC incubated at 37°C overnight, section 
2.2.12) were divided into 2 aliquots, one of which was incubated with 
FITC labelled anti-CD8 monoclonal antibody, and passed through the 
cell sorter (section 2.2.12). The isolated population containing CD8+ 
cells was discarded and the remaining unlabelled cells, which were 
depleted of CD8+ cells was assessed for viability (>95% viable cells) 
and adjusted to 5 x 106 cells/ml for use in the cytotoxicity assay; after 
sorting <4%) (+1- 2%, n=3) of CD8+ cells remained. The second aliquot 
was assessed for viability (section 2.2.16, >95% viable cells, n=3), 
adjusted to 5 x 106 cellslml and included in the cytotoxicity assay. 
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FIGURE 3.11. Effect of CD8+ cell depletion on lymphocyte killing of A375 cells. 
Lymphocytes were depleted of CD8+ cells as described in section 2.1.12. Cell 
viability was >95% for the whole and CD8+ cell depleted populations. The 
effector cells were incubated with untreated or Act-D pre-treated A375 cells for 
18h at an E:T of 50:1 and specific cytotoxicity determined. In 3 experiments 
(means and SEMs are shown), removal of CD8+ cells from the lymphocyte 
population resulted in a 79% decrease in cytotoxicity (p<0.05 by MWU and PTT). 
Killing by fresh lymphocytes and CD8+ depleted cells was augmented by 
pretreatment of the target cells with Act-D (p<0.05 by MWU and PTT). However, 
cytotoxicity of Act-O pre-treated A375 cells by C08+ depleted lymphocytes was 
significantly lower than that of whole lymphocytes against untreated tumour 
cells (p<0.05 by MWU and PTT). 
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Figure 3.11 shows that depletion of CD8+ cells almost completely 
abrogated the cytotoxic activity of lymphocytes against A375 cells. Pre-
treatment of the target cells with Act-D enhanced the low level of killing 
(3%,) by the CD8+ depleted cell population, as well as that of the whole 
lymphocyte population (as previously observed in section 3.2.2), but not 
to the same level of cytotoxicity observed in the whole lymphocyte 
population. It would therefore appear that the majc~ity of lymphocyte 
cytotoxicity against A375 cells is due to cytotoxic CD8+ T-cells, rather 
than NK cells since this population was still present in the CD8+ 
depleted cell preparation. The residual cytotoxicity observed may have 
been due to some remaining CD8+ cells, monocytes or NK cells. 
3.2.5 Lymphocyte Cytotoxicity to All Tumour Cell Lines 
Non-adherent lymphocytes were tested for their cytotoxic activity against 
the 4 human melanoma cell lines A375, DX3, L T5.1 and SK23, as well 
as NK sensitive K562 cells (erythroblastoma) and NK resistant Daudi 
cells (EBV transformed B cells). Table 3.3 shows the mean maximal 
(Effector:Target Ratio 50: 1) lymphocyte cytotoxicity for each cell line 
alone and following pre-incubation with Act-D. 
Lymphocytes were directly cytotoxic for all lines tested and Act-D pre-
incubation of the target cells resulted in increased tumouricidal activity 
only with the A375 and DX3 and SK23 melanoma lines. The melanotic 
melanoma cell line SK23 was the least susceptible to the action of 
lymphocytes. Daudi cells were moderately sensitive to lymphocyte 
killing, indicating either that an effector cell population other than NK 
cells was present or that Daudi cells become sensitive to lymphocyte 
killing after 18h The standard assay for the cytotoxicity of an NK 
resistant cell line is normally 4h. 
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Source n Cytotoxicity Cytotoxicity Significance 
-ActO (%) +ActO (%) 
A375 Melanoma 19 27 (3) 48 (3) p<0.05 
OX3 Melanoma 3 31 (5) 56 (2) p<0.05 
SK23 Melanoma 3 18 (3) 48 (5) p<0.05 
LT5.1 Melanoma 3 32 (2) 41 (4) p>O.05 
K562 Erythroblast 4 42 (5) 47 (5) p>O.05 
Oaudi EBV, B-Cell 3 27 (7) 22 (1) p>O.05 
U937 Promonocyte 3 57 (5) 53 (1) p>O.05 
.. . TABLE 3.3. Summary of lymphocyte CytOtOXICity against 7 cell lines. Untreated or 
Act-O pre-treated tumour cells were incubated with lymphocytes at an E:T ratio 
of 50:1 for 18h at 370C. Lymphocytes were cytotoxic for all cell lines (p<0.05 
compared to spontaneous release by MWU and PTT). Pretreatment of the tumour 
cells with Act-O significantly increased (significance column) lymphocyte killing 
of A375, OX3 and SK23 cells compared to untreated target cells. 
Cytotoxicity of tumour cell lines by lymphocytes was greater than that 
seen by any cytokine alone (sections 3.1.2 and 3.1.3) or in combination 
(pairs, section 3.1.3). There are several possible explanations for this, 
two of which have already been mentioned in the above sections (i.e. 
increased cytokine concentration at membrane junctions between 
effector and target cells, and effector cells may secrete a "cocktail" of 
effector molecules which are synergistic in their cytotoxic activity). Other 
explanations include 1. lymphocytes may not use these cytokines at all, 
but employ an entirely different mechanism of killing such as perforins or 
proteolytic enzymes. 2. Cytokines bound to the cell surface may behave 
differently to those secreted into the medium, as is the case with 
membrane bound TNFu. Further experiments on the mechanism of 
lymphocyte killing will be covered together with the possible mechanism 
of action of LAK cells in the next chapter. 
Actinomycin-D enhanced the killing of some, but not other, cell lines to 
killing by cytokines and lymphocytes (table 3.3, significance column). Its 
mechanism of action is thought to work through protein synthesis 
inhibition at the level of mRNA synthesis. 
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3.2.6 Monocyte Cytotoxicity against Tumour Cell Lines 
In addition to lymphocytes, monocytes are also present as infiltrating 
cells in many solid tumours, and have a large repertoire of direct 
cytotoxic effector mechanisms. Additionally, monocytes can present 
antigens and, thus, specifically activate T -cells to become tumouricidal. 
They also produce monokines which can modulate the behaviour of 
other monocytes, lymphocytes and tumour cells, as well as the 
extracellular matrix and the coagulation system. The direct cytotoxic 
activity of monocytes for A375 and K562 cells was therefore assessed. 
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FIGURE 3.12. Monocyte cytotoxicity of A375 cells +/- Act-D. Monocyte 
cytotoxicity was assessed against untreated or Act-D pre-treated A375 cells at 
E:T ratios between 1.6:1 - 50:1 in an 18h Na51Cr04 releas eassay. The means and 
SEMs from 8 experiments are shown. On untreated A375 cells, monocytes were 
cytotoxic at an E:T of 3.1:1 (5%; compared to spontaneous release by WSR and 
PTT), which reached a maximum of 17% at an E:T of 50:1 (p<0.05 compared to 
25:1 by WSR and PTT). Pre-treatment of A375 cells with Act-D significantly 
enhanced monocyte cytotoxicity at E:T of 3.1:1 and above, reaching a maximum 
of 35% at 50:1 (p<0.05 compared to 25:1 by WSR and PTT). 
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Freshly isolated monocytes were incubated for 18h with fresh A375 cells 
or A375 cells pre-treated with Act-O for 3h. Figure 3.12 shows the mean 
dose response curves from 8 experiments. Maximal monocyte killing 
occurred at an effector:target cell ratio of 50: 1. Pre-treatment of A375 
cells with Act-O significantly increased monocyte tumouricidal activity at 
all effector:target cell ratios. 
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FIGURE 3.13. Monocyte cytotoxicity of K562 cells. Monocytes were incubated 
with Na51Cr04 labelled K562 cells at E:T ratios of 1.6:1 - 50:1. The means and 
SEMs from 3 experiments are shown. After 18h incubation, monocytes were 
cytotoxic against K562 cells (p<0.05 compared to spontaneous release by MWU 
and PTT), which increased in a dose dependent fashion to 73% at 50:1. 
Cytotoxicity at 50:1 was significantly greater (p<0.05 by MWU and PTT) than that 
at 6.3:1, but not 12.5:1 or 25:1. 
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50:1 
Monocyte cytotoxicity against untreated K562 cells was also evaluated. 
Figure 3.13 shows the mean dose response curve from 3 experiments. 
Maximal cytotoxicity seen at an effector:target cell ratio of 50: 1, was 
considerably higher than that observed at 50: 1 against A375 cells, 
indicating that K562 cells were more sensitive to killing by monocytes. 
Pre-treatment of K562 cells with Act-O was not performed since no 
augmentation of killing was seen with TNFa or lymphocytes as effectors 
(sections 3.1.2 and 3.2.2 respectively). 
3.2.7 Role of LPS in Monocyte Cytotoxicity of A375 Cells 
Bacterial lipopolysaccharide activates resting monocytes causing 
production and secretion of cytokines including TNFa, IFNy and IL-1. 
The presence of LPS in the monocyte separation medium could, 
therefore, activate monocytes to become non-specifically tumouricidal. 
Lipopolysaccharide was incubated with A375 cells at concentrations of 
0.001, 0.01, 0.1, 1.0, 10, 100 and 1 OOO~g/ml for 18h. Cytotoxicity was 
only seen at the highest concentrations tested (i.e. 100 and 1 OOO~g/ml, 
see Figure 3.14) 
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FIGURE 3.14. LPS cytotoxicity of A375 cells. Lipopolysaccharide (0.001-
1000pg/ml) was incubated with Na51Cr04 labelled A375 cells for 18h at 37°C. The 
supernatants were harvested and specific cytotoxicity calculated. The means 
and SEMs from 4 experiments are shown. Significant cytotoxicity (7%; p<0.05 by 
MWU compared to spontaneous release) was observed at 100llg/mi LPS, which 
rose to 19% at 1000pg/ml (p<O.05 compared to 100pg/ml by MWU). 
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These concentrations are far in excess of those which may be present in 
any tissue culture medium and thus it can be considered that any 
contaminating LPS would not be cytotoxic to the tumour cells. However, 
monocytes are activated by as little as 0.01 ~g/ml LPS (Chen et al., 1986) 
which may be present in the tissue culture medium. To test whether 
monocytes could be activated (or further activated) by LPS to become 
cytotoxic, monocytes were incubated with A375 cells for 18h in the 
presence or absence of LPS (1 O~g/ml). In 2 experiments LPS had no 
effect on monocyte killing. However, the monocytes may have already 
been activated by contaminating LPS in the tissue culture medium. To 
circumvent this problem, monocyte cytotoxicity was performed in tissue 
culture media containing polymyxin-B (an antibiotic which inhibits LPS 
activity). No difference in monocyte killing of A375 cells (pre-treated with 
Act-D) was seen between experiments performed in 10% FCS or 10% 
FCS containing polymyxin-B. In addition, samples of the tissue culture 
media were sent to Wickham laboratories for a rabbit pyrogenicity test 
(British Pharmacopoeia 1993, page A 172), which is a standard test used 
to judge the suitability of pharmaceuticals for injection into patients. 
RPMI and 10% FCS induced a temperature rise of 0.50C and 0.30C 
respectively, and were thus considered to have "passed" the test, and 
have been non-pyrogenic. These results suggest that any small amounts 
of LPS contaminating the tissue culture media did not contribute 
significantly to the monocyte cytotoxicity observed. 
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3.2.8 Comparison of A375 Cell Killing by TNFO', Lymphocytes and 
Monocytes. 
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FIGURE 3.15. Comparison of TNFa, monocyte and lymphocyte killing of A375 
cells. Cytotoxicity of untreated and Act-D pre-treated A375 cells by TNFa (n=12; 
section 3.1.2), lymphocytes (n=19; section 3.2.5) and monocytes (n=8; section 
3.2.6) is shown. Statistical analysis comparing the levels of killing by each 
effector is presented in table 3.4. 
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Figure 3.15 shows the mean maximal cytotoxicity of A375 cells in the 
presence or absence of Act-D, induced by TNFa (1000U/ml; data from 
section 3.1.2), lymphocytes (data from section 3.2.5) or monocytes (data 
from section 3.2.6). Direct killing of untreated A375 cells by lymphocytes 
was not significantly greater than that of monocytes, but both effector 
cell types were significantly more cytotoxic than TNFa. Act-D pre-
treatment of A375 cells significantly enhanced cytotoxicity over that 
observed using untreated A375 cells for each effector. On Act-D pre-
treated target cells however, lymphocyte killing was significantly higher 
than that of monocytes which was in turn significantly higher than that of 
TNFa. Table 3.4 summarises the p-values obtained from a Mann-
Whitney U-test between each effector-target combination. 
TNF +Act-D Lymphocytes Lymphocytes Monocytes Monocytes 
+Act-D +Act-D 
TNF <0.0001 <0.0001 <0.0001 <0.001 <0.0001 
TNF +Act-D NS <0.0001 NS <0.01 
Lymphocytes <0.001 NS NS 
Lymphocytes 0.0001 <0.05 
+Act-D 
Monocytes <0.01 
.. TABLE 3.4. Statistical comparison of TNFa, monocyte and lymphocyte klllmg of 
A375 cells +/- Act-D. Statistical analysis was carried out on the data presented in 
figure 3.15, to compare the cytotoxic activities of TNFa (1000U/ml), lymphocytes 
(E:T 50:1) and monocytes (E:T 50:1) against untreated or Act-D pre-treated A375 
cells. On untreated A375 cells, lymphocytes and monocytes killed to a similar 
degree, but were both more cytotoxic than TNF a. Pre-incubation of the tumour 
cells with Act-D increased killing by the 3 effectors, and the levels of cytotoxicity 
were in the order lymphocytes> monocytes > TNF a. 
These results show that lymphocytes and monocytes killed A375 cells 
more effectively than did TNFa, either reaffirming that local 
concentrations of cytokine at effector-target cell junctions may be much 
higher than those used here, or that lymphocytes and monocytes do not 
exclusively employ TNFa as an effector molecule. Pre-treatment of A375 
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cells with Act-O enhanced lymphocyte and monocyte cytotoxicity to the 
same degree (54 010), although the non-significantly higher value for 
lymphocyte killing of untreated target cells became significantly higher 
than that of monocytes after Act-O pretreatment. A possible explanation 
for this is that monocytes produce TNFa (among other effector 
molecules), whereas lymphocytes can also secrete LT, the cytotoxic 
action of which is augmented by target cell pre-treatment with Act-D. 
3.3.0 Leucocyte Killing of Cytokine Pre-treated A375 Cells 
Having established the direct cytotoxic activities of the selected 
cytokines and leucocytes, it was next important to evaluate the effect of 
combined cytokine and lymphocyte treatment on tumour cell cytotoxicity. 
Simple addition of cytokines and leucocytes together and observation of 
the resultant tumour cell killing would not produce meaningful results 
since many secondary interactions (such as the induction of other 
effector molecules) could occur between cytokines and cells, each of 
which might be responsible for any changes in cytotoxicity observed. 
Experiments were therefore performed to evaluate the effect of cytokine 
pre-treatment of tumour cells (with or without Act-D pre-treatment), on 
lymphocyte and monocyte killing of A375 cells. 
3.3.1 Effect of Cytokine Pre-treatment of A375 Cells on Lymphocyte 
Cytotoxicity 
A375 cells were pre-treated with IL-2 (500-2000U/ml), TNFa (100-
500U/ml), or IFNy (100-1 OOOU/ml) for 3-72h. The cells were washed to 
remove any remaining cytokine and their sensitivity to lymphocyte 
cytotoxicity assessed. In some experiments the target cells were 
incubated with Act-O for 3h prior to inclusion in the cytotoxicity assay. 
In 3 experiments, IL-2 and TNFa pre-treatment of A375 cells did not 
result in any increase in lymphocyte cytotoxicity compared to untreated 
A375 cells at any concentration tested, even after 72h, indicating that 
these cytokines are unable to augment lymphocyte cytotoxicity of A375 
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cells, even though IL-2 has some effect on the growth of these cells and 
TNFa will kill Act-O presensitised A375 cells (see section 3.1.2). 
At 3h and 24h, IFNy (concentration range 100-1 OOOU/ml) pre-treatment 
had no effect on lymphocyte cytotoxicity of A375 cells, but in one 
experiment it induced a 57%) increase in killing after 48h, and a 35% 
increase after 72h in a separate experiment. Maximal cytotoxicity was 
observed at an IFNy concentration of 250U/ml (Figure 3.16) 
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FIGURE 3.16. Lymphocyte killing of IFN-y pre-treated A375 cells. A375 cells were 
incubated with IFN-y (0-500U/ml) for 48h, Na51Cr04 labelled and their killing by 
lymphocytes assessed (E:T 50:1). In 3 experiments (means and SEMs shown), a 
significant increase in cytotoxicity was observed at an IFNy concentration of 125 
and 250U/ml (p<0.05 compared to untreated A375 cells by MWU and PTT), which 
subsequently decreased at 500U/ml IFN-y to a level which was similar to that of 
untreated A375 cells (p>0.05 compared to untreated A375 cells by MWU and 
PTT). Pre-incubation of A375 cells with IFN-y at 63U/ml had no significant effect 
on lymphocyte cytotoxicity (p>0.05 compared to untreated A375 cells by MWU 
and PTT). 
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At IFNy concentrations above 250U/ml there was a decrease in 
lymphocyte cytotoxicity. This pattern of killing could be explained by the 
previous observation (section 3.1.4) that IFNy significantly reduced the 
yield of A375 cells from culture at concentrations above 250U/ml. 
Concentrations of IFNy up to 250U/ml may have been sufficient to 
sensitise (possibly by cytostasis) A375 cells for killing by lymphocytes, 
but concentrations greater than 250U/ml were directly cytotoxic to A375 
cells. In the latter case, IFNy, and possibly lymphocyte, sensitive target 
cells may have been selected out, leaving only resistant cells as targets 
in the cytotoxicity assay. Incubation of target cells with IFNy for 48h 
followed by Act-D (0.1 /-lg/ml) for 3h (Figure 3.17), augmented lymphocyte 
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FIGURE 3.17. Effect of IFN-y and/or Act-O pretreatment on lymphocyte 
cytotoxicity of A37S cells. A37S cells were incubated for 48h in RPMIIFCS alone 
(2 x 2Scm2 TC flasks) or containing IFN-y (2S0U/ml) (2 x 2Scm2 TC flasks). One 
flask from each treatment was further incubated for 3h with Act-O (0.1 Jlg/ml). 
After labelling with Na51Cr04, the cells were included as target cells in a 
lymphocyte cytotoxicity assay (E:T SO:1). In 3 experiments, killing was 
augmented by pretreatment of the target cells with either IFN-y or Act-O (p<O.OS 
by MWU and PTT). Combined pre-incubation with IFN-y and Act-O increased 
lymphocyte killing to a level which was only slightly greater than the sum of the 
increases observed with the individual agents (p<O.OS by MWU and PTT) This 
increase was not synergistic (p>O.OS compared to untreated cells plus the 
increases due to both IFN-y and Act-O individually; by MWU and PTT). 
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killing in 3 experiments. These results indicated that IFNy and Act-D 
were synergistic in their sensitisation of A375 cells to killing by 
lymphocytes. 
The results of pre-incubation of tumour cells with combinations of IFNy 
and IL-2 or IFNy and TNFa were not significantly different to those for 
IFNy alone (data not shown), suggesting that there were no interactions 
between these cytokine combinations on A375 cells, as has been 
reported previously for IL-2 and IFNy (Dealtry et a/. , 1987). 
3.3.2 Monocyte Killing of Cytokine Pretreated A375 Cells 
Freshly isolated peripheral blood monocytes were assessed for their 
cytotoxic activity against untreated A375 cells, or A375 cells pre-treated 
with single cytokines, pairs of cytokines and/ or subsequent incubation 
with Act-D. 
A375 cells were pre-incubated with IFNy, and IL-2, with or without Act-D 
stimulation (section 2.2.4). In the absence of Act-D, none of the 
cytokines tested had any effect on monocyte killing when compared with 
untreated A375 cells (figure 3.18). Simultaneous pre-treatment of target 
cells with two cytokines again had no effect with the exception of the 
combination of IFNy and IL-2 which induced an increase in monocyte 
cytotoxicity, thus demonstrating a synergistic interaction between these 
cytokines in the induction of monocyte cytotoxicity for A375 cells. 
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FIGURE 3.18. Tumour cells (A375) were incubated in duplicate 25cm2 TC flasks 
for 48h in RPMIIFCS alone or containing IFNI' (250U/ml), IL-2 (250U/ml) or IFNI' 
and IL-2. One flask from each group was subsequently treated with Act-D 
(0.1Ilg/ml) for 3h. After Na51Cr04 labelling, the A375 cells were cultured for 18h in 
the presence of purified monocytes (E:T 50:1) and specific cytotoxicity assessed. 
In 3 experiments, Act-D (p<0.05 compared to untreated cells by MWU and PTT), 
but not IFNI' or IL2 (p>0.05 by MWU and PTT), augmented monocyte cytotoxicity. 
Combined pre-treatment with either cytokine and Act-D resulted in increased 
cytotoxicity, but was not significantly different from that of Act-D alone (p>0.05 
by MWU and PTT). However, increased monocyte killing was observed using a 
combination IFNI' and IL-2 pre-incubation (p<0.05 by MWU and PTT). Since IFNI' 
and IL-2 alone had no augmenting activity alone, the increase produced by their 
combination was synergistic. 
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3.4.0 Summary of Results 
1. Tumour cell lines were heterogeneous in their response to TNFa. 
A375, OX3 and L T5.1 cells were relatively unresponsive «10% 
cytotoxicity), whilst SK23, K562 , Oaudi (18h) and U937 cells were more 
sensitive (16-23% ). 
2. Act-O pre-treatment of tumour cells increased TNFa cytotoxicity in 3 of 
the 4 melanoma cell lines as well as U937 after 18h, but not K562 or 
Oaudi cells, again demonstrating heterogeneity of response between 
different tumour cell lines. 
3. Little or no killing of A375 cells was seen by IL-1~, IL-2, IFNy or L T, 
but Act-O pre-treatment induced cytotoxicity by 3 of the 4 cytokines (the 
exception being IL-2), to levels between 13-19% specific cytotoxicity. 
4. Incubation of A375 cells with IFNy caused a decrease in the cell yield 
after 48-72h, indicating that IFNy was either cytotoxic or cytostatic for 
this cell line. 
5. Incubation of A375 cells with IL-2 resulted in an increased yield of 
cells after 72h. Flow cytometry demonstrated the presence of IL-2 
receptors (a-chain) but not the ~-chain on these cells. 
6. Lymphocytes were cytotoxic for all cell lines tested, but there was 
heterogeneity in sensitivity between cell lines. The most sensitive lines 
were K562 (42%) and U937 (570/0), and the least sensitive was SK23 
(18%). Lymphocyte killing of the other cell lines tested ranged between 
27 -32% specific cytotoxicity. 
7. Act-O pre-treatment augmented lymphocyte killing of 3 (A375, DX3 
and SK23) of the melanoma cell lines, but not L T5.1, K562 , Daudi or 
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U937. In contrast, pre-treatment of A375 cells with cycloheximide had no 
effect on lymphocyte killing. 
8. Depletion of CD8+ cells from the lymphocyte population resulted in 
over 75% decrease in lymphocyte killing of untreated and Act-D pre-
treated A375 cells. The effector lymphocytes in this system were, 
therefore, predominantly CD8+ cytotoxic T lymphocytes. 
9. Monocytes were cytotoxic for A375 and K562 cells, and killing of A375 
cells was augmented by pre-treatment with Act-D. Monocytes were 
probably not activated by low levels of contaminating LPS. 
10. Fresh lymphocytes were significantly more cytotoxic for A375 cells 
than monocytes, which in turn were more cytotoxic than TNFa (at 
1000U/ml). 
11. Lymphocyte killing of A375 cells was only increased by incubation of 
target cells with IFNy for 48-72h, and IFNy treatment synergised with 
subsequent Act-D treatment of the target cells. No increase in killing was 
seen after A375 cells were pre-incubated with IL-2 or TNFa, even when 
the tumour cells were subsequently incubated for 3h in the presence of 
Act-D. No synergistic augmentation was observed between any pair of 
cytokines composed of IFNy, IL-2 or TNFa. 
12. Monocyte cytotoxicity of A375 cells was not augmented by pre-
incubation of the target cells with IL-1~, IFNy, TNFa or IL-2, but a 
synergistic increase in killing was observed with combined IFNy and IL-2 
pre-treatment. Incubation with IFNy or IL-2 followed by Act-D pre-
treatment of A375 cells also synergistically increased monocyte killing. 
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CHAPTER 4 
LYMPHOKINE ACTIVATED KILLER (LAK) CELLS 
4.0 Introduction 
Interleukin-2 activates lymphocytes to become highly cytotoxic for a wide 
range of tumour cell lines (but not normal cells) in vitro (Grimm et a/., 
1982). Over the past decade clinical trials have been undertaken to 
determine the therapeutic effects of injected recombinant IL-2 alone in 
patients with terminal cancer (Rosenberg, 1989; Mitchell, 1992). 
However, IL-2 at high concentrations (i.e., sufficient to activate 
lymphocytes in vivo) proved to be highly toxic (Rosenberg et a/., 1987), 
and the therapeutic effect was marginal. In a total of 174 patients tested 
in six clinical trials with IL-2 (5 X104 - 3 x 107U/m2) there was only 1 
complete remission and 10 partial (>50% reduction in tumour mass) 
remissions (Lotze et a/. , 1986; Creekmore et a/. , 1987; Rosenberg et a/., 
1987; Sa no et a/., 1987; Thompson et a/., 1987; Whitehead et a/., 1987). 
Since the in vivo mechanism of action of IL-2 therapy was thought to be 
via the generation of LAK activity in the circulation and in the tumour 
infiltrating lymphocytes (Rosenberg et aI., 1985), further protocols were 
devised in which large numbers (typically 1-5 x 1010 cells) of peripheral 
blood mononuclear cells (lymphocytes and monocytes) were removed 
from patients, activated with high concentrations (between 500 -
2000U/106 cells) of IL-2, and re-introduced into the patient, together with 
lower doses of IL-2. In some trials this process was repeated on 2 or 3 
occasions. Combined results from five such trials (Dutcher et aI., 1987; 
Fisher et aI., 1987; Paciucci et al., 1987; Rosenberg et aI., 1987; West et 
aI., 1987) showed improved (but still relatively low) clinical response 
rates than was previously obtained using IL-2 alone. Of 228 patients 
treated there were 9 complete and 42 partial responses (i.e., 4% 
complete and 18% partial compared to 0.6% complete and 6% partial 
responses using IL-2 alone). Although it was not possible to identify if 
patients were likely to respond to IL-2/LAK cell therapy, patients with 
renal cell carcinoma and malignant melanoma demonstrated an 
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increased responsiveness to this immunotherapy than other cancers 
(Rosenberg et al., 1989). 
The aims of the next series of experiments were: (1.) To compare the 
cytotoxic activity of LAK cells and IL-2 activated monocytes with 
untreated lymphocytes, monocytes and cytokines on the 7 tumour cell 
lines (with or without Act-O pre-treatment) in vitro; (2.) to determine the 
ability of LAK cells to kill autologous and heterologous normal cells; (3.) 
to assess the tumouricidal activity of LAK cell supernatants, and; (4.) to 
investigate the mechanism(s) by which unstimulated leucocytes and LAK 
cells adhere to and kill tumour cells. 
4.1 LAK Cell Cytotoxicity Against Tumour Cells 
4.1.1 IL-2 Activation of Lymphocytes 
Various concentrations of IL-2 were used in previous studies to induce 
LAK activity. It was therefore necessary to determine the optimal 
concentration of IL-2 required for LAK cell generation in this study. In 3 
experiments, peripheral blood lymphocytes at a concentration of 2 x 
106/ml were incubated for three days alone or in the presence of r1L-2 
(10, 50, 250 and 500U/ml), and their cytotoxicity against untreated or 
Act-O pre-treated A375 cells measured (figure 4.1). 
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FIGURE 4.1. Effect of IL-2 on lymphocyte killing of A375 cells. Lymphocytes were 
incubated with RPMIIFCS alone (control cells) or containing IL-2 (10-500U/ml) for 
72h, and their cytotoxicity against untreated or Act-D pre-treated A375 cells 
assessed (E:T 50:1). In 3 experiments (means and SEMs are shown), killing was 
augmented (compared to no IL-2; p<0.05 by PTT and MWU) by IL-2 at all 
concentrations tested. Maximal cytotoxicity was observed at 50U/ml IL-2 
(compared to 10U/ml; p<0.05 by PTT and MWU), which did not increase further at 
higher IL-2 concentrations (p> 0.05 by PTT and MWU). Pre-incubation of A375 
cells with Act-D resulted in increased lymphocyte cytotoxicity at 0 and 10Ulml IL-
2 (p<0.05 by PTT and MWU), but not at the higher IL-2 concentrations (p>0.05 by 
PTT and MWU). 
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Control cells (lymphocytes cultured in the absence of IL-2 for 72h) were 
more cytotoxic (53%) than freshly isolated lymphocytes (mean 27% +1_ 
0/0, see section 3.2) for untreated A375 cells. This may have been due to 
partial activation of the effector cells after 72h in culture. As with fresh 
lymphocytes, control cell killing was augmented by preincubation of the 
target cells with Act-D (Figure 4.1). Incubation of lymphocytes with IL-2 
increased their killing of A375 cells in a dose-dependent manner, but no 
significant increase in killing was seen when A375 cells were pre-treated 
with Act-D, except at the lowest concentration of IL-2 tested (10U/ml). 
Since the cytotoxicity seen with 10U/ml IL-2 was not significantly 
different from that of the control (OU/ml IL-2) it is probable that this 
concentration of IL-2 was insufficient to induce LAK activity. Maximal 
cytotoxicity was seen at IL-2 concentrations of 50-250U/ml, and this 
higher concentration (250U/ml) was used to generate LAK cells in all 
further experiments. In contrast to lymphocytes (control cells), LAK cells 
were highly cytotoxic for A375 cells, generating over 90% specific 
cytotoxicity of these cells after 18h. 
There are two possible explanations for the failure of Act-D pre-
treatment of A375 cells to enhance LAK cell killing. Either LAK cells are 
extremely efficient at killing A375 cells, and at this level any increase 
induced by Act-D sensitisation would not be seen, or alternatively, LAK 
activity employs effector mechanisms distinct from those of unstimulated 
lymphocytes, which are independent of the action of Act-D. 
4.1.2 Time Course of IL-2 Activation of Lymphocytes 
Having determined the optimal concentration of IL-2 required for LAK 
cell production, the optimum incubation time for the culture of 
lymphocytes with IL-2 was assessed. Figure 4.2 shows the mean (3 
experiments) cytotoxicity of untreated and Act-D pre-treated A375 cells 
by fresh lymphocytes and lymphocytes which had been incubated with 
IL-2 (250U/ml) for 4h, 1, 2, 3 and 7days. 
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FIGURE 4.2. Time course for LAK cell generation. An aliquot of freshly isolated 
lymphocytes from a single donor were assessed for their cytotoxicity against 
untreated and Act-O pre-treated A375 cells (time 0). The remaining lymphocytes 
were divided between 5 culture flasks (at 2 x 106/ml), which were incubated in the 
presence of IL-2 (250U/ml) for 4h, 24h, 48h, 72h, or 1wk, and their killing of 
untreated or Act-O pre-treated A375 cells measured. In 3 experiments (means and 
SEMs are shown), significant killing of A375 cells was observed using fresh 
lymphocytes as effectors (compared to spontaneous release; p<0.05 by MWU 
and PTT), and cytotoxicity was increased by A375 cell treatment with Act-O 
(p<O.05 by MWU and PTT). Lymphocyte culture with IL-2 enhanced killing at all 
time pOints (compared to fresh lymphocytes; p<O.05 by MWU and PTT) to a 
maximum at 24h. Incubation with IL-2 for longer than 24h did not further increase 
cytotoxicity (compared to 24h; p>O.05 by MWU and PTT). Pre-incubation of A375 
cells with Act-O did not increase cytotoxicity by IL-2 stimulated lymphocytes 
(p>0.05 by MWU and PTT). 
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As previously observed in section 3.2, a relatively low level of 
cytotoxicity to A375 cells by fresh lymphocytes was observed, but Act-O 
pre-treatment of the target cells resulted in increased killing. A significant 
increase in cytotoxicity was observed after as little as 4h incubation of 
lymphocytes with IL-2, and reached a maximum after 24h. Incubation of 
lymphocytes with IL-2 for longer than 24h did not result in a further 
increase in cytotoxicity. Act-O pre-treatment of A375 cells did not 
consistently enhance their killing by IL-2 activated lymphocytes. In 
further experiments LAK cells were prepared by incubation of 
lymphocytes with IL-2 for 24-72h. 
4.1.3 Time Course for LAK Cell Cytotoxicity of A375 Cells 
Since LAK cell killing of A375 cells was significantly greater than that of 
unstimulated lymphocytes, the next series of experiments compared the 
time course for LAK cell and lymphocyte (control cell) killing of A375 
cells. LAK or control cells were incubated with untreated or Act-O pre-
treated A375 cells for 1, 2, 4 or 18h, and the resulting cytotoxicity 
measured. 
138 
100 
80 
~ 
.-(.) 
')( 60 
o 
.., 
o 
~ (.) 
CD 
C) 
CO 1: 40 
CD (.) 
"-CD 
a.. 
20 
o 
1 
Control Control LAK LAK 
-ACT -0 +ACT -0 -ACT -0 +ACT-O 
• _.-+-_. • 
1 
... ~ .. 
~ ..............•............... ~ 
.......... 
1 
/1 
: 
/ 
:' 
/ 
I' I 
i 
: 
:" 
............. -_ ........ 
2 
Time (h) 
,i 
i 
.. 
/ 
.: 
I 
,/' 
I 
.:" 
: 
l 
-1" 
4 18 
FIGURE 4.3. Time course of control and LAK cell cytotoxicity of A375 cells. 
Cytotoxicity of untreated or Act-D pretreated A375 cells by LAK cells 
(lymphocytes incubated with IL-2 (250U/ml), for 24h), or control cells 
(lymphocytes cultured for 24h in the absence of IL-2) was measured after 1, 2, 4 
or 18h in co-culture. In 3 experiments (means and SEMs shown), significant LAK 
cell cytotoxicity against A375 cells was observed after 1 h (compared to 
spontaneous release; p<0.05 by MWU and PTT), which further increased to a 
maximum at 18h (p<O.05 compared to previous time point for 2, 4 and 18h, by 
MWU and PTT). LAK cell cytotoxicity was not augmented by A375 cell pre-
incubation with Act-D. Control cells were cytotoxic to A375 cells only after 18h 
incubation (compared to spontaneous release; p<O.05 by MWU and PTT), and 
killing was enhanced by target cell pre-treatment with Act-O (p<O.05 by MWU and 
PTT), but was still lower than the level of cytotoxiCity observed for LAK cells 
(p<O.05 by MWU and PTT). 
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Figure 4.3 shows the mean maximal cytotoxicity (effector: target cell 
ratio 50: 1) from three experiments. As with fresh lymphocytes, control 
cells did not show appreciable cytotoxicity until 18h, and this killing was 
augmented by Act-D pre-treatment of A375 cells. In contrast, LAK cells 
were cytotoxic for A375 cells after only one hour, and a time dependent 
increase in killing was seen up to a maximum of 93%) specific cytotoxicity 
at 18h. Further time pOints were not measured because LAK cell 
cytotoxicity was already maximal (i.e., approaching 100% ) after 18h, and 
longer incubation times may result in altered cytotoxicity due to nutrient 
deprivation. In contrast to control cells, Act-D pre-treatment of target 
cells had no significant effect on LAK cell killing. LAK cell cytotoxicity 
was significantly greater than that of control cells (p<O.05; even control 
cell cytotoxicity of Act-O pre-treated A375 cells), at all time points. 
4.1.6 TNFa Activation of Lymphocytes 
IL-2 is the most important cytokine in the induction of LAK activity, but 
other cytokines, such as TNFa, have been reported to synergise with IL-
2 in the modifying the number and activity of LAK cells generated in 
culture (Lee et a/., 1987), and to induce directly LAK activity. Freshly 
isolated lymphocytes were therefore incubated with TNFa for 72h, and 
their cytotoxicity against K562 and A375 (+/- Act-D) measured. 
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Figure 4.3 shows the mean maximal cytotoxicity (effector: target cell 
ratio 50: 1) from three experiments. As with fresh lymphocytes, control 
cells did not show appreciable cytotoxicity until 18h, and this killing was 
augmented by Act-D pre-treatment of A375 cells. In contrast, LAK cells 
were cytotoxiC for A375 cells after only one hour, and a time dependent 
increase in killing was seen up to a maximum of 93% specific cytotoxicity 
at 18h. Further time points were not measured because LAK cell 
cytotoxicity was already maximal (i.e., approaching 100%) after 18h, and 
longer incubation times may result in altered cytotoxicity due to nutrient 
deprivation. In contrast to control cells, Act-D pre-treatment of target 
cells had no significant effect on LAK cell killing. LAK cell cytotoxicity 
was significantly greater than that of control cells (p<0.05; even control 
cell cytotoxicity of Act-D pre-treated A375 cells), at all time points. 
4.1.6 TNFa Activation of Lymphocytes 
IL-2 is the most important cytokine in the induction of LAK activity, but 
other cytokines, such as TNFu, have been reported to synergise with IL-
2 in the modifying the number and activity of LAK cells generated in 
culture (Lee et a/., 1987), and to induce directly LAK activity. Freshly 
isolated lymphocytes were therefore incubated with TNFu for 72h, and 
their cytotoxicity against K562 and A375 (+1- Act-D) measured. 
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FIGURE 4.4. Effect of TNFa stimulation on lymphocyte killing of K562, A375 cells 
and A375 cells + Act-D. Lymphocytes were cultured in the presence of TNFa 
(1000U/ml) for 48h, and their cytotoxicity (at an E:T of 50:1) against K562 cells, 
A375 cells or Act-D pre-treated A375 cells compared to that of TNFa or 
unstimulated lymphocytes (cultured in RPMIIFCS for 48h). Three experiments 
were perfonned (means and SEMs shown). Unlike IL-2, pre-treatment of 
lymphocytes did not result in increased cytotoxicity against any cell line 
compared to unstimulated lymphocytes (p>0.05 by MWU and PTT), but increased 
killing was observed against Act-D pre-treated A375 cells (as previously shown 
in table 3.3). As a control, TNFa alone was incubated with the tumour cells. It 
was cytotoxic for untreated K562 and A375 cells (compared to spontaneous 
release; p<0.05 by MWU and PTT), and Act-D pre-treatment augmented TNFa 
killing of A375 cells (as previously shown in table 3.1; p<0.05 by MWU and PTT). 
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Figure 4.4 shows the mean maximal cytotoxicity from 3 experiments for 
TNFa, control cell, and TNFa stimulated lymphocyte cytotoxicity of K562 
cells, untreated and Act-D pre-treated A375 cells. 
As demonstrated previously (section 3.1.2), TNFa was cytotoxic for K562 
and untreated A375 cells to a low level «10% cytotoxicity), and Act-D 
pre-treatment of A375 cells enhanced their susceptibility to TNFa action. 
Control cells were cytotoxic for K562 and to a lesser extent A375 cells, 
but as before, pre-treatment of A375 cells with Act-D enhanced 
lymphocyte killing. In contrast to IL-2 stimulated lymphocytes, cytotoxicity 
of the above cell lines by TNFa stimulated lymphocytes was not 
significantly different from that of control lymphocytes. These results 
demonstrate that TNFa did not enhance the tumouricidal activity of 
lymphocytes. 
4.1.5 Subset Depleted Control and LAK Cell Killing of A375 Cells 
Previous experiments in this study (section 3.2.4) showed that depletion 
of the CD8+ lymphocyte subpopulation resulted in decreased 
lymphocyte killing of A375 cells. It was, therefore, of interest to 
determine whether depletion of CD8+ cells from LAK cell populations 
would produce a similar effect. Control (lymphocytes cultured for 24h in 
the absence of IL-2) and LAK cells were prepared as described in 
section 2.2.13, and each divided into 2 aliquots. One aliquot was 
adjusted to 5 x 106cells/ml and added directly to the A375 cells (section 
2.3.1.3), and the other washed in Facsflow, labelled with antibody to 
CD8. Fluorescently labelled CD8+ cells were removed by fractionation in 
a cell sorter. The resulting cells were tested for viability (section 2.2.16), 
adjusted to 5 x 106 cells/ml and added to A375 cells in the cytotoxicity 
assay (section 2.3.1.3). 
Figures 4.5 and 4.6 show the mean cytotoxicity dose response curves for 
killing of A375 cells by control and LAK cells respectively, as well as 
dose response curves for CD8+ depleted control and LAK cell killing. 
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Figure 4.5. Cytotoxicity of A375 cells by control and CD8+ depleted control cells. 
Control cells (lymphocytes cultured in RPMI/FCS for 24h) were depleted of CD8+ 
cells (>96% depletion in 3 experiments) as described in section 2.1.12, and their 
cytotoxicity against untreated A375 cells compared with that of the whole 
lymphocyte population. In 3 experiments (>97% viability of both effector cell 
populations; means and SEMs shown), control cells were cytotoxic at an E:T of 
6.3:1 (compared to spontaneous release; p<0.05 by MWU and PTT). reaching a 
maximum at 50:1 (p<0.05 compared to 25:1 by MWU and PTT). Depletion of CD8+ 
cells resulted in abrogation of control cell cytotoxicity (compared to the whole 
population; p<0.05 at E:T >=6.3:1 by MWU and PTT). 
144 
100 
so 
~ 
.-(.) 
60 .->< 0 
..., 
0 
..., 
~ 
U 
Q) 
C) 
ca 40 ..., c 
Q) 
(.) 
~ 
Q) 
D.. 
20 
o 
1.6 
LAK LAK -CDS+ 
II ... ~ ... 
• , 
, 
, 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• , 
• 
... J: 
•• - I .... 
3.1 6.3 12.5 25 
Effector: Target Cell Ratio 
50 
Figure 4.6. Cytotoxicity of A375 cells by LAK and CD8+ depleted LAK cells. 
Depletion of the CD8+ subset from 24h LAK cells (>94% depletion in 3 
experiments) was perfonned as described in section 2.1.12. Cell viability was 
>97% for both populations. Cytotoxicity of LAK cells and CD8+ depleted LAK 
cells (E:T 1.6:1 to 50:1) against untreated A375 cells was detennined in an 18h 
cytotoxicity assay. In 3 experiments (means and SEMs shown), significant 
cytotoxicity (compared to spontaneous release) was observed at all E:T for LAK 
cells, but only at 50:1 for CD8+ depleted cells (p<0.05 by MWU and PTT). 
Depletion of CD8+ cells resulted in significant inhibition of LAK cell cytotoxicity 
at all E:T above 1.6:1; p<0.05 by MWU and PTT). 
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Depletion of the CD8+ subpopulation from control cells (figure 4.5) 
resulted in complete abrogation of cytotoxicity in 2 experiments (in 
triplicate) at the highest effector:target cell ratio tested, whereas the 
same treatment of LAK cells in 3 experiments (in triplicate) resulted in a 
75% inhibition of cytotoxicity (figure 4.6). In all experiments the CD8+ 
cell depletion was >94% and the viability of the sorted cells >97%. Since 
control cell cytotoxicity was initially fairly low (14%; but consistent with 
lymphocyte killing in section 3.2.2), the sensitivity of the assay may not 
have been sufficient to detect any residual cytotoxicity due to any 
remaining CD8+ or other contributing cell populations. In contrast, LAK 
cells were highly cytotoxic and a small (up to 6% CD8+ may have 
remained in the effector cell preparations) contamination of the depleted 
cell population with CD8+ cells was possibly responsible for a proportion 
of the residual cytotoxicity. 
A contribution to the residual cytotoxicity by another cell population such 
as NK cells could not be discounted. Three further experiments were 
therefore performed to determine whether depletion of CD16+ (NK cells) 
would inhibit lymphocyte (control cell) cytotoxicity. No significant (p>O.3) 
reduction in control cell killing of A375 cells was observed (Figure 4.7). 
These results thus indicated that the cytotoxic activities of control 
(lymphocytes) and LAK cells against A375 cells were primarily due to the 
action of CD8+ MHC unrestricted cytotoxic lymphocytes. 
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Figure 4.7 
Cytotoxicity of A375 Cells by Lymphocytes and 
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FIGURE 4.7. Cytotoxicity of A375 cells by lymphocytes and CD16+ depleted 
lymphocytes. Control cells (lymphocytes cultured in RPMIIFCS for 24h) were 
depleted of CD16+ cells (>95% depletion in 3 experiments) as described for CD8+ 
cell depletion in section 2.1.12, and their cytotoxicity against untreated A375 
cells compared with that of the whole lymphocyte population. In 3 experiments 
(>97% viability of both effector cell populations; means and SEMs shown), 
control cells were maximally cytotoxiC at an E:T of 50:1. Depletion of CD16+ cells 
did not result in any significant decrease in control cell cytotoxicity (compared 
to the whole lymphocyte population; p>0.05 by MWU and PTT). 
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4.1.6 LAK Cell Cytotoxicity of All Tumour Cell Lines 
The tumouricidal activity of control and LAK cells was also tested against 
the other 6 tumour cell lines chosen for this study. Table 4.1 summarises 
the maximal cytotoxicity of control and LAK cells to the various target 
cells untreated or pre-treated with Act-D. 
Target Cells -Act-D Target Cells + Act-D Statistical Analysis 
Target n Control LAK Control LAK Control LAK 
A375 13 38 (3) 78 (4) 50 (3) 73 (2) p<0.05 p>O.05 
DX3 3 34 (5) 71 (6) 59 (4) 72 (5) p<0.05 p>O.05 
SK23 3 30 (4) 73 (6) 63 (5) 79 (7) p<0.05 p>O.05 
LT5.1 3 44 (3) 62 (5) 51 (6) 69 (5) p>O.05 p>O.05 
K562 3 42 (6) 76 (4) 46 (4) 79 (4) p>O.05 p>O.05 
DAUDI 3 32 (3) 97 (4) 22 (5) 92 (5» p>O.05 p>O.05 
U937 3 64 (3) 75 (4) 51 (5) 79 (4) p>O.05 p>O.05 
TABLE 4.1. Cytotoxicity of tumour cell lines +/- Act-D by control and LAK cells. 
The cytotoxic activity of control and LAK cells was assessed against seven 
untreated or Act-D pre-treated tumour cell lines in an 18h cytotoxicity assay. 
Results are expressed as the mean maximal cytotoxicity (at an E:T of 50:1) from 
"n" experiments, and numbers in brackets are SEMs. Statistical analysis by MWU 
and PTT of any increased cytotoxicity induced by Act-D pre-treatment of tumour 
cells is shown for control and LAK cells. Pre-incubation with Act-D only induced 
increased control cell cytotoxicity of A375, DX3 and SK23 cells. In addition, 
tumour cell killing by LAK cells was Significantly greater than that of control 
cells against all untreated and Act-D pre-treated cell lines (p<0.05 by MWU and 
PTT). 
Control cell (lymphocytes cultured in RPMIIFCS for 24h) killing of the 
various cell lines was very similar to that of fresh peripheral blood 
lymphocytes (section 3.2.5). Act-D pre-incubation of the target cells also 
augmented control cell cytotoxicity to a similar degree and in the same 
pattern as that previously observed for freshly isolated lymphocytes 
(section 3.2.2) These results indicate that unstimulated lymphocytes 
cultured for 24h at 37°C (control cells) compared well with freshly 
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isolated lymphocytes with respect to tumour cell killing, and as such 
acted as a good autologous lymphocyte control for LAK activity. 
In contrast, LAK cells were highly cytotoxic for all tumour cell lines 
tested; an effect that was not increased by pre-incubation of target cells 
with Act-D. Stimulation of lymphocytes with IL-2 would, therefore, seem 
to be an efficient way of generating highly tumouricidal cells prior to re-
inoculation into the patient. Having determined the cytotoxic activity of 
LAK cells on a number of tumour cell lines, it was important to determine 
if normal cells such as autologous leucocytes, endothelial cells and 
fibroblasts were also susceptible to LAK cell activity. 
4.2 LAK Cell Cytotoxicity Against Normal Cells 
Most clinical protocols for LAK cell immunotherapy favour the re-
introduction of LAK cells into cancer patients via the peripheral 
circulation. Here they encounter circulating immune cells and endothelial 
cells lining vessel walls. On crossing the vessel wall LAK cells may 
interact with fibroblasts prior to, and during, their infiltration into the 
tumour mass. 
Experiments were performed to investigate the cytotoxicity of LAK and 
control cells to autologous lymphocytes and monocytes, and 
subsequently to heterologous human umbilical vein endothelial cells and 
fibroblasts. 
4.2.1 Cytotoxicity of Autologous Lymphocytes and Monocytes by 
Control and LAK Cells 
Control and LAK cells were prepared as previously described in section 
2.2.13. A second sample of peripheral blood was the taken from the 
same donor who provided the control and LAK cells, lymphocytes and 
monocytes purified, Na51 Cr04 labelled and used as target cells in the 
cytotoxicity assay. Act-D pretreated A375 cells were also tested as a 
positive control for cytotoxicity. 
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FIGURE 4.8. Control and LAK cell cytotoxicity of autologous monocytes and 
lymphocytes. Control and LAK cells (24h cultures) were prepared as described in 
section 2.1.13. After 24h, lymphocytes and monocytes were prepared from the 
peripheral blood of the same donor, Na51Cr04 labelled (0.1 J,1Ci/5x1 06 cells for 
30min), and their susceptibility to killing by autologous control and LAK cells 
(E:T 50:1) detennined. Actinomycin-D pre-treated A375 cells were included in the 
assay as a positive control. In 3 experiments (means and SEMs are shown), 
control and LAK cells were not cytotoxic against autologous monocytes and 
lymphocytes (compared to spontaneous release; p>0.05 by MWU and PTT). In 
contrast, Act-D pre-treated A375 cells were efficiently killed by control cells (56%) 
and LAK cells (73%). LAK cell killing of A375 cells was significantly greater than 
that of control cells (p<0.05 by MWU and PTT). 
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Figure 4.8 shows the results of 3 experiments in which both control and 
LAK cells were highly cytotoxic for A375 cells, but not for autologous 
lymphocytes or monocytes. Extrapolation of these results to the in vivo 
environment suggests that circulating leucocytes would not be damaged 
by re-introduced LAK cells, and would therefore be available for further 
recruitment by IL-2, LAK cells and other released cytokines to become 
tumouricidal. 
4.2.3 Endothelial Cell and Fibroblast Killing by Control and LAK 
Cells 
Since capillary, venous or arterial endothelial cells cannot be obtained 
form normal donors, heterologous endothelial cells and fibroblasts were 
isolated from human umbilical vein (human umbilical vein endothelial 
cells, HUVEC) as described in section 2.2.14, and their cytotoxicity by 
LAK and control cells assessed (section 2.3.3). 
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FIGURE 4.9. LAK cell cytotoxicity of human umbilical vein endothelial cells. 
Human umbilical vein endothelial cells (HUVEC) were isolated as described in 
section 2.1.14, Na51Cr04 labelled, and their cytotoxicity by control and LAK cells 
(24h culture: [IL-2] 250U/ml) assessed at an E:T of 50:1, after 18h incubation (see 
section 2.2.9). The results are expressed as the means and SEMs from 7 
experiments. LAK cells were highly cytotoxic (93% specific cytotoxicity) against 
HUVEC, and killing was significantly greater than that observed for control cells 
(38%; p<0.05 by WSR, MWU and PTT). 
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Figure 4.9 shows the mean maximal cytotoxicity of endothelial cells by 
control and LAK cells. Control cells were moderately cytotoxic (38% ) 
after 18h, but LAK cells were highly cytotoxic for endothelial cells, 
producing over 90% killing after 18h. In order to determine the time 
course for LAK cell killing of endothelial cells, experiments were 
performed in which LAK cell cytotoxicity was measured after 1, 2, 4 or 
18h. 
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FIGURE 4.10. Time course of endothelial cell cytotoxicity by LAK cells. Control 
and LAK cells were incubated with Na51Cr04 labelled HUVEC at an E:T of 50:1 for 
1, 2, 4 or 18h, and the level of cytotoxicity assessed as described in section 2.2.9. 
In 3 experiments (means and SEMs shown), endothelial cells were sensitive to 
killing by LAK cells after 1 h incubation (compared to spontaneous release; 
p<0.05 by MWU and PTT). LAK cell cytotoxicity increased after 2h (compared to 
1h; p<0.05 by MWU and PTT), and again at 18h (compared to 2h and 4h; p<0.05 
by MWU and PTT). Control cells were only cytotoxic after 4h incubation 
(compared to spontaneous release; p<0.05 by MWU and PTT), and killing was 
further increased after 18h (p<0.05 by MWU and PTT). Cytotoxicity by control 
cells was significantly less than that of LAK cells at all corresponding time 
pOints (p<0.05 by MWU and PTT). 
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Figure 4.10 shows that LAK cells were cytotoxic for endothelial cells 
after one hour, and that this killing increased after 2h and 4h (p>0.05 
between 2h and 4h) and again after 18h incubation. Within the same 
time period, control cells generated little or no cytotoxicity until 18h. 
The fact that the HUVEC used in these experiments were allogeneic to 
the LAK cells may have contributed to the high levels of cytotoxicity 
observed. The umbilical cord is situated between the placenta and the 
foetus, and thus possesses the foetal genotype, which has a 50% 
homology to the maternal genotype. Since it was impractical to remove 
up to 60ml of peripheral blood from a newborn baby to produce LAK 
cells which were genetically identical to the HUVEC, an experiment was 
devised in which maternal LAK cells were tested for cytotoxicity against 
endothelial cells derived from the umbilical cord vein. 
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FIGURE 4.11. Cytotoxicity of autologous and heterologous HUVEC by control 
and LAK cells. Human umbilical vein endothelial cells from 2 donors were 
isolated as described in section 2.1.14. Lymphocytes from 3 donors were 
cultured in the presence (LAK cells), or absence (control cells) of IL-2 (250U/ml) 
for 24h, and their cytotoxicity against the cultured HUVEC assessed in an 18h 
Na51Cr04 release assay. The results are the means and SEMs of triplicate 
samples from a single assay. Effector 1 and HUVEC A were lymphocytes and 
endothelial cells from mother and offspring respectively. No other donors of 
lymphocytes or HUVEC were related. LAK cells from all 3 donors were highly 
cytotoxic for both HUVEC, and were not significantly different from each other 
(p>O.05 by MWU and PTT). Control cells from all donors were less cytotoxic than 
LAK cells (p<O.05 by MWU and PTT). Donor 3 cells were the least cytotoxic 
(p<O.05 by MWU and PTT) to both HUVEC 1 and HUVEC 2. Control cells from 
donor 1 and 2 were equally cytotoxic for HUVEC 1 (p>O.05 by MWU and PTT), but 
donor 1 cells were more cytotoxic against HUVEC 2 than were cells from donor 1. 
(p<O.05 by MWU and PTT). 
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Figure 4.11 shows the results of an experiment in which control and LAK 
cells from a mother (Effector 1) and 2 other normal unrelated donors 
(Effectors 2 and 3) were tested for their cytotoxicity against HUVEC from 
the offspring (of the mother mentioned above; HUVEC A) and another 
unrelated donor (HUVEC 8). Control cells from all three donors were 
cytotoxic for both endothelial cell cultures, but control cells from effector 
3 were less cytotoxic than control cells from the other 2 donors. LAK 
cells from all donors were highly cytotoxic for both HUVEC cultures. The 
finding that LAK cells from mother were highly cytotoxic to HUVEC 
derived from their offspring's umbilical cord suggests that genetic 
differences between the LAK cells and the HUVECs are not important in 
the mechanism of LAK cell killing of HUVEC. However, this result is not 
conclusive since there was only a 50% similarity in the genotypes of 
mother LAK cells and offspring HUVEC. 
Further experiments were performed in which cultured fibroblasts from 
human umbilical veins were used as target cells for control and LAK 
cells. Figure 4.12 shows that LAK cells, but not control cells, were highly 
cytotoxic for fibroblasts at all effector:target cell ratios tested. 
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FIGURE 4.12. LAK cell cytotoxicity against cultured fibroblasts. Lymphocyte and 
LAK cell cytotoxicity against human umbilical vein fibroblasts was determined in 
an 18h Na51Cr04 release assay, as described in section 2.2.9. Means and SEMs 
from 3 experiments are shown. LAK cells were cytotoxic against fibroblasts at an 
E:T of 1.6:1 (compared to spontaneous release; p<0.05 by MWU and PTT), which 
increased significantly above 12.5:1 (p<0.05 by MWU and PTT) to a maximum at 
50:1. Control cells were not significantly cytotoxic (compared to spontaneous 
release; p>0.05 by MWU and PTT) for fibroblasts at any effector: target cell ratio 
tested. 
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4.3 Cytotoxic Activity of LAK Cell Supernatants to Tumour Cells 
Control and LAK cells may secrete cytotoxic effector molecules such as 
TNFa or L T into the surrounding medium, which are then able to kill 
tumour cells independent of their cell of origin. Alternatively, control and 
LAK cells may require direct adherence to their target cells in order to 
induce maximal cytotoxicity of tumour cells. 
In order to determine whether lymphocytes and LAK cells secrete 
cytocidal molecules into their environment, thus causing tumour cell 
death, the cytotoxic activity of supernatants taken from control and LAK 
cell cultures was measured against the 7 tumour cell lines untreated or 
pre-incubated for 3h with Act-D. 
Cytotoxicity -Act-D (%) Cytotoxicity +Act-D (%) Statistical Analysis 
Target n Control LAK Control LAK Significance Significance 
1 2 
A315 6 1 (1) 3 (2) 4 (1) 15 (4) p>O.05 p<0.05 
DX3 4 3 (1) 20 (2) 8 (2) 60 (6) p<0.05 p<0.05 
SK23 4 4 (2) 11 (2) 7 (1) 15 (3) p>O.05 p>O.05 
LT5.1 4 10 (2) 12 (4) 15 (2) 36 (3) p>O.05 p<0.05 
K562 3 15 (2) 36 (2) 18 (3) 32 (4) p>O.05 p>O.05 
DAUDI 3 0 10 (2) 0 13 (3) p>O.05 p>O.05 
U931 3 26 (2) 25 (2) 35 (2) 35 (4) p<0.05 p<0.05 
. TABLE 4.2. Cytotoxicity of tumour cell hnes +/- Act-D by control and LAK cell 
supernatants. Supernatants from cultures of control and LAK cells were 
collected after 24h incubation and stored at -10°C prior to testing for cytotoxic 
activity against seven untreated and Act-O pre-treated tumour cell lines. The final 
dilution of supernatant was 1 in 4, and the incubation time with the tumour cells 
18h. n = number of experiments, and numbers in brackets are SEMs. Statistical 
analysis by MWU and PTT of the effect (increased killing) of Act-D pretreatment 
on tumour cell killing by control (significance 1) and LAK cell (significance 2) 
supernatants is also shown. In addition, all Act-D pre-treated cell lines were more 
susceptible to killing by LAK cell supernatants than by those of control cells 
(p<0.05 by MWU and PTT). Of the untreated tumour cell lines, only DX3, SK23, 
K562 and Daudi cells were more efficiently killed by LAK cell supernatants 
(p<0.05 by MWU and PTT). 
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Table 4.2 shows that LAK cell supernatants were cytotoxic against all 
cell lines except A375 cells (compared to spontaneous counts; p<0.05). 
Pretreatment of target cells with Act-D significantly increased LAK 
supernatant killing of A375, DX3, L T5.1 and U937 cells. ACT-O pre-
treatment of DX3 cells resulted in the largest increase in supernatant 
cytotoxicity observed (20 010 to 60% ). 
Control cell supernatants were cytotoxic against L T5.1, K562 and U937 
cells (p<0.05 compared to spontaneous counts). Pre-incubation of the 
tumour cells with Act-O significantly enhanced control cell supernatant 
killing of DX3 and U937 cells. 
The pattern and magnitude of TNFa killing of the cell lines untreated and 
pretreated with Act-D (section 3.1.2) was also very similar (except for 
SK23) to LAK supernatant cytotoxicity. 
Killing of tumour cells by control and LAK cell supernatants was 
considerably lower than when the cells (section 3.2) were present in the 
assay. There are several possible explanations for this. First, the 
concentration of cytokine in the supernatants may be considerably less 
than that generated in the small volume within the cytotoxicity assay. 
Second, killing of tumour cell targets by control and LAK cells may 
require cell to cell contact. Third, control and LAK cells may only 
produce cytolytic effector molecules when in the presence of the target 
cells. 
To address some of these points an experimental system was devised in 
which control and LAK cells were either in direct contact with A375 
tumour cells, or separated from them by a porous polycarbonate 
membrane (section 2.3.2). This membrane ensured that the effector and 
target cells were relatively close to each other within the assay chamber, 
but no cell to cell contact could occur, although molecules were able to 
pass freely between the two cell layers. 
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FIGURES 4.13 and 4.14. Control and LAK cell cytotoxicity against untreated and 
Act-O pre-treated A375 cells was assessed after 18h incubation in the presence 
or absence of 0.8mm pore size polycarbonate membranes, as described in 
section 2.2.7. In 3 experiments (means and SEMs are shown), control and LAK 
cell killing of untreated A375 cells was completely inhibited by the presence of 
membranes (p< 0.05 compared to no membrane: p>0.05 compared to 
spontaneous release by MWU and PTT). As previously observed, control cell 
(p<0.05 by MWU and PTT), but not LAK cell killing (p>0.05 by MWU and PTT) was 
augmented by pre-treatment of the tumour cells with Act-D. Significant killing 
was also observed against Act-D pre-treated A375 cells in the presence of 
membranes (p<0.05 by MWU and PTT) and control or LAK cells, but was less 
than when the membranes were absent (p<0.05 by MWU and PTT). 
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Figure 4.13 again shows control cell cytotoxicity against A375 cells and 
that this killing is augmented by preincubation of the target cells with Act-
D. As demonstrated in section 4.1.7, LAK cells (figure 4.14) were highly 
cytotoxic for A375 cells (Figure 4.14), and Act-D pre-treatment had no 
effect on this killing. However, when the O.8mM membrane was placed 
between effector and target cells cytotoxicity was almost completely 
inhibited. Pre-treatment of the target cells with Act-D resulted in a partial 
restoration of cytotoxicity, but not to the levels seen with cells in direct 
contact. Cytotoxicity in the presence of membranes was similar to that 
observed for A375 cell killing by control and LAK cell supernatants. 
These results suggest that control and LAK cells produce soluble factors 
which are not directly cytotoxic for A375 cells, but become tumouricidal 
to target cells pretreated with Act-D. Possible candidates for these 
factors include TNFa, L T and IFNy (or a combination of these: section 
1.1 ) 
Direct contact between effector and target cells results in much greater 
target cell death than with either high dose recombinant cytokines or cell 
supernatants in the presence or absence of target cell pretreatment with 
Act-D. There are several possible explanations for these results. 1. 
Control and LAK cells require to adhere to their targets in order to 
generate very high concentrations (i.e., higher than tested in this study) 
of cytolytic effector molecules at the cell junctions. 2. Control and LAK 
cells kill A375 cells by a cytokine independent mechanism (e.g. perforins 
or proteolytic enzymes). 3. A combination of both 1 and 2. Some of these 
possible mechanisms of killing will be investigated further in the next 
sections 
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4.4 Inhibition of Control and LAK Cell Killing by Anti-TNFa and Anti-
L T Antibodies 
To investigate if TNFa and L T had a prominent role in the mechanism of 
control and LAK cell killing of A375 cells, monoclonal blocking antibodies 
against TNFa and L T were included in the cytotoxicity assay, together 
with a non-reactive monoclonal antibody (PDS1, an anti-retinal-S-
antigen IgG1, (Banga et a/., 1989); appendix V). 
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FIGURE 4.1S. Effect of anti-TNFa and anti-L T on control cell killing of A37S cells. 
Control cell killing of Act-D pretreated A37S cells was assessed alone and in the 
presence of monoclonal anti-TNFa (100Jlg/ml), anti-LT (100Jlg/ml) or anti retinal 
S-antigen (100Jlg/ml) for iSh at an E:T of SO:1. The results are expressed as 
means and SEMs from 6 experiments. Cytotoxicity was partially inhibited (SO%; 
p<O.OS by WSR and PTT) by anti-TNFa and almost completely inhibited by anti-
LT (95%; p<0.05 by WSR and PTT compared to No antibody and anti-TNF; also 
p>O.OS for anti-L T compared to spontaneous release.). No inhibition was 
observed in the presence of anti-S-antigen (p>O.OS by WSR and PTT). 
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FIGURE 4.16. Effect of anti-TNFa and anti-L T on LAK cell killing of A375 cells. 
Killing of Act-D pretreated A375 cells by LAK cells was assessed alone and in the 
presence of monoclonal anti-TNFa (100Jlg/ml), anti-L T (100Jlg/ml) or anti-retinal 
S-antigen (100Jlg/ml) for 18h at an E:T of 50:1. The results are expressed as 
means and SEMs from 6 experiments. Cytotoxicity was partially inhibited (48%; 
p<0.05 by WSR and PTT) by anti-TNFa and by anti-L T (57%; p<0.05 by WSR and 
PTT; also p>0.05 for anti-L T compared to anti-TNFa.). No inhibition was 
observed in the presence of anti-S-antigen (p>0.05 by WSR and PTT). 
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Figures 4.15 and 4.16 show the mean maximal cytotoxicity (from six 
experiments) of control and LAK cells in the presence or absence of the 
various antibodies. Control cell killing was inhibited by anti-TNFa, and 
almost completely by anti-LT. LAK cell cytotoxicity was inhibited to a 
similar degree (p>Q.Q5) by anti-TNFa and anti-L T. No inhibition of 
cytotoxicity by anti-S-antigen was observed. 
4.5 Effect of IL-2 on Monocyte Killing of A375 Cells 
IL-2 stimulation of monocytes has been reported to increase their 
cytotoxicity to tumour cells (Malkovsky et al., 1987). Experiments were 
therefore performed to determine whether IL-2 augmented monocyte 
killing of A375 cells. Monocytes were incubated for 1-3 days with IL-2 
(5QQU/ml) prior to their incubation with A375 cells. In 4 experiments no 
enhancement of monocyte cytotoxicity by IL-2 was seen. 
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Summary of Results 
1. The optimal concentration of IL-2 for LAK cell production was between 
50-250U/ml, and the optimal time of production was between 24-48h. 
Increased killing of A375 cells was seen after as little as 1 h incubation of 
lymphocytes with IL-2 (250U/ml). 
2. TNFa was unable to induce LAK activity by purified lymphocytes. 
3. Depletion of CD8+ lymphocytes completely abrogated control cell 
killing of A375 cells (pretreated with Act-D), and caused LAK cell 
cytotoxicity to decrease by a mean of 69%), indicating that lymphocyte 
and LAK cell cytotoxicity was caused predominantly by CD8+ cells. 
4. Control cell killing of the 7 tumour cell lines was very similar to 
lymphocyte killing for DX3, Daudi and U937 cells, but slightly greater for 
the other 4 cell lines. This may have been due to activation of control 
cells by a component of FCS. Control cells were cytotoxiC to Act-O 
pretreated tumour cells in the same pattern as that observed using fresh 
lymphocytes. 
5. LAK cell killing of the 7 tumour cell lines was considerably greater 
than that of control cells (62-97°A,), and killing was not augmented by 
pretreatment of target cells with Act-D. 
6. LAK or control cells were not cytotoxic to autologous lymphocytes or 
monocytes, but were highly cytotoxiC to heterologous HUVEC after as 
little as 1 h incubation. Control cells were less cytotoxic than LAK cells to 
HUVEC, but did not kill heterologous fibroblasts, which were very 
sensitive to LAK cell killing. 
7. Control cell supernatants were cytotoxic to L T5.1, K562 and U937 
cells (10-26°A,), but not to the other cell lines «5°A, cytotoxicity). Act-D 
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pretreatment of tumour cells caused increased killing by supernatants in 
the same pattern as control cells and fresh lymphocytes, but to a lesser 
degree. 
8. LAK cell supernatants were cytotoxic for 5 of the cell lines (10-36%), 
whilst A375 and SK23 cells were relatively unresponsive «8%). Act-O 
pretreatment of tumour cells augmented killing in the same pattern as 
fresh lymphocytes, control cells and control cell supernatants. 
9. Control and LAK cell cytotoxicity to A375 cells was considerably 
reduced when cell-cell contact was inhibited by polycarbonate 
membranes. The remaining cytotoxicity in wells containing membranes 
was augmented by tumour cell pretreatment with Act-O (in a similar 
fashion to that observed with TNFa and control and LAK cell 
supernatants), as were control cells, but not LAK cells, in the absence of 
membranes. 
10. Control and LAK cell killing of A375 cells was inhibited by blocking 
antibodies directed against TNFa and L T, thus implicating these 
cytokines in the mechanism of lymphocyte and LAK cell cytotoxicity. 
11. IL-2 pretreatment of monocytes did not affect monocyte cytotoxicity 
of A375 cells. 
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CHAPTER 5 
THE ROLE OF COAGULATION IN LAK CELL CYTOTOXICITY OF 
A375 CELLS 
5.0 Introduction 
It was demonstrated in the previous section that LAK cells were extremely 
cytotoxic for all tumour cell lines tested, as well as endothelial cells and 
fibroblasts in vitro. It was, therefore, of interest to investigate why LAK cells re-
injected into cancer patients did not apparently kill tumour cells as effectively 
as they do in vitro. There are two possible reasons for this. Firstly, LAK cells 
may never reach the tumour mass, possibly because they lack the appropriate 
homing mechanism(s), or their function is inhibited in the circulation, either by 
inhibitory molecules or by non-specific adherence to the vessel wall. Secondly, 
inhibition of LAK cell activity may occur when the LAK cells infiltrate the tumour 
mass, either by the release of immunosuppressive molecules (e.g. TGFP) from 
the tumour cells, or by some component of the tumour stroma (e.g. laminin, 
fibrin). 
One important observation is that all measurements of LAK activity in vitro in 
this and other studies have been performed in tissue culture medium with or 
without human or bovine serum where all coagulation mechanisms have been 
activated and fibrin produced, whereas the in vivo circulation consists almost 
exclusively of plasma, containing the full complement of coagulation 
components. The experiments reported here were designed to compare the 
effects of plasma and serum on control and LAK cell killing of A375 cells in 
vitro. 
Fibrinogen and other coagulation/fibrinolytic molecules are also present in the 
extracellular matrix in inflammation and cancer. Here the coagulation system 
can be activated by leucocytes (or LAK cells) and tumour cells to generate 
fibrin which becomes part of the tumour stroma. In order to metastasise, 
tumour cells must also be capable of degrading their extracellular matrix, 
including fibrin. Further experiments were therefore performed to investigate 
the procoagulant and fibrinolytic activities of control, LAK and A375 cells, and 
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the correlation between these cellular activities with possible LAK cell-tumour 
cell interactions in vivo. 
5.1 Inhibition of Cellular Cytotoxicity by Plasma Components 
5.1.1 Effect of Plasma on Control and LAK Cell Cytotoxicity of A375 
Cells 
To determine whether lymphocyte and LAK cell killing were inhibited by 
plasma, blood was taken from a single donor into either sodium citrate 
(citrated plasma) or glass (serum), and the resulting plasma compared with 
serum for it's ability to modify lymphocyte and LAK cytotoxicity. 
Initial experiments investigated the effect on control and LAK cell cytotoxicity 
of RPMI containing serum or plasma at graded concentrations. Four 
experiments were performed to investigate the effect of different 
concentrations of serum on lymphocyte cytotoxicity of A375 cells (figure 5.1 ). 
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FIGURE 5.1. Effect of serum dilution on lymphocyte cytotoxicity of A375 cells. Freshly 
isolated lymphocytes (5x106 cells/ml) were incubated with Act-O pre-treated A375 cells 
(1x105 cells Iml) for 18h, in RPM I alone or containing heat inactivated serum at 
concentrations of 1.25, 2.5, 5 and 10%. The results are means and SEMs from 4 
experiments. No significant difference was observed between RPMI or any serum 
dilution (p>0.05 by MWU and PTT). 
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There was little or no change in cytotoxicity at any concentration of serum 
tested, although a slight, but not significant (p>O.05) decrease was observed in 
RPMI alone compared with any of the serum dilutions. This indicated that 
reduction of the serum concentration to 1.25%) in the assay did not result in 
any change in the level of cytotoxicity due to nutrient deprivation, nor were any 
components of the serum (such as PF4 or TGF~) responsible for increasing 
cellular cytotoxicity in serum compared to tissue culture medium alone. The 
cytotoxicity values for 5°,1> serum will be shown in subsequent experiments, 
except where stated. In addition, sodium citrate was not directly cytotoxic for 
A375 cells at the same concentrations that were present when plasma was 
added to the assay plate, nor did it directly inhibit control and LAK cell killing of 
A375 cells. Any inhibition of cytotoxicity observed was therefore due to the 
presence of plasma. 
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FIGURE 5.2. Effect of plasma on control and LAK cell killing of tumour cells (A375). 
Lymphocyte (control) and LAK cell cytotoxicity (at an E:T of 50:1) against Act-O pre-
treated A375 cells was assessed in the presence of 5% serum or plasma at 1.25, 2.5, 5 
and 10%. Means and SEMs from 6 experiments are shown. Cytotoxicity by LAK cells 
was significantly inhibited at plasma concentrations of 2.5%, 5% and 10% compared to 
serum (p<O.OS by WSR, PTT and MWU. Control cell killing was inhibited at all plasma 
concentrations tested (p<O.OS by WSR, PTT and MWU). No Significant difference in 
inhibition was observed at plasma concentrations >2.S% for LAK cells and 1.2S% for 
control cells. LAK cell cytotoxicity was Significantly greater than that of control cells in 
serum, and at all plasma concentrations (p<O.OS by WSR, PTT and MWU). 
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Figure 5.2 is a summary of 6 experiments comparing plasma with donor 
matched serum. LAK cell killing was significantly inhibited by plasma at 2.5%, 
5% and 10% , and control cell killing was significantly inhibited by all 
concentrations of plasma tested. 
Following the observation that the addition of plasma rather than serum to the 
cytotoxicity assay resulted in significant inhibition of killing, further experiments 
were carried out to investigate the molecular component(s) responsible for this 
inhibition. 
5.1.2 Effect of Heat Inactivation on Plasma Inhibition of Killing 
In contrast to fresh plasma no significant (p>0.05) inhibition of killing was seen 
when plasma was incubated for 30min at 56°C prior to inclusion in the 
cytotoxicity assay (figure 5.3). These results indicate that a heat labile 
molecule, or molecules, are either directly responsible for inhibition, or 
contribute to inhibition by another factor. 
174 
100 
90 
80 
~ 70 ~ 
.-(J 
.-
>< 
0 60 ~ 
0 
~ 
~ 50 0 
(1) 
en 40 ns 
~ 
c: 
(1) 30 (J 
L. 
(1) 
a. 20 
10 
o 
Control LAK 
Serum Plasma HI Plasma 
FIGURE 5.3. Comparison of serum, plasma and heat inactivated plasma on control and 
LAK cell cytotoxicity of A375 cells. Matched serum and plasma was obtained as 
described in section 2.3.1. The serum and an aliquot of plasma were heat inactivated 
(HI) at 5SoC for 30min. Lymphocyte and LAK cell cytotoxicity (at an E:T of 50:1) against 
Act-O (0.1J,lg/ml) pretreated A375 cells was assessed in the presence of 5% HI-serum, 
plasma, or HI-plasma after 18h. In 3 experiments (means and SEMs are shown), plasma 
significantly inhibited control and LAK cell killing (compared to HI-serum; p<0.05 by 
MWU and PTT), but heat inactivation of plasma resulted in restoration of cytotoxicity to 
the level of HI-serum (p>0.05 compared to serum by MWU and PTT). 
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5.1.3 Effect of Aluminium Hydroxide Adsorption on Plasma 
Inhibition of Killing 
Incubation of plasma with a saturated solution of aluminium hydroxide causes 
adsorption of the vitamin-K dependent clotting factors (II, VII, IX and X as well 
as proteins C and S), resulting in plasma deficient in these factors (The 
preparation of aluminium hydroxide adsorbed plasma is described in section 
2.4.2.). In 3 experiments addition of this factor-deficient plasma to the 
cytotoxicity assay did not result in inhibition of cytotoxicity (p>O.05), observed 
using whole plasma (figure 5.4), indicating either that one or more of the 
vitamin-K dependent clotting factors contributed to the inhibition of killing, or 
that inhibition was a result of their action in clot formation. 
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FIGURE 5.4. Control and LAK cell cytotoxicity against A375 cells in the presence of 
plasma or aluminium hydroxide adsorbed plasma. Aluminium hydroxide adsorbed 
plasma was prepared (section 2.3.2) and compared with matched HI-serum and plasma 
for its effect on lymphocyte (control cell) and LAK cell cytotoxicity (at an E:T of 50:1) 
against Act-O pre-treated A375 cells after 18h. In 3 experiments (means and SEMs are 
shown), removal of the vitamin-K dependent clotting factors rendered plasma unable to 
inhibit control and LAK cell cytotoxicity (p>0.05 compared to serum by MWU and PTT), 
which was observed in whole fresh plasma (p<0.05 compared to plasma by MWU and 
PTT). 
177 
5.1.4 Effect of Afibrinogenaemic Plasma on Control and LAK Cell 
Cytotoxicity of A375 Cells 
Plasma was obtained from a patient suffering from congenital 
afibrinogenaemia prior to fibrinogen replacement therapy. The fibrinogen 
concentration in this plasma was less than 1 % of the normal value. Figure 5.5 
shows the results of 3 experiments in which afibrinogenaemic plasma was 
compared with normal serum and matched plasma for it's effect on control and 
LAK cell killing. As before, killing was inhibited by plasma when compared with 
serum, whereas the afibrinogenaemic plasma did not significantly inhibit either 
control or LAK cell cytotoxicity (p>O.05). 
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FIGURE 5.5. Effect of afibrinogenaemic plasma on control and LAK cell cytotoxicity of 
A375 cells. Lymphocyte and LAK cell cytotoxicity (at an E:T of 50:1) against Act-O 
(0.1 J.lg/ml) pre-treated A375 cells was assessed in the presence of 5% HI-serum, 
matched plasma or plasma obtained from a patient with congenital afibrinogenaemia. 
In 3 experiments (means and SEMs shown), control and LAK cell cytotoxicity was not 
Significantly inhibited in the presence of afibrinogenaemic plasma. In contrast, whole 
plasma inhibited control cell killing by 59% (p<0.05 compared to serum by MWU and 
PTT), and LAK cell killing by 49% (p<0.05 by MWU and PTT). 
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A major difference in composition between plasma and afibrinogenaemic 
plasma is the absence of fibrinogen in the latter. Since aluminium hydroxide 
adsorption did not remove fibrinogen, but was unable to inhibit cytotoxicity, it 
was unlikely that fibrinogen itself was the inhibitory factor, and that the process 
of clot formation itself (i.e. fibrin formation) was responsible for inhibition. 
However, the possibility also remained that fibrinogen may either be directly 
cytotoxic to A375 cells, or may upregulate the cytotoxic activity of control and 
LAK cells. Further experiments were, therefore, performed to examine the role 
of purified fibrinogen in lymphocyte and LAK cell cytotoxicity. 
5.1.5 The Role of Fibrinogen in Control and LAK Cell Killing of A375 
Cells 
A commercially purified fibrinogen preparation (CRTS, Lille, France) was 
tested for it's direct cytotoxic activity against A375 cells and for it's effect on 
control and LAK cell killing. Figure 5.6 (inset) shows that this preparation of 
fibrinogen was directly cytotoxic for tumour cells at physiological 
concentrations (3mg/ml), in a dose dependent manner. Control and LAK cell 
killing were not significantly affected (p>0.05) by addition of fibrinogen at 
3mg/ml (figure 5.6). 
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FIGURE 5.6. Effect of fibrinogen on control and LAK cell cytotoxicity of A375 cells. A 
commercial fibrinogen (Fg) preparation was tested (at 0.09 - 3.0mg/ml: 3mg/ml is the 
physiological concentration of Fg in the circulation) for its cytotoxicity against A375 
cells in the presence or absence of 5% serum (inset graph). In 3 experiments (means 
and SEMs shown), a dose dependent increase in cytotoxicity was observed (compared 
to spontaneous release; p<0.05 by MWU and PTT), but the level of killing was lower in 
the presence of serum at Fg concentrations of 0.75, 1.5 and 3.0mg/ml (p<0.05 by MWU 
and PTT). The main figure shows that Fg (at 3mg/ml) did not Significantly affect control 
or LAK cell cytotoxicity (at an E:T of 50:1) against A375 cells (in 3 experiments; means 
and SEMs shown), either in the presence, or absence, of 5% serum (p>0.05 by MWU and 
PTT). 
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To determine whether fibrinogen itself was responsible for the observed 
cytotoxicity, the preparation was further purified by gel filtration (section 2.4.9). 
The fibrinogen concentrations of the fractions were determined by ELISA. The 
fibrinogen concentrations of the fractions corresponding to the protein peak 
from the gel filtration column were adjusted to 3mg/ml (i.e., physiological 
concentrations), where possible, in RPMI and tested for direct cytotoxicity 
against A375 cells (figure 5.7). 
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FIGURE 5.7. Effect of fibrinogen and gel filtered fractions on A375 cells. After gel 
filtration, the fibrinogen containing fractions (see section 2.3.9-11) were assessed for 
their cytotoxic activity against A375 cells. The concentration of Fg in the assay was 
physiological (i.e. 3.0mg/ml) for fractions 14 and 15, but the initial concentration of Fg 
in fractions 13 (5.0mg/ml) and 16 (2.8mg/ml), combined with the 1 in 2 dilution in the 
cytotoxicity assay, required these fractions to be tested at concentrations of 2.5 and 
1.4mg/ml. In 3 experiments (means and SEMs are shown), fractions 13 and 16 were 
cytotoxic against A375 cells (compared to spontaneous release; p<O.05 by MWU and 
PTT), but killing was considerably less than that of the original product (p<O.001 by 
MWU and PTT). No significant killing was observed in the presence of fractions 14 and 
15 (compared to spontaneous counts; p>O.05 by MWU and PTT). 
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Fractions 13, 14, 15 and 16, which contained fibrinogen (figure 5.7; see also 
phast gels, section 2.4.11) showed little cytotoxicity for A375 cells, compared 
with the unfractionated product. One of the low molecular weight fractions 
(fraction 23) was more acidic than other fractions (as determined by colour 
change of phenol red in the RPMI) and was also assessed for its cytotoxic 
activity, and found to be highly cytotoxic (figure 5.8). 
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FIGURE 5.8. Cytotoxicity of A375 cells by fraction 23. Fraction 23 from the gel filtration 
of fibrinogen, which constituted the low molecular weight fraction, was examined for 
its cytotoxic activity (at a dilution range of 1/64 - 1/2 final) against A375 cells in an 18h 
Na51Cr04 release assay. In 3 experiments (means and SEMs shown, significant 
cytotoxicity (compared to spontaneous release; p<O.05 by MWU and PTT) was 
observed at a dilution of 1/64, and rose to a maximum of 88% at 1/2 (p<O.05 compared 
to 1/4 by MWU and PTT). 
The dose-dependent cytotoxic activity of fraction 23 was probably not caused 
by low molecular weight peptides since silver staining (which is a more 
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sensitive stain than coomassie blue for the detection of proteinacious material) 
of the PHAST gels (performed by Andrew Lawrie from the Research and 
Development coagulation laboratory) failed to resolve any proteinacious 
material. The osmolality of fraction 23 was then measured and found to be 
367mOsm/Kg which was considerably above the normal range (280-
300mOsm/Kg). This raised osmolality may have accounted for the observed 
cytotoxicity. 
Since fraction 14 was the least cytotoxic of the fractions in the fibrinogen peak, 
it was retested in place of the unpurified original commercial Fg preparation for 
its influence on LAK and control cell killing of A375 cells. Figure 5.9 shows that 
after gel filtration, fibrinogen (fraction 14) was not directly cytotoxic for A375 
cells, and had no significant (p>0.05) effect on LAK and control cell 
cytotoxicity. 
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FIGURE 5.9. Effect of purified (fraction 14) fibrinogen on control and LAK cell killing of 
A375 cells. Gel filtered fibrinogen (fraction 14) was tested for cytotoxicity against A375 
cells in the presence or absence of serum (inset graph) at concentrations of 0.09 -
3.0mg/ml after 18h. No significant killing was observed by this fraction at any 
concentration tested. The main figure shows that lymphocyte (control) and LAK cell 
cytotoxicity (at an E:T of 50:1) of A375 cells was not affected by the presence of 
fibrinogen or serum, alone or in combination (p>0.05 by MWU and PTT). 
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The requirement for fibrinogen to be present in order for inhibition to occur (as 
shown in experiments using afibrinogenaemic plasma; section 5.1.4), coupled 
with the observation that fibrinogen itself was ineffective, either directly, or as 
a contributory factor in control and LAK cell cytotoxicity, suggested that the 
inhibitory factor was fibrin. The removal of the vitamin-K dependent clotting 
factors by aluminium hydroxide would significantly reduce fibrin production, 
and account for the restoration of cytotoxicity to the level observed in the 
presence of serum. 
Visual observation of the microtitre plates during the incubation period of the 
cytotoxicity assay showed that clot formation occurred in the wells containing 
plasma and target cells (with or without effector cells) in 2-4h. However, no clot 
formation was observed after the full incubation time, suggesting that the fibrin 
had been degraded during this period. As a result of this fibrinolysis, effector 
and target cells would not be in the presence of solid fibrin for the full 18h 
assay period, resulting in possible restoration of cytotoxicity. Thus, prior to 
further investigation of the causative factor(s) of inhibition, it was necessary to 
evaluate the procoagulant and fibrinolytic properties of the effector and target 
cells alone and together. 
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5.2 Procoagulant and Fibrinolytic Activities of LAK and A375 Cells 
5.2.1 Observation of Clot Formation and Dissolution in the 
Cytotoxicity Assay 
In order to observe clot formation more clearly during the 18h cytotoxicity 
assay period the volumes of all constituents were scaled up from a total of 
200J..l1 in 96 well microtitre plates to 2ml total volume in 24 well plates. Control, 
LAK or A375 cells were added to the plates alone or in combination. Cell 
concentrations and thus effector:target cell ratios were those which produced 
maximum killing in the cytotoxicity assay. After 0, 1, 2, 4, 6 or 18h one plate 
was removed from the incubator and each well inspected for clot formation or 
dissolution. 0.5ml aliquots were taken for analysis of thrombin and D-dimer. 
Time (h) Control LAK A375 A375 +Control A375 +LAK RPM I 
0 
- - - - - -
1 +++ +++ + ++ ++ -
2 +++ +++ ++ ++ + + 
4 +++ +++ - - - + 
18 +++ +++ 
- - -
+ 
TABLE 5.1. Visual assessment of clot fonnation by A375, control and LAK cells. Control 
lymphocytes, LAK cells, A375 cells, RPM I and mixtures of control and LAK cells with 
A375 cells (at an E:T of 50:1) were incubated in the presence of nonnal plasma (5%) for 
0, 1, 2, 4 or 18h, as described in section 2.3.4, and a visual assessment of clot 
fonnation made. Supernatants were taken from relevant wells after each time point and 
stored for analysis of thrombin and D-dimer generation. The results shown were 
repeated in 2 further experiments. A score of: (-) indicated no observable clot 
fonnation; (+) - partial clotting, resulting in increased viscosity of the cell suspension; 
(++) - a solid clot which disintegrated on agitation; (+++) - a solid clot which was not 
dispersed by agitation. Solid clots were observed after 1 h when control or LAK cells 
were incubated alone, but in all cultures containing A375 cells, clot fonnation was less 
strong than control or LAK cells alone and no clots were present after 4h incubation. 
Table 5.1 shows the visual assessment of clot integrity over 18h for control, 
LAK, A375 cells and tissue culture medium alone. In addition, clot visualisation 
is shown for mixtures of control and LAK cells with target cells at an 
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effector:target cell ratio of 50: 1. The plasma concentration was 5% throughout. 
After 1-2h control and LAK cells induced the formation of a solid clot which 
was still apparent after 18h. A375 cells, alone or in combination with control or 
LAK cells induced a sticky, but not solid, clot after 1-2h, which had 
disappeared after 4h. Plasma (5%) added to RPMI alone generated a very 
stringy, friable clot after 2-4h which remained after 18h. These results 
demonstrated that control, LAK and A375 cells expressed procoagulant 
activity. Furthermore, A375 cells possessed fibrinolytic activity, demonstrated 
by clot dissolution in all wells in which these cells were present. The following 
two sections further evaluate the procoagulant and fibrinolytic properties of 
control, LAK and A375 cells. 
5.2.2 Evaluation of the Procoagulant Activities of Lymphocytes, 
LAK and A375 Cells 
In order to quantify the above observations (see table 5.1), thrombin activity 
(using the chromogenic substrate 82238) was measured in supernatants 
collected from each well and time point (see figure 5.10). 
In 3 experiments, RPMI induced minimal thrombin activity throughout the 18h 
assay period. A375 cells induced a sharp peak in activity after 1 h which 
subsequently decreased over the assay period reaching a level slightly above 
the starting value after 18h. Control and LAK cells alone induced a sharp rise 
in thrombin activity after 1 h which decreased slightly over 18h (p>O.05 
compared to 1 h), but still remained considerably higher than the initial 
observation. Combination of control or LAK cells with A375 cells induced the 
greatest increase in thrombin activity after 1-2h which then fell to levels similar 
to those of control and LAK cells alone after 18h. The decrease in thrombin 
activity after 18h was probably due to partial breakdown of the thrombin. 
Experiments were carried out to further elucidate the mechanism(s) of the 
procoagulant activities of LAK and A375 cells. 
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FIGURE 5.10. Time course of thrombin generation during LAK cell cytotoxicity of A375 
cells. Supernatants collected from cultures of RPMI, control (5x106 cells/ml), LAK (5x106 
cells/ml), or A375 cells (1x105 cells/ml), alone, and control or LAK cells together with 
A375 cells in the presence of 5% normal plasma, were assessed for thrombin activity 
using the chromogenic substrate S2238 (see section 2.3.5). Three experiments were 
performed, of which the data shown are means from a representative experiment All 
cell types alone or in combination induced a sharp increase in absorbance after 1 h 
(compared to values at time 0; p<0.05 by MWU and PTT), with the absorbance for A375 
cells < control or LAK cells (p<0.05 by MWU and PTT) < control or LAK + A375 cells 
(p<0.05 by MWU and PTT). Absorbances for control or LAK cells alone decreased 
slightly (but not significantly) after 18h, but a marked drop in absorbance was observed 
after 18h (2h for A375 cells alone) in supernatants from cultures containing A375 cells 
(p<0.05 by MWU and PTT). 
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Tumour cell lines have been reported to possess direct factor X activating 
activity, also known as cancer procoagulant activity (Gordon et a/., 1975). 
Experiments were therefore performed to assess the ability of A375 cells to 
directly activate factor-X. A375 cells were incubated with factor X (0.16, 0.31 J 
0.63, 1.25, 2.5 and 5U/ml) for 0.25, 1, 4 and 18h, after which the supernatants 
were removed and stored at -70DC. In addition the cells were washed and the 
plates stored at -70DC. Supernatants and cell Iysates were subsequently 
thawed, and incubated in triplicate with the chromogenic substrate S2222. As 
a positive control factor Xa was also assayed. No change in absorbance was 
measured in any of the test wells, but the positive control reacted with the 
substrate within minutes, indicating that A375 cells did not secrete cancer 
procoagulant into the supernatant. The absence of colour change in the cell 
Iysates indicated that factor X had not been adsorbed or internalised and 
subsequently activated to factor Xa by the cells. 
To investigate the mechanism of procoagulant activity further, LAK and A375 
cells were incubated separately with plasma, factor V, VII, VIII, IX and X 
deficient plasmas (5% final dilution), as well as RPMI alone, for 4h, the 
supernatants removed and tested for thrombin activity. The absorbance values 
for the plasmas in tissue culture medium alone (RPMI) were subtracted from 
those of the plasmas mixed with cells. Figure 5.11 shows the results of a 
representative experiment (of 3 performed). After 4h, plasma in RPMI 
generated a tenuous clot which was reflected in the generation of thrombin 
(absorbance of 0.166). No clots or thrombin activity were seen in any wells 
containing factor deficient plasmas in the absence of cells (i.e., cultured in 
RPMI). LAK cells induced greater thrombin activity in whole plasma than the 
control (whole plasma in RPMI). In addition thrombin activity (and also clotting) 
was also observed with LAK cells in factor V, VII I and IX and to a lesser extent 
factor VII, but not factor X deficient plasma. A375 cells induced thrombin 
activity in plasma (above that of the control) factor VII, VIII and IX, but not 
factor X deficient plasma. The absorbance values for A375 cells were lower 
than those for LAK cells because the A375 cell density was lower. The cell 
concentrations reflected those in the cytotoxicity assay (i.e. LAK 50: 1 A375). 
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FIGURE 5.11. Thrombin generation 'by LAK cells and A375 cells. LAK cells (5x106 
cells/ml), or A375 cells (1 x1 05 cells/ml), were incubated with normal plasma (5%) or 
plasmas deficient in coagulation factors V, VII, VIII, IX or X for 4h, supernatants 
collected and thrombin activity determined using the chromogenic substrate S2238 
(see section 2.3.5). RPM I was also incubated with each plasma and the absorbances 
subtracted from those of LAK or A375 cells. The results are means and SEMs from 3 
experiments. Thrombin activity was induced by LAK cells to a similar degree (p>0.05 by 
MWU and PTT) in the presence of normal and factor V, VIII and IX deficient plasmas, 
but the absorbance was significantly decreased in factor VII deficient plasma. LAK cells 
were unable to induce thrombin activity in factor X deficient plasma. Significant 
(compared to background (RPMI); p<0.05 by MWU and PTT), but reduced (p<0.05 
compared to normal plasma) thrombin activity was induced in factor VII, VIII and IX 
defiCient plasmas by A375 cells, but not in factor V and X deficient plasmas. 
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Factor VIII and factor IX deficient plasmas supported thrombin generation in 
the presence of LAK or A375 cells, suggesting that the procoagulant activities 
of these cells are primarily via the extrinsic, or tissue factor, coagulation 
pathway. Both cell types were unable to induce clotting of factor X deficient 
plasma, indicating that they were unable to directly activate prothrombin to 
thrombin. The inability of A375 cells to clot factor X deficient plasma confirmed 
the earlier observation in this section that A375 cells were unable to directly 
activate factor X (i.e., did not produce cancer procoagulant), or prothrombin 
(some cancers lines have been reported to release enzymes which were able 
to activate prothrombin directly (Semeraro and Donati, 1981 b)). 
The ability of LAK cells to induce thrombin activity in factor V deficient plasma 
suggested that these cells possessed factor Va activity. However, a small 
number of contaminating monocytes in the LAK cell preparations may have 
been responsible for the clotting of factor V deficient plasma. In contrast, A375 
cells were unable to clot factor V deficient plasma. Both LAK cells and A375 
cells supported thrombin generation in the presence of factor VII deficient 
plasma. LAK cells may have induced clot formation in factor VII deficient 
plasma as a combined result of cell surface factor Va and activation of the 
intrinsic pathway to supply factor Xa for the conversion of prothrombin to 
thrombin. Alternatively, both cell types may have produced tissue factor (a cell 
derived cofactor required for factor Vila activity) which was bound to residual 
amounts of factor Vila derived from the serum in which the cells were cultured 
prior to assay. However, lymphocytes are not known to produce tissue factor, 
and it is more likely that LAK cells adsorbed tissue factor/factor Vila complexes 
from the serum in which they were cultured. From these results, further 
experiments were performed to determine if LAK cells, monocytes and A375 
cells possessed factor V, tissue factor or factor VII on their surface, using flow 
cytometry (section 2.5). Figures 5.12 - 5.14 are representative histograms of 
the test fluorescence intensity (FL 1) versus the fluorescence intensity of the 
FITC labelled isotype control on the X axis versus the number of positive 
events on the Y axis, for factor V, tissue factor and factor VII respectively, on 
the surface of A375 cells (a.), LAK cells (b.) and monocytes (c.). 
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FIGURE 5.12. A375 cell, LAK cell and monocyte surface factor V expression. A375 cells, 
LAK cells or monocytes were stained with anti-factor-V or isotype control, and flow 
cytometry performed as described in section 2.4. Ten thousand events were counted in 
each experiment. Three (A375 and monocytes) or 5 experiments (LAK) were performed, 
of which this result is representative. Both LAK cells and monocytes were positive for 
cell surface factor V (compared to the isotype control), but A375 cells showed no 
positive events with greater fluorescence than the isotype control. 
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FIGURE 5.13. A375 cell, LAK cell and monocyte cell surface tissue factor expression. 
A375 cells, LAK cells or monocytes were stained with anti-TF or isotype control, and 
flow cytometry performed as described in section 2.4. Ten thousand events were 
counted in each experiment. Three (A375), 7 (LAK cells) or 6 experiments (LAK) were 
performed, of which this result is representative. All cell types were positive for tissue 
factor expression compared to the isotype control. 
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a. A375 Cell Surface Factor VII 
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b. LAK Cell Surface Factor VII 
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FIGURE 5.14. A375 cell and LAK cell surface factor VII expression. A375 cells or LAK 
cells were stained with anti-factor VII or isotype control, and flow cytometry performed 
as described in section 2.4. Ten thousand events were counted in each experiment. 
Three experiments were performed, of which this result is representative. Both cell 
types were positive for factor VII expression compared to the isotype control. 
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Table 5.2 shows the mean number of factor V, tissue factor and factor VII 
antibody binding sites present on the surface of A375 cells, LAK cells and 
monocytes (calculations are described in section 2.5) . 
.......................................... l .. ~.~!.~ .. ~~~.~~ .......................... 1 .. ~~.~~.!.1.~ ....................... .L..~.~n~.~~es 
Antigen ~ n Binding Sites 1 n 1 Binding Sites l n .. ein·iii·n·g .. Sites .................. · .. · .... · .. 
Factor V 1 3 _ None Detected i 5 1 650 (109) 1 3 4422 (1032) 
··~~ci~·;·~IT~~·~·~······t··j···· .. · · .. }~:jl·1(~~;·?2········t··j·····f··~~~·J1~·~~)········ .. ··I···~····· ··~iIt~T~~~d················ .. ··· .. ···· .. ··· .. ·· 
TABLE 5.2. Detection of factor-V, factor VII and tissue factor on A375 cells, LAK cells 
and Monocytes. A375 cell, LAK cell and monocyte cell surface factor-V, TF and factor-
VII antibody binding sites were measured (in n experiments) by flow cytometry (see 
section 2.4). Anti-TF was a directly labelled antibody and anti-factorV and anti-factor-VII 
binding sites were assessed indirectly. Results are means and SEMs (in brackets). Cell 
surface factor-V was present on monocytes in approximately 7 fold greater numbers 
than LAK cells, and was not detected on the surface of A375 cells. Tissue factor was 
expressed by A375 cells in approximately 7 fold greater numbers than monocytes and 
23 times greater than LAK cells. Factor-VII was present on A375 cells in approximately 
50% greater amounts than on LAK cells. 
A375 cells possessed tissue factor and factor VII, but not factor V on their 
surface, which is in agreement with their ability to induce thrombin activity in 
factor VII, but not factor V deficient plasma. The most likely mechanism of 
A375 cell procoagulant activity is the expression of tissue factor on the cell 
surface, which then binds activated factor VII from the culture environment, 
enabling the cells to initiate the coagulation system. 
LAK cells also expressed cell surface tissue factor and factor VII (although to a 
lesser extent than tumour cells), indicating that the mechanism of procoagulant 
activity was similar to that of A375 cells. However, in addition to TF and factor 
Vila expression, LAK cells also expressed cell surface factor V, which acts at a 
later stage of coagulation than factor Vila. Thus, in the presence of factor Xa 
(activated by factor Vila), and calcium ions (the phospholipid component is 
provided by the cell membrane), lymphocyte cell surface factor Va can activate 
prothrombin to thrombin, and hence fibrinogen to fibrin. It is probable that LAK 
cells synthesised the cell surface factor V, since recent reports have also 
shown that lymphocytes express mRNA for factor V (Shen et aI., 1993). 
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Monocytes were also positive for both factor-V and tissue factor which has 
been previously reported (Kappelmayer et aI, 1993; Shen et a/., 1993), and are 
thus able to activate coagulation in a similar fashion to lymphocytes or LAK 
cells. 
These results are thus consistent with the patterns of thrombin generation in 
factor deficient plasmas shown previously in this section. 
Since the presence of A375 cells in cultures containing plasma resulted in 
dissolution of the fibrin formed (as shown in table 5.1 above), experiments 
were performed to characterise the fibrinolytic activity of these cells. 
5.2.3 Evaluation of the Fibrinolytic Activities of Lymphocyte, LAK 
and A375 Cells 
Supernatants taken from experiments described in section 5.2.1 (observation 
of cell induced clot formation in normal plasma) were assessed for D-dimer 
production as an indicator of the fibrinolytic activity of the cells (figure 5.15). 
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FIGURE 5.15. D-dimer production during LAK cell cytotoxicity of A375 cells. 
Supernatants collected from cultures (from 1 experiment, assayed x3; means shown; 
see section 2.3.4) of RPMI, control (5x106 cells/ml), LAK (5x106 cells/ml), or A375 cells 
(1x105 cells/ml), alone, and control or LAK cells together with A375 cells in the presence 
of 5% normal plasma, were assessed for the presence of D-dimer as described in see 
section 2.3.8. Cultures containing lymphocytes (control cells) or LAK cells alone 
induced significant D-dimer production only after 18h incubation (compared to RPMI; 
p<0.05 by MWU and PTT). A375 cells alone or a combination of A375 and control cells 
induced significant (A375 cells alone < A375/control; p<0.05 by MWU and PTT) D-dimer 
production after 2h (compared to RPMI; p<0.05 by MWU and PTT). Supernatants from 
cultures of A375 and LAK cells induced D-dimer after 1 h (p<0.05 by MWU and PTT). The 
supernatants from cultures containing A375 cells induced levels of D-dimer of 
>2000ng/ml after 2h (A375/control, A375/LAK) or 4h (A375 cells alone), which dropped 
significantly after 6h incubation (compared to 4h; p<0.05 by MWU and PTT). 
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In wells containing RPMI and plasma no D-dimer production was seen over the 
assay period. A375 cells alone or in combination with control and LAK cells 
induced very high levels (plateau shown where results were above the 
standard curve, i.e.,. >2000ng/ml) of D-dimer after 1-2h which subsequently 
decreased (except LAKlA375) between 6-18h. In the wells containing control 
or LAK cells alone some D-dimer production was seen after 6-18h (p<0.05 
compared to RPMI). These results show that control and LAK cells possessed 
very little fibrinolytic activity as measured by D-dimer production. This 
confirmed the previous observation that clots were still present after 18h when 
these cells were incubated with whole plasma. A375 cells however were highly 
fibrinolytic, and were thus likely to be responsible for the observed clot 
dissolution when cultured with lymphocytes or LAK cells. 
As previously observed (table 5.1), cocultures of A375 cells with either 
lymphocytes (control cells) or LAK cells in the presence of plasma resulted in 
clot dissolution after 2-4h. However, in the microplate cytotoxicity assay 
(section 5.1.1), significant inhibition of cytotoxicity was observed after 18h. 
Further experiments were therefore performed to identify the mechanism of 
A375 cell fibrinolytic activity, and to determine the effect of antifibrinolytic 
agents on plasma inhibition of cellular cytotoxicity. 
5.2.4 Fibrinolytic Activity of A375 Cells 
As mentioned above, fibrin is a major constituent of the extracellular matrix in 
most, if not all, solid tumours. In order for tumour cells to grow and 
metastasise, they must be able to break down their extracellular matrix. There 
are two main ways in which this can be achieved. Firstly, production and 
secretion of proteolytic enzymes such as cathepsins, collagenases and 
elastase, all of which have specificity for fibrin in addition to their major 
substrates. Secondly, adsorption of plasminogen/fibrin complexes onto their 
surface, and secretion of plasminogen activators (u-PA and t-PA) to activate 
the plasminogen to plasmin, which subsequently degrades fibrin. Experiments 
were performed to identify the mechanism of A375 cell fibrinolytic activity. 
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A375 cells were grown to confluence in 96 well microtitre plates. The tissue 
culture medium was replaced with medium containing plasma, matched serum 
or plasma which had been passed through a Iysine-sepharose column (to 
remove plasminogen; plasminogen-depleted plasma) at concentrations of 
0.63, 1.25, 2.5, 5, 10 and 20% for 4h (the peak time of D-dimer production). 
Supernatants were washed from the cells and the chromogenic substrate S-
2251 (specific for plasmin) added overnight at 37°C, and the absorbance at 
405nm measured. 
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FIGURE 5.16. Plasmin activity on A375 cells treated with plasma, serum or plasminogen 
depleted plasma. Adherent A375 cells were incubated with HI serum, matched plasma, 
plasminogen depleted plasma or RPM I for 4h at 37°C. The supernatants were removed 
and the cells further incubated with the chromogenic substrate 52251 (see section 
2.3.7), and the absorbance at 405nm measured after colour development. The 
absorbance from RPMI and 52251 (blank; 0.147) was subtracted from test absorbances, 
and The means and 5EMs from triplicate results are shown are shown. Plasmin activity 
from whole plasma was significantly greater than either serum or PDP at 
concentrations of 2.5% and above (p<0.05 by MWU and PTT), but some activity was 
observed in serum and PDP at 10% and 20%. 
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A375 cells incubated with serum and plasminogen depleted-plasma showed 
some plasmin activity at 10% and 20% (figure 5.16). The serum probably still 
contained some plasmin(ogen) after clotting had occurred, and the 
plasminogen depleted plasma may have contained residual amounts of 
plasminogen which was able to bind to the fibrin, and hence become activated 
by the A375 cells. Plasma however, showed higher absorbance values than 
either of the other preparations at concentrations of 2.5% and above (p<O.05 
compared to serum). Maximal absorbance occurred in 20% plasma, which was 
considerably higher than that of serum and plasminogen depleted plasma 
(p<0.05), reflecting an increase in plasmin activity. 
Clot formation was observed during the course of these experiments. Table 
5.3 shows that no clot formation was observed in the serum control. 
Time (h Serum (5% Nonnal Plasma (%) Plasminogen Depleted Plasma RPMI 
2.5 5 10 20 2.5 5 10 20 
0 
- - - - - - - - - -
0.5 
- - - - - - - - - -
1 - ++ ++ - - - - - - + 
2 
-
++ ++ ++ 
-
+ + 
- -
+ 
4 
- - - - -
++ ++ + 
-
+ 
18 - - - - -- +++ ++ + + + 
. TABLE 5.3. Visual assessment of clot fonnation in serum, plasma and plasmmogen 
depleted plasma. A375 cells (1x105/ml) were incubated in the presence of serum (5%), 
matched plasma (2.5-20%) or plasminogen-depleted plasma (PDP; 2.5-20%) at 37°C in 24 
well microtitre plates, and clot fonnation observed visually for 0-18h. This experiment 
was repeated twice and these results are representative. A score of: (-) indicated no 
observable clot fonnation; (+) - partial clotting, resulting in increased viscosity of the 
cell suspension; (++) - a solid clot which disintegrated on agitation; (+++) - a solid clot 
which was not dispersed by agitation. Clot fonnation was observed in 2.5% and 5% 
plasma after 1 h, and in 2.5%, 5% and 10% plasma after 4h, but no clotting was seen in 
20% plasma. No clots were present at any concentration of plasma after 4h. Clotting 
was observed in 2.5% PDP and solid clots were still present after 18h. The strength of 
clot observed decreased with increasing PDP concentration. 
Clotting was observed with plasma and A375 cells at 1 and 2h, but as before 
(table 5.1, section 5.2.1), the clots were no longer present after 4h. 
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plasminogen depleted plasma took longer to clot than whole plasma, but clots 
were still present after 18h, indicating that fibrinolysis had been inhibited. 
Since solid clots were still present after 18h in cultures of A375 cells and PDP , 
experiments were performed to compare LAK cell killing of A375 cells in the 
presence of either plasma or PDP. 
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FIGURE 5.17. Inhibition of LAK cell killing of A375 cells by plasma and plasminogen 
depleted plasma (PDP). Cytotoxicity of Na51Cr04 labelled A375 cells by LAK cells was 
performed in the presence of HI serum (5%), plasma (5%; matched to the serum) and 
plasminogen depleted plasma (PDP; 5%; see section 2.3.3) after 18h. The means and 
SEMs from 3 experiments are shown. As previously observed LAK cell cytotoxicity was 
inhibited by plasma (compared to serum; p<O.05 by MWU and PTT), and inhibition was 
increased in the presence of PDP (compared to plasma; p<O.05 by MWU and PTT). 
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Figure 5.17 shows the mean maximal LAK cell cytotoxicity obtained from 3 
experiments. As previously observed (section 5.1.1, figure 5.2) killing was 
inhibited when plasma was included in the assay, but inclusion of plasminogen 
depleted plasma resulted in increased inhibition compared with plasma 
(p<O.05). In addition, clots were still visible in wells containing plasminogen 
depleted plasma after 18h, whereas no solid clots were observed in wells 
containing whole plasma after 4h (see also table 5.3). The presence of a fibrin 
clot in the assay wells was probably responsible for the increased inhibition of 
cytotoxicity observed. 
These results suggested that plasmin was probably the major fibrinolytic agent 
when A375 cells were combined with plasma, since removal of plasminogen 
resulted in increased inhibition of killing. Plasmin activity in fresh plasma can 
also be inhibited by the addition of synthetic lysine analogues such as epsilon-
amino-caproic-acid (6-amino-hexanoic acid (eACA)). The following 
experiments examined the effect of eACA addition to plasma on inhibition of 
LAK cell cytotoxicity against A375 cells. 
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5.3 Fibrin Structure and LAK Cell Cytotoxicity of A375 Cells 
5.3.1 Effect of eACA on Plasma Inhibition of Lymphocyte and LAK 
Cell Cytotoxicity 
The synthetic lysine analogue eACA, functions by binding to lysine binding 
sites on plasminogen, resulting in a conformational change in the plasminogen 
molecule (Brockway and Castellino, 1971). For plasmin to cleave fibrin( ogen), 
it must bind via its lysine binding sites to lysine residues on fibrin(ogen). 
Blocking these lysine binding sites on plasminogen prevents the formed 
plasmin from binding to and enzymatically degrading fibrin(ogen). 
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FIGURE 5.18. Killing of A375 cells by LAK cells in plasma or serum: effect of eACA. LAK 
cell cytotoxicity (E:T 50:1) against Na51Cr04 labelled A375 cells was determined after 
18h in the presence of HI serum (5%) or matched plasma (5%)./ Parallel cultures also 
included the synthetic lysine analogue eACA (20mmol/l). The means and SEMs from 5 
experiments are shown. Solid clots were observed in all wells containing eACA after 
18h, but not in wells in which eACA was absent. Killing of A375 cells by LAK cells was 
inhibited in plasma (compared to serum; p<0.05 by WSR and PTT), and inhibition was 
further increased in the presence of eACA (compared to plasma; p<0.05 by WSR and 
PTT). Addition of eACA to cultures containing serum had no effect on LAK cell 
cytotoxicity (p>0.05 by WSR and PTT). 
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Having determined that A375 cell fibrinolytic activity was due primarily to 
plasmin, experiments were performed to determine the effect of halting 
fibrinolysis on the inhibition of cytotoxicity by plasma (figure 5.18). Addition of 
eACA (20mmol/l) to the cytotoxicity assay allowed solid clot formation to occur 
which was still present after 18h. A375 cells were not directly killed by eACA at 
concentrations below 50mmol/L. However, 20mmol/l or greater was required 
for inhibition of fibrinolysis after 18h. A concentration of 20mmol/l eACA was 
thus chosen for use in further experiments. LAK cell killing of A375 cells was 
not affected by addition of eACA in the presence of serum (p>0.05), but 
considerable inhibition (greater than with plasma alone (p<O.05)) of 
cytotoxicity was seen when eACA was added in the presence of plasma. One 
explanation for this is that the fibrinolytic activity of the A375 cells allowed 
greater cell-cell contact in the later stages of the assay in the presence of 
plasma alone resulting in a partial restoration of cytotoxic activity (and thus 
partial inhibition). Inhibition of fibrinolysis by eACA (i.e.,. retention of fibrin 
throughout the assay period) inhibited LAK cell killing of A375 cells to a 
greater extent than in plasma alone (p<O.05). 
These results further suggest that fibrin is the factor responsible for inhibition 
of cytotoxicity. However, fibrin formation from fibrinogen to cross-linked fibrin is 
a multi-step process. It was, therefore, necessary to determine which form, or 
forms, of fibrin were responsible for inhibition of cytotoxicity. 
5.3.2 Effect of Fibrin Crosslinking on Inhibition of LAK Cell 
Cytotoxicity 
Fibrinogen is converted into fibrin by the thrombin-induced release of two 
small peptides, fibrinopeptides A and B. The resulting fibrin monomers 
spontaneously bind to each other to form a non-covalently linked polymer. 
Thrombin also activates another enzyme, factor XIII, which covalently cross-
links the formed fibrin. Experiments were performed to determine whether 
cross-linking of fibrin was necessary for inhibition of cytotoxicity to occur. 
Plasma was obtained from a patient with factor XIII deficiency (kindly provided 
by Dr Osier, Bournmouth General Hospital). Factor XIII was measured and the 
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a-subunit was not present in detectable amounts, indicating that no fibrin 
crosslinking was possible in the cytotoxicity assay (the factor XIII assay was 
kindly performed by Dr Ian Mackie, University College Hospital, London). 
Factor XIII-deficient plasma was compared with whole plasma and serum for 
its effect on LAK cell cytotoxicity against A375 cells (figure 5.19) .. 
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FIGURE 5.19. LAK cell cytotoxicity of A375 cells in plasma, FXIII deficient plasma or 
serum: effect of eACA. LAK cells were incubated with Na51Cr04 labelled A375 cells (+1-
eACA 20mmol/l) for 18h in the presence of HI serum (5%), matched plasma (5%) or 
plasma deficient in factor XIII (5%). Results are means and SEMs from 6 experiments. 
Solid clots were present in wells containing eACA after 18h, but not in those in which 
eACA was absent. Cytotoxicity was inhibited by plasma and FXIII deficient plasma 
(compared to serum; p<O.05 by WSR and PTT) to a similar degree (p>O.05 by WSR and 
PTT compared to each other). Inhibition by both plasmas was increased when eACA 
was present in the assay (compared to plasmas -eACA; p<O.05 by WSR and PTT), but 
no difference in inhibition was observed between whole plasma and factor XIII deficient 
plasma (p>O.05 by WSR and PTT). Killing in serum was not affected by the presence of 
eACA (p>O.05 by WSR and PTT). 
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In 6 experiments Factor XIII deficient plasma significantly inhibited LAK cell 
killing compared with serum, as did whole plasma (p<0.05). Inspection of clot 
formation during the assay again showed that fibrinolysis had occurred. 
Inclusion of eACA with whole plasma or Factor XIII-deficient plasma resulted in 
greater inhibition of killing than with the plasmas alone. Inhibition of killing by 
plasma and factor XIII deficient plasma were not Significantly different, either in 
the presence or absence of eACA. These results show that polymerised fibrin 
inhibited LAK cell killing of A375 cells, irrespective of whether it was 
crosslinked by activated factor XIII. 
Polymerised and cross-linked fibrin in the extracellular matrix of the tumour 
may be a contributory factor to the inhibition of LAK cell activity in vivo. 
However, many cancer patients also have various intravascular coagulation 
problems (Lindahl et a/" 1990), among which are elevated levels of fibrin 
monomer. It was, therefore, of interest to continue this series of experiments to 
investigate whether fibrin monomer also inhibited LAK cell killing of A375 cells. 
5.3.3 Effect of Fibrin Monomer on LAK Cell Killing of A375 Cells 
Fibrin monomer is formed by the sequential thrombin induced cleavage of 
fibrinopeptides A and B (FPA and FPB) from the Aa and B~ chains 
respectively of fibrinogen. The N-terminal regions of the a chains of fibrin end 
in the tripeptide Gly-Pro-Arg in many species, including man, and are thought 
to be involved in the spontaneous polymerisation of fibrin monomer. In 1978, 
Laudano and Doolittle prepared Gly-Pro-Arg and found that it inhibited fibrin 
polymerisation. The addition of a fourth residue such as sarcosine or proline 
significantly increased the activity of the peptide, but addition of proline had an 
additional advantage of making the peptide more resistant to proteolytic attack 
because of the presence of the imino acid. Gly-Pro-Arg-Pro was, therefore, of 
use in this study to distinguish between the effects of fibrin monomer and 
polymerised fibrin on LAK cell killing of A375 cells. 
Initial experiments showed that GPRP was not directly cytotoxiC to A375 cells 
or LAK cells at concentrations between 1-20mmolll. In 3 experiments GPRP 
(20mmolll final concentration) was added to plasma, and their combined effect 
on LAK cell cytotoxicity was measured. However, if GPRP was added to 
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plasma alone, the fibrin monomer formed could be degraded by plasmin. For 
this reason, a combination of GPRP and eACA was also included in the assay. 
Since fibrin monomer can also be cross-linked by factor XIII, a combination of 
GPRP and eACA were added to factor XIII-deficient plasma and the effect of 
all these combinations on LAK cell cytotoxicity was determined. In one 
experiment supernatants were collected from all wells after the 18h incubation 
period and stored at _lODC for subsequent measurement of thrombin and 0-
dimer activity. 
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FIGURE 5.20. Killing of A375 cells by LAK cells in plasma, FXIII deficient plasma or 
serum: effect of eACA and GPRP. LAK cell cytotoxicity (at an E:T of 50:1) of A375 cells 
was performed in the presence of HI serum (5%), matched plasma (5%) or factor XIII 
deficient plasma after 18h. In addition the effect of eACA (20mmolll), GPRP (20mmolll) 
or eACA and GPRP was investigated. Supernatants were taken from each well for 
subsequent thrombin and D-dimer estimation. Solid clots were observed after 18h only 
in wells containing plasma or FXIII deficient plasma and eACA alone. In 3 experiments 
(means and SEMs shown), plasma and factor XIII deficient plasma inhibited cytotoxicity 
(compared to serum; p<O.05 by WSR and PTT), to a similar degree (p>0.05 by MWU and 
PTT compared to each other). As before, eACA increased inhibition, but cytotoxicity in 
all cultures containing GPRP was not Significantly different to that in serum (p>0.05 by 
MWU and PTT). LAK cell cytotoxicity in serum was not affected by addition of eACA, 
GPRP or eACA and GPRP (p>0.05 by MWU and PTT). 
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Figure 5.20 shows the mean maximal (effector:target cell ratio 50:1) 
cytotoxicity generated by LAK cells in the presence of the above combinations 
of agents. LAK cell cytotoxicity in serum was unaffected by GPRP, eACA or 
GPRP + eACA. As previously observed, cytotoxicity in plasma (section 5.1.1) 
and factor XIII-deficient plasma (section 5.2.6) was lower than that in serum. 
Cytotoxicity in either plasma was greatly reduced by addition of eACA, but 
when GPRP alone or GPRP together with eACA were present in the assay 
cytotoxicity was restored almost to the serum level. 
These results showed that inhibition of fibrinolysis (by eACA) resulted in a 
marked increase in the inhibition of LAK cell cytotoxicity induced by plasma 
and factor XIII-deficient plasma, and suggests that cross-linked (normal 
plasma) and uncross-linked (factor XIII-deficient plasma) polymerised fibrin 
were both able to inhibit killing. Analysis of D-Dimer in the supernatants taken 
during the experiment showed that <30ng/ml D-Dimer was produced in any 
wells containing eACA, compared with >2000ng/ml for normal plasma alone 
and factor XIII-deficient plasma alone. 
No solid clots were observed in wells containing GPRP, but this was not due to 
inhibition of thrombin formation, since thrombin activity was measured in all 
wells containing plasma, factor XIII-deficient plasma or serum in combination 
with eACA, GPRP or eACA and GPRP (figure 5.21). 
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FIGURE 5.21. Thrombin activity from wells containing serum, plasma or FXIII deficient 
plasma +/- eACA, GPRP or eACA+GPRP. Supernatants collected from 18h cocultures of 
LAK cells (5x106/ml) with A375 cells (1x105/ml) in the presence of HI serum, matched 
plasma or factor XIII deficient plasma (+/- eACA (20mmolll), GPRP (20mmolll) or eACA + 
GPRP) were assessed for thrombin activity using the chromogenic substrate 52238 
(see section 2.3.5). The results shown are means and 5EMs of absorbances from 3 
experiments. Cell cultures in whole plasma and factor XIII deficient plasma exhibited 
greater thrombin activity than in serum (p<O.05 by MWU and PTT), but not to each other 
(p>O.05 by MWU and PTT). In addition, thrombin activity in plasma and factor XIII 
deficient plasma was greater in cultures also containing GPRP (compared to plasmas 
alone; p<O.05 by MWU and PTT). 
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It is interesting that more thrombin generation was seen in wells containing 
GPRP and either plasma or factor XIII-deficient plasma (but not in serum) than 
when GPRP was not present. Since thrombin converts fibrinogen to fibrin, 
even in the presence of GPRP, it can be considered that in wells containing 
GPRP, fibrin was present as fibrin monomer. Although an assay for fibrin 
monomer is available (COA-SET fibrin monomer, KABI Diagnostica, Uxbridge, 
Middlesex), it is inappropriate for use in the present study because it measures 
the amount of fibrin monomer by its ability to increase the conversion of 
plasminogen to plasmin, which subsequently interacts with the chromogenic 
substrate 82390. Many of the samples of interest contained eACA, which 
would inhibit the reaction in the fibrin monomer assay, resulting in negative or 
falsely low values for fibrin monomer production. From the these results it 
would appear that fibrin monomer was not able to inhibit the cytotoxicity of 
A375 cells by LAK cells. 
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5.4 Summary of Results 
1. Control and LAK cell cytotoxicity of A375 cells was inhibited in the presence 
of whole plasma at concentrations of 1.25%, 2.5%), 5%, and 10%. 
2. Heat-inactivated plasma was not inhibitory to control and LAK cell killing of 
A375 cells, demonstrating that the inhibitory factor(s) were heat labile. 
3. Plasma which had been adsorbed with aluminium hydroxide did not inhibit 
control or LAK cell killing of A375 cells, suggesting that one, or more, of the 
vitamin-K dependent clotting factors (FII, FVII, FIX, FX, Proteins S and C), 
were involved in the inhibitory process. 
4. Afibrinogenaemic plasma did not inhibit control or LAK cell cytotoxicity of 
A375 cells, suggesting that either fibrinogen or one of its products was 
responsible for the inhibition of cytotoxicity observed in whole plasma. 
5. Purified fibrinogen did not influence control or LAK cell killing of A375 cells, 
and these results suggested that fibrin formation (or a later stage of 
coagulation or fibrinolysis) was required for inhibition of cytotoxiCity to occur. 
6. Control cells, LAK cells and A375 cells all demonstrated procoagulant 
activity in recalcified whole plasma, as measured by observation and thrombin 
generation. 
7. LAK cells induced clot formation in factor V, VII, VIII and IX, but not factor X 
deficient plasmas, suggesting that the procoagulant activity of these cells was 
predominantly via the extrinsic (tissue factor) coagulation pathway, and that 
they possessed FVa activity. Subsequent flow cytometry demonstrated the 
presence of factor V, factor VII and low levels of TF on the surface of these 
cells. Since lymphocytes do not synthesise tissue factor, it was probably 
absorbed onto the cell surface bound to factor Vila. 
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8. A375 cells induced clot formation in factor VII, VIII and IX, but not factor V or 
X deficient plasmas. These results showed that A375 cell procoagulant activity 
was probably via the extrinsic (tissue factor) coagulation pathway, and that 
these cells did not possess factor V activity. As with LAK cells, clotting of factor 
VII deficient plasma by A375 cells may have been due to tissue factor bound 
to contaminating factor Vila derived from serum in the medium used to culture 
the cells prior to assay. Flow cytometry confirmed the presence of TF, but not 
factor Von the surface of these cells. 
9. A375 cells were highly fibrinolytic, and clots formed in whole plasma were 
lysed within 4-6h in coculture. Elevated levels of D-dimer were observed after 
as little as 1 h in culture. Cultures of control and LAK cells induced relatively 
little (compared with A375 cells) D-dimer production after 18h, but solid clots 
were still observed in these cultures after 18h incubation. 
10. A375 cells had the ability to activate plasminogen on their surface, as 
measured by reaction with the chromogenic substrate 52251. Incubation of 
these cells with plasminogen depleted plasma resulted in the presence of solid 
clots in these cultures after 18h, suggesting that plasminogen activation was 
the predominant fibrinolytic activity of these cells. Plasminogen depleted 
plasma inhibited LAK cell killing of A375 cells to a slightly greater extent than 
whole plasma. This may have been due to the presence of solid clots in the 
assay wells for the whole 18h incubation period. 
11. Addition of eACA (an antifibrinolytic agent) to the cytotoxicity assay also 
increased inhibition of LAK cell cytotoxicity of A375 cells over that observed in 
whole plasma alone. 
12. Inhibition of LAK cell cytotoxicity to A375 cells was also observed in the 
presence of factor XIII-deficient plasma, suggesting that fibrin cross-linking 
was not important in the inhibitory mechanism. As with whole plasma, addition 
of eACA caused increased inhibition of LAK cell killing of A375 cells in factor 
XIII deficient plasma. 
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13. Addition of Gly-Pro-Arg-Pro (a fibrin polymerisation inhibitor) to plasma or 
factor XIII-deficient plasma, in the presence or absence of eACA, almost 
completely restored LAK cell cytotoxicity of A375 cells to the level seen in 
serum, suggesting that fibrin monomer was unable to inhibit killing. 
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Chapter 6 
DISCUSSION 
The main objective of this study was to investigate why poor clinical 
responses are obtained with LAK cell immunotherapy, when LAK cells 
are highly cytotoxic to tumour cells in vitro. To this end, experiments 
were performed firstly to evaluate the cytotoxic activities of lymphocytes, 
monocytes and LAK cells against a variety of unstimulated and cytokine 
pretreated tumour cell lines in vitro; secondly, to establish in vitro the 
efficacy of chemotherapeutic drugs (Act-D and cycloheximide) on the 
enhancement of leucocyte, cytokine and LAK cell cytotoxicity to tumour 
cells; thirdly, to investigate the mechanism(s) and predominant leucocyte 
subtype( s) involved in lymphocyte cytotoxicity of tumour cells: and lastly 
to determine whether any factor(s) present in the circulation or the 
tumour environment inhibit the cytotoxic activity of infiltrating leucocytes 
and LAK cells. 
The interactions between cytokines, cytotoxic drugs, immune cells, 
cancer cells and the vasculature during immunotherapy is highly 
complex. The main purpose of the experiments in chapter 3 was to 
isolate and investigate in vitro, the interactions between cytokines, 
tumour cells and unstimulated peripheral blood mononuclear cells, in 
order to better understand the contributions made by these components 
to tumour destruction during immuno/chemo-therapy. 
Unstimulated normal lymphocytes were cytotoxic to K562 and U937 cells 
after 4h, but a longer incubation time (18h) was required for killing of the 
melanoma cell lines. Daudi cells were also insensitive to killing by 
lymphocytes after 4h. but moderate cytotoxicity (27%) was observed 
after 18h. In many previous studies (e.g., clinical trials undertaken by 
Amgen Corp. in the Rayne Institute at St Thomas' Hospital London 
(unpublished data)) the K562 and Daudi (or Raji, another EBV 
transformed cell line) cell lines have been used as standard in vitro 
indicators of NK and LAK cell activity respectively in 4h cytotoxicity 
assays. However, these cell lines may not be appropriate markers of the 
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in vivo effect of immunotherapy, since the patient's tumour cells may be 
more or less responsive to treatment. Inclusion of a tumour cell line of 
the same type as that of the patient (or cells grown directly from a biopsy 
of the specific tumour to be treated) may therefore yield more information 
about the potential efficacy of treatment in the individual patient. 
Lymphocytes were cytotoxic against the seven cell lines after 18h but , 
there was a heterogeneous response between the tumour cell lines. The 
most sensitive cell lines were K562 and U937. Lymphocyte killing of 
A375, DX3 and SK23 cells was augmented by target cell pre-treatment 
with Act-D, but cycloheximide (another protein synthesis inhibitor), was 
unable to augment lymphocyte cytotoxicity against any of the cell lines 
tested. In 2 further experiments (data not shown), no enhancement of 
lymphocyte cytotoxicity was observed after pre-treatment of the tumour 
cell lines with the cytotoxic drugs melphalan and vinblastine. 
It may be inferred from these results that the mechanism of action of 
these cytotoxic drugs on sensitive tumours in vivo may not be wholly due 
to their direct cytotoxic activity, but may be due in part to their 
sensitisation of tumour cells to the cytotoxic action of lymphocytes and 
monocytes already present in the tumour. This may be especially 
important in the areas of tumour which are distant from blood capillaries, 
where drug concentrations can be considerably lower than those in 
areas closer to capillaries. It may be useful prognostically therefore, to 
culture cells from tumour biopsies for short periods of time in order to 
determine their sensitivity to killing by leucocytes in combination with 
various chemotherapeutic agents prior to treatment. 
Freshly isolated monocytes were also cytotoxic against the melanoma 
cell line A375 and to K562 cells after 18h. Monocyte killing was maximal 
at an effector:target cell ratio of 50: 1 on both cell lines. There is some 
controversy as to whether unstimulated monocytes are able to kill tumour 
cells at all (Chen et aI., 1986), since monocytes in culture may be 
inadvertently activated by contaminating LPS. To address this point, the 
antibiotic polymyxin-8 (which bind to and inactivates LPS) was added to 
the tissue culture media and monocyte cytotoxicity reassessed. No 
difference in monocyte killing of A375 and K562 cells between untreated 
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and polymyxin-B treated media was seen, indicating that LPS was not 
responsible for the monocyte cytotoxicity observed. In addition the 
, 
media used in these experiments was determined to be non-pyrogenic in 
a rabbit pyrogenicity test, again indicating low levels or the absence of 
contaminating LPS. A more direct (and thus conclusive) test for the 
presence of LPS would have been the limulus amoebocyte lysate (LAL) 
assay, but this was not available in the department at the time these 
experiments were carried out. 
Depletion of CD8+ cells from freshly isolated lymphocytes resulted In 
over 75°k inhibition of A375 cell cytotoxicity, suggesting that CD8+ 
lymphocytes were primarily responsible for killing in this system. 
Cytokines are important in the modulation of immune reactivity to 
tumours in three main ways. (1) They can activate immune cells and thus 
increase their cytotoxic activity towards tumour cells (e.g. IL-2, IFNy,). 2. 
Some cytokines can sensitise tumour cells to the cytotoxic action of 
leucocytes (IFNy, IL-1), and (3), they can act directly as cytotoxic effector 
molecules (e.g. TNFa; IFNy, L T). Experiments were therefore carried out 
to examine the direct cytotoxic activity of several cytokines (section 3.1) 
which had been reported to have direct or modulatory activities on 
leucocyte killing of tumour cells. 
TNFa cytotoxicity was assessed against the seven cell lines untreated or 
preincubated with Act-D and as with lymphocyte killing a heterogeneous 
response was observed. Three of the four melanoma cell lines (A375, 
DX3 and L T5.1) were relatively unresponsive to the action of TNFa, but 
increased sensitivity was seen when these cells were pretreated with 
Act-D. In contrast, the melanoma cell line SK23, as well as K562 and 
Daudi cells were more sensitive (untreated) to TNFa killing than the 
three melanoma lines mentioned above, but Act-D pretreatment failed to 
enhance TNFa cytotoxicity of these cells. Not surprisingly, U937 was the 
most TNFa sensitive cell line and killing was greatly augmented by 
pretreatment with Act-D. With the exception of SK23 and U937, the 
pattern of augmentation of TNFa cytotoxicity by Act-D was similar to that 
seen using lymphocytes as effector cells, implying that TNFa may be an 
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effector molecule in lymphocyte killing of these tumour cell lines. The 
percentage cytotoxicity values for TNFa (1000U/ml) killing were 
consistently lower than those observed for maximal lymphocyte 
(effector:target cell ratio 50: 1) killing of the corresponding cell lines, 
whether untreated or preincubated with Act-D (section 3.2.8). This may 
be because TNFa was only one of a number of effector molecules in 
lymphocyte killing. Alternatively, the local concentration of cytokine 
generated when lymphocytes adhere to tumour cells may greatly exceed 
that used in these experiments. 
The cytotoxic activities of several other cytokines were also measured on 
the A375 melanoma cell line. (section 3.1.3). A375 cells were resistant to 
killing by IL-1~, but cytotoxicity was seen when the target cells were 
preincubated with Act-D. IL-1 ~ has been reported to be cytostatic for 
A375 cells (Onozaki et a/., 1985), but cytostasis could not be measured 
in the Na51 Cr04 release assay because the target cells would still remain 
intact and thus retain chromium. Since neither IL-1 ~ nor Act-D were 
cytotoxic in their own right at the concentrations used, their combination 
was therefore synergistic in the induction of A375 cell cytotoxicity. In 
these experiments IL-1 ~ behaved similarly to TNFa, which is consistent 
with the considerable overlap in their reported biological activities 
(Balkwill, 1989). 
IFNy is known to exert it's cytotoxic activity by the de novo synthesis of 
protein (Branca and Baglioni, 1982) in the target cell, and thus requires 
up to 72h incubation with target cells (Stuart et a/., 1988) to induce 
maximal killing. The observed lack of direct cytotoxicity by IFNy on A375 
cells after 18h was therefore consistent with these reports. As with IL-1 ~ 
and TNFa, IFNy and L T were cytotoxic to Act-D pretreated but not 
untreated A375 cells. These results suggested that combined cytokine 
and cytotoxic drug therapy may increase the response in cytokine or 
drug resistant tumours. IL-2 was not cytotoxic alone or when the target 
cells had been pretreated with Act-D. IL-2 has not been reported to be 
cytotoxic to tumour cell lines, but was included in this series of 
experiments to confirm that any residual IL-2 remaining in LAK cell 
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preparations was not directly responsible for any increased cytotoxicity 
observed (section 3.1.3). It is clear from these results that only relatively 
low levels of cytotoxicity could be obtained using cytokines alone or in 
various combinations, even when the target cells were preincubated with 
Act-D. With the exceptions of IFNa treatment of hairy cell leukaemia and 
some lymphomas, clinical trials using one or more cytokines in 
combination have also shown significant therapeutic value in the minority 
of cases (Wong and Goeddel, 1986; Pfizenmaier et a/., 1987; Fransen et 
al., 1986)). However, in the present study, the target cells remained in 
direct contact with cytokine for only 18h, whereas tumour cells in vivo 
may be subjected to infiltrating leucocyte derived cytokines for much 
longer periods of time. Further experiments were thus devised in which 
A375 cells were cocultured with IFNy, IL-2 or TNFa at various 
concentrations for up to 72h prior to their use as target cells (+/- Act-D) 
for lymphocyte or monocyte cytotoxicity (section 3.3). In the course of 
these experiments the initial number of cells placed in each flask was the 
same. After the incubation with cytokine the number of viable cells was 
assessed. When A375 cells were incubated with IFNy for 72h, a 
significant dose dependent decrease in cell yield was observed 
compared to that of untreated cells This could either have been due to 
the direct cytotoxic action of IFNy on A375 cells after 72h, whereas 18h 
(see above) was insufficient to demonstrate IFNy cytotoxicity, or IFNy 
was cytostatic for A375 cells after 72h, and the observed decrease in 
cell yield was the result of natural cell wastage over the incubation 
period. 
Under the same experimental conditions, a significant increase in cell 
yield was observed when A375 cells were incubated with IL-2 for 48h, 
suggesting that IL-2 was a growth stimulatory factor for these cells. In 
order for IL-2 to stimulate cell growth it must first bind to its receptor. 
Further experiments using flow cytometry were therefore carried out to 
determine if these receptors were present on A375 cells (3.1.4). In 3 
experiments no p75 receptors were found on A375 cells, but a mean of 
11456 +/- 4267 p55 (CD25) receptors were detected. The presence of 
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IL-2 receptors on A375 cells provided further evidence for IL-2 as a 
growth stimulatory molecule for A375 cells. Other tumour cell lines 
(Rimoldi et a/., 1993) have recently been reported to express low affinity 
(p75) and (p55) as well as high affinity IL-2 receptors (both p75 and 
p55). The presence of IL-2 receptors on the tumour cells of patients 
undergoing IL-2 immunotherapy may be a negative prognostic indicator 
for this form of treatment. However, in the case of IL-2/LAK cell therapy 
this growth stimulatory effect of IL-2 on tumour cells may be outweighed 
by IL-2 stimulation of tumouricidal activity by LAK cells and tumour 
infiltrating lymphocytes. As with tumour sensitivity to cytotoxic drugs, the 
determination of IL-2 receptor numbers on tumour biopsies prior to 
treatment may be clinically beneficial. Incubation of A375 cells with 
TNFa had no significant effect on the yield of viable cells after 72h 
compared with the untreated cultures. 
Pretreatment of A375 cells with IFNy for 48h or 72h resulted in increased 
killing of these cells by lymphocytes and monocytes. IFNy pretreatment 
may upregulate certain molecules (e.g. MHC class I and II) on the target 
cell surface which enhance lymphocyte recognition of or adherence to 
tumour cells, resulting in increased cytotoxicity. IFNy is known to 
upregulate the expression of HLA class II molecules on tumour cells 
(Pfizenmaier et a/., 1987). This increase in class II molecule expression 
may have been responsible for the observed increase in lymphocyte 
killing of A375 cells. Alternatively, the target cells may have been 
"weakened" by incubation with IFNy, resulting in increased sensitivity of 
the tumour cells to killing by leucocytes. Incubation of A375 cells with 
IFNy for 48h, followed by Act-O for 3h induced a synergistic increase in 
lymphocyte cytotoxicity. This may be the result of target cell attack via 
both of the above mechanisms. Act-O may have weakened the target 
cells by inhibition of protein synthesis, and hence inhibition of the target 
cell repair systems, whereas IFNy may have induced the target cells to 
express molecules recognised by lymphocytes. These results thus 
provide further evidence to support the use of combined immunotherapy 
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and chemotherapy, although the sensitivity of each tumour to these 
cytotoxic agents should be determined prior to treatment. 
Preincubation of A375 cells with a combination of IFNy and IL-2 (section 
3.3.1) did not result in any increase in lymphocyte cytotoxicity over that 
induced by IFNy alone, which is in agreement with other published data 
(Dealtry et a/ 1987). In contrast, monocyte cytotoxiCity was 
synergistically augmented by IFNy and IL-2 presensitisation of tumour 
cells. This combination of cytokines has been reported to produce an 
additive therapeutic effect when administered to mice bearing pulmonary 
metastases or intraperitoneal growths of weakly immunogenic tumours 
(Kedar et aI, 1992). Tumour cell pretreatment with IFNy and TNFa has 
been reported to result in a synergistic increase in lymphocyte 
cytotoxiCity (Balkwill and Smyth, 1987). However, in this study, no further 
increase in cytotoxicity was observed when TNFa was added in 
combination with IFNy. Act-D pretreatment did not induce any further 
increase in lymphocyte or monocyte cytotoxicity using combinations of 
cytokines than with IFNy alone. 
During cytokine/cytotoxic drug treatment of cancer, the therapeutic 
agents (such as TNFa, L T and IFNy) may interact, not only with tumour 
cells directly, but with host lymphocytes and monocytes, both in the 
peripheral blood and in the tumour mass, to further augment the anti-
tumour response. Since IL-2 was not cytotoxiC for the tumour cell lines 
used in this study (IL-2 has not been reported to be cytotoxic for any 
tumour cell lines), it is likely that its main therapeutic effect is activation 
of lymphocytes in vivo to the tumouricidal state (LAK cell production). In 
order to overcome the toxic side effects of high dose IL-2 infusion into 
patients undergoing immunotherapy clinical trials, leucocytes were 
removed from the peripheral blood of cancer patients, and activated with 
high concentrations of IL-2 prior to their reinfusion into the cancer 
patients. The next phase of experimentation in this study was thus to 
investigate the tumouricidal properties of LAK cells, and to assess their 
interactions with other blood components and normal cells (in vitro), 
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which they encounter on their passage through the peripheral blood and 
extravascular environment towards the tumour (Chapter 4). 
IL-2 stimulates lymphocytes to become highly cytotoxic to a wider variety 
of cell lines than unstimulated lymphocytes (LAK activity). The optimum 
concentration of IL-2 required to generate LAK activity against A375 
cells was found to be between 50-250U/ml, and maximal cytotoxicity was 
demonstrated by lymphocytes which had been cultured in the presence 
of IL-2 (2S0U/ml) for as little as 24h (section 4.1.3). The mean 
cytotoxicity of control (lymphocytes cultured for the same period of time 
as LAK cells, but excluding IL-2) cells for the melanoma and Daudi cell 
lines was slightly higher than that seen using fresh lymphocytes as 
effector cells (section 4.1.7, Table 1). This slight increase may be due to 
activation of the lymphocytes by a component of FCS (Lamph et al., 
1988). Cytotoxicity of some tumour cell lines (A375, DX3, SK23 L T5.1) 
by control cells was augmented when they were pretreated with Act-D. 
This occurred in the same general pattern, and to a similar degree, as 
that observed for fresh lymphocytes (section 4.1.7). In contrast, LAK 
cells were considerably more cytotoxic to all cell lines than either fresh 
lymphocytes or control cells, and this cytotoxic activity was not further 
increased by preincubation of the tumour cells with Act-D. The very high 
levels of LAK cell cytotoxicity to the tumour cells may mask any effect 
due to Act-D. Another explanation of these results is that LAK cell killing 
may employ a different mechanism of cytotoxicity than lymphocytes or 
control cells, which is independent of tumour cell repair systems 
involving protein synthesis. Whereas lymphocytes required 18h 
incubation with target cells, LAK cells were cytotoxic to tumour (A375) 
cells after as little as 1-2h in coculture (section 4.1.3). 
Fresh lymphocyte, control and LAK cell cytotoxicity against A375 cells 
was almost completely depleted when the CD8+ lymphocyte population 
was removed by cell sorting (section 4.1.6), indicating that these cells 
were primarily responsible for cytotoxicity against this cell line. This 
hypothesis was supported by the observation that CD16+ cell depletion 
did not significantly alter lymphocyte cytotoxicity against A375 cells. 
Reports in the 1980s (Herberman et aI., 1987) suggested that LAK 
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activity was induced primarily in the CD16+, CD3- large granular 
lymphocyte population (NK cells). CD8+ cytotoxic T-cells were 
subsequently found to possess LAK activity after stimulation with IL-2 
(ref). The predominant lymphocyte subtype present in many solid 
tumours are of this latter type (Lotzova, 1992). It is now considered that 
activated NK cells may act within the circulation and have a role in the 
prevention of metastatic tumour spread, while CD8+ LAK cell 
tumouricidal activity is directed more towards extravasation, infiltration 
and cytotoxicity of neoplastic cells within the tumour mass. 
IL-2 treated monocytes (>95% purity) did not generate any increased 
cytotoxicity of A375 cells compared to unstimulated monocytes (E:T ratio 
50: 1). In 1987 Malkovsky and co-workers reported that recombinant IL-2 
enhanced monocyte cytotoxicity against tumour cells. However, of the 
two target cell lines tested only one (T24, a human bladder cancer cell 
line) demonstrated increased sensitivity to IL-2 treated monocytes (E:T 
ratio 40: 1), whereas McSa-1 (derived from a murine fibrosarcoma), 
which is a known LAK cell sensitive cell line, was not sensitive to IL-2 
stimulated monocytes. These data suggest that although increased 
monocyte cytotoxicity may be stimulated against some cell lines by IL-2, 
LAK cells are able to kill a much wider spectrum of tumour cell types. 
LAK cells would therefore be a better choice of effector cell for adoptive 
immunotherapy than would monocytes. In addition, monocytes are 
adherent to their culture vessels, and would require additional treatment 
in order to remove them from the flasks. This treatment (usually EDTA) 
may block the function of the cell adhesion molecules on the monocyte 
surface, which could be involved in monocyte homing to the tumour site. 
Lastly, monocytes are present in peripheral blood in much lower 
numbers than lymphocytes. It would therefore be much more difficult to 
obtain monocytes in sufficient numbers for immunotherapy. 
There are several mechanisms by which lymphocytes and LAK cells are 
able unrestrictedly to kill tumour cells. These include the release of 
soluble molecules such as TNFu, L T and IFNy, or the release of the 
calcium dependent pore forming proteins, perforins. Monoclonal blocking 
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antibodies against TNFa and L T were available in the department, and 
were included in the cytotoxicity assay to determine whether they would 
inhibit control or LAK cell killing of A375 cells (section 4.4). In addition 
an "irrelevant" monoclonal antibody of the same IgG subtype (anti retinal 
antigen-S) was included as an antibody control. Control (lymphocyte) 
killing was partially inhibited by anti-TNFa and almost completely 
inhibited by anti-LT. Anti-antigen-S had no effect on control cell killing. 
These results suggest that Iymphotoxin and tumour necrosis factor were 
the primary effector molecules used by lymphocytes in this system. LAK 
cell killing was again partially inhibited by anti-TNFa, and in contrast to 
lymphocyte killing, was only partially inhibited by anti-L T. This may have 
been because the percentage specific cytotoxicity was much higher 
using LAK effectors than control cells. The percentage inhibition of 
cytotoxicity was very similar for control (41 %) and LAK (43°,1,) cells. Thus 
the amount of antibody added to the LAK cell cultures was insufficient to 
completely inhibit killing, even though the amount used was the highest 
which could be obtained (1 in 2 final dilution of stock antibody) in this 
assay system. Alternatively, LAK cells may employ another effector 
mechanism such as perforin mediated cell lysis, in addition to secretion 
of TNFa and LT. It can be concluded from these results however, that 
TNFa and L T play a highly significant (if not exclusive) role in 
lymphocyte and LAK cell mediated killing of A375 cells. 
TNFa and L T alone were relatively ineffective as direct cytotoxiC agents 
on tumour cells, even at over 1 DDDU/ml, but were directly implicated (see 
antibody inhibition of killing above) in lymphocyte and LAK cell killing of 
A375 cells. This apparent contradiction could be explained by the 
previously stated hypothesis that cell adhesion is required for cytotoxicity 
to occur, and that the concentration of cytokine secreted into the 
intercellular junction may far exceed that used in these experiments. The 
sensitivity of the tumour cell lines to control and LAK cell supernatants 
was therefore examined (section 4.3.1). Cytotoxicity of the tumour cell 
lines by control and LAK cell supernatants was consistently considerably 
lower than the killing observed with control and LAK cells. The maximum 
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level of tumour cell killing by the control cell supernatants was very 
similar to TNFa cytotoxicity in five of the seven cell lines (SK23 and 
Daudi cells were more responsive to TNFa than to supernatant). Slight 
(but not statistically significant) increases in killing were observed on 
some cell lines when the target cells were preincubated with Act-D 
, 
which generally matched the augmentation seen with TNFa or control 
cells as effectors. LAK cell supernatants were more cytotoxic to all cell 
lines than control cell supernatants, and this killing was augmented on 
five of the tumour cell lines in the same pattern as TNFa. As with control 
cell supernatants, the maximum killing seen with LAK cell supernatants 
was considerably lower than that observed using intact cells as effectors. 
It was interesting to observe such a general similarity between the 
cytotoxicity of the cell supernatants with that of TNFa (and L T), 
considering that the supernatants comprise a heterogeneous mixture of 
effector molecules (Limb et a/., 1989). Since control and LAK cell killing 
was inhibited by monoclonal antibodies to TNFa and L T, this data would 
suggest that these cytokines behave in a similar fashion to the 
recombinant forms when contained in complex mixtures. TNFa can also 
be expressed as a 23kDa membrane bound cytokine on activated 
lymphocytes (Ichinose et a/., 1988; Bakouche et a/., 1988), and this may 
account in part for the increased LAK cell cytotoxicity compared with that 
of the supernatants, as well as the inhibition of LAK cell killing by anti-
TNFa. In addition, another member of the TNF family, fas or AP01, is 
implicated in cytotoxic lymphocyte mediated killing of target cells 
(Tartaglia et ai, 1993). T-cell mediated crosslinking of the fas ligand on 
the target cell surface can result in the initiation of apoptosis, and this 
mechanism may also account for the increased cytotoxicity observed 
when effector and target cells were in direct contact. 
To test whether cell-cell contact was necessary for cytotoxicity, control or 
LAK cells were incubated with A375 cells (+/- Act-D) in the presence or 
absence of 0.8u pore size polycarbonate membranes (section 4.3.1). 
The membranes allowed the diffusion of soluble molecules from effector 
cells to target cells (and vice-versa), while preventing the cells from 
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coming into direct contact. Cytotoxicity of A375 cells by control and LAK 
cells was almost completely inhibited by the presence of the membranes. 
However, some killing was observed when the target cells were 
pretreated with Act-D, indicating that a soluble effector molecule or 
, 
molecules, had come into contact with the tumour cells, and that 
sensitisation of the tumour cells was required for killing to occur. This 
pattern of cytotoxicity has already been observed using recombinant 
soluble cytokines (TNFa, L T, IL-1 ~ and IFNy) (section 4.1.7), and it is 
likely that these molecules were responsible for cytotoxicity in the 
presence of the membranes. In summary, cell-cell contact between 
effector and target cells resulted in more efficient killing of the target 
cells than with cytokines alone, and this increased cytotoxicity may have 
been caused by an increased cytokine concentration at the intercellular 
junction, or by exposure of the target cells to membrane bound effector 
molecules or by a combination of these mechanisms. 
Prior to their infiltration into the tumour mass, LAK cells first come into 
contact with autologous unstimulated peripheral blood leucocytes and 
endothelial cells and, on passing out of the blood stream, fibroblasts. In 
this study LAK cells were not cytotoxic to autologous lymphocytes or 
monocytes (section 4.2.2). There are conflicting reports as to whether 
LAK cells kill autologous lymphocytes and monocytes in vitro (8alkwill, 
1989). LAK cells were highly cytotoxic for allogeneiC human umbilical 
vein endothelial cells and fibroblasts. Control cells showed some 
cytotoxic activity to endothelial cells after 4-18h, but this may have been 
due to partial activation of the lymphocytes by components of the FCS, 
as discussed previously. However, control cells did not kill fibroblasts 
after 18h in culture. This may be because fibroblasts are more robust 
cells than HUVEC and would thus be more resistant to killing by partially 
activated lymphocytes. Extrapolation of these results to the in vivo 
environment would suggest that reinjected LAK cells adhere to and non-
specifically kill endothelial cells and underlying fibroblasts. These 
interactions would result in severe damage to the blood vessel lining, 
allowing the extravasation of both blood cells and plasma. This vascular 
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leakage syndrome has been reported as a common side effect of IL-
2/LAK cell immunotherapy (Gemlo et aI., 1988). The non-specific 
adherence of LAK cells to endothelium in the peripheral circulation may 
inhibit LAK cell homing to the tumour site (assuming that LAK cells are 
able to home), resulting in the observed low numbers of effector cells 
arriving at the tumour, compared with the number of cells inoculated. 
Having determined that IL-2 activated leucocytes effiCiently killed a wide 
range of tumour cell types in vitro, the following chapter of results 
investigates the difference between the high levels of cytotoxicity 
observed in vitro, and the relatively poor clinical responses obtained in 
clinical trials using adoptive immunotherapy with LAK cells (chapter 5). 
Blood samples taken from patients who have undergone LAK cell 
therapy show considerable LAK cell activity against allogeneic and 
autologous tumour cells for several days after the initial infusion, 
although little LAK cell homing or tumour cytotoxicity has been observed 
in vivo. Reintroduction of IL-2 activated lymphocytes into the 
bloodstream of cancer patients results not only in their interaction with 
cellular components of the blood and extravascular tissue, but also with 
various molecules in the circulation and extracellular matrix. One major 
environmental difference between LAK cell therapy and the cytotoxicity 
assay is that LAK cells are introduced into an in vivo environment 
conSisting predominantly of plasma, and in vitro assays are generally 
performed in serum. Experiments were therefore performed to determine 
if LAK cell cytotoxicity in vitro was altered by the presence of plasma 
instead of serum in the assay. A375 cell killing by control and LAK cells 
was significantly, but not completely, inhibited in the presence of plasma 
compared with serum. Using purified fibrinogen and thrombin Gunji and 
Gorelik in 1988 reported that 5-10°A> plasma or serum could be toxic to 
effector or target cells in a murine system. No data was shown to 
SUbstantiate this claim, and the only reference quoted (Fogel et a/., 
1978) did not include plasma in the study. Thereafter, in the murine 
report and a later paper using human effector and target cells (Gunji et 
aI., 1990), they only reported data using a 5% or lower concentration of 
plasma in the cytotoxicity assays. A similar unsubstantiated claim for the 
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toxicity of serum or plasma at concentrations greater than 5% was made 
in a paper by Shinji Atagi in 1992, although in this study, cytotoxicity in 
1 Q0A, serum was not different from that in 5°A, or lower. 
Having determined that control and LAK cell cytotoxicity of A375 cells 
was inhibited in the presence of plasma it was next necessary to 
determine which component( s) of plasma was responsible for the 
inhibition. There were two main ways in which this could be approached. 
First, the use of purified molecules such as fibrinogen and thrombin to 
generate a clot in the assay plate, and to examine the effect of this and 
various anticoagulants and inhibitors of fibrin polymerisation on the 
inhibition of cytotoxicity. This was the main approach taken by Gorelik 
and others. Although the use of such purified systems gives more 
definitive results than the use of whole plasma, the results do not 
accurately reflect the physiological environment to which LAK cells are 
exposed on reinjection into the patient. In addition, the integrity and pore 
size of the fibrin gels generated using purified molecules is different to 
those produced using plasma, and thus are not representative of the 
structure and composition of fibrin formed within and around solid 
tumours. The second approach was to continue using plasma derived 
clots in the assays, but to modify the plasma in such a way that the role 
of the individual components of the coagulation system in the inhibition 
of cytotoxicity could be identified. The advantage of this is that all the 
components of the coagulation system are present together, so the 
interactions between them are more representative of those which occur 
in the tumour environment. It was this second approach which was 
chosen for further experiments in this study. 
No inhibition of A375 cell killing by control or LAK cells was seen in 
plasma which had been heat inactivated at 56 degrees for 45 minutes, 
indicating that a heat labile molecule was involved in inhibition of 
cytotoxicity. (section 5.1.2) A similar (though not complete) restoration of 
cytotoxicity was seen when plasma had been adsorbed with aluminium 
hydroxide. This showed either that one of the vitamin-K dependent 
clotting factors was responsible for inhibition or that the process of clot 
formation itself ( i.e. fibrin formation) was the causative agent. To test 
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this, the cytotoxicity assay was performed in the presence of 
afibrinogenaemic plasma from one of the patients attending the 
haemophilia centre. Again, no inhibition of killing was observed, 
indicating firstly that fibrinogen or some later component of the clotting 
process was the inhibitory factor, and secondly that cytotoxicity was not 
inhibited by any of the other components of the coagulation system 
present in normal plasma. 
The role of fibrinogen in the inhibition of cytotoxicity was examined by 
addition of a commercial fibrinogen preparation to the cytotoxicity assay, 
either alone or in the presence of serum. Serum was present as a control 
for potential nutrient deprivation during the course of the experiments. 
Unfortunately, this preparation of fibrinogen proved to be directly 
cytotoxic for the tumour cells. It was therefore decided to further purify 
the fibrinogen by gel filtration (section 2.4.9). After gel filtration the 
cytotoxic activity was present in the low molecular weight fraction, 
whereas the fractions containing clottable fibrinogen were no longer 
cytotoxic to A375 cells (section 5.1.5). The presence of fibrinogen in the 
assay neither enhanced nor inhibited control or LAK cell cytotoxicity of 
A375 cells, thus confirming that the process of clot formation (fibrin 
generation) was required for inhibition of cytotoxicity to occur. These 
results are in general agreement with those published by Gorelik and 
others using purified fibrinogen and thrombin, and would suggest that 
fibrin deposition within the stroma of solid tumours prevents the 
adherence of infiltrating lymphocytes (and monocytes) to the tumour 
cells, resulting in a suppression of immune reactivity towards the tumour 
mass. 
Many tumour cell types exhibit procoagulant activity, which may be 
specific or non-specific. Specific mechanisms include the production of 
factors (such as tissue factor, factor X, thrombin) by the tumour cells 
which result in the activation the of prothrombin, or the secretion of 
cytokines which activate mononuclear leucocytes and/or endothelial 
cells. Non-specific mechanisms include activation of the coagulation 
system by products released from necrosing tumour cells or from normal 
cells which have been disrupted by tumour invasion, or by the 
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stimulation of a host inflammatory response. Experiments were therefore 
performed in which RPMI, control cells, LAK cells and A375 cells alone 
or in combination with control or LAK cells at an effector:target cell ratio 
of 50: 1 were incubated with fresh citrated plasma for 0, 1, 2, 4 or 
18h.(Results Chapter 3} Observation of clot formation showed that both 
control and LAK cells induced the formation of solid clots within 1 h , 
which were still present after 18h. In contrast, A375 cells induced clot 
formation within 1-2h, but no solid clot was evident after 4h even when 
A375 cells were mixed with either effector cell type. Thrombin activity 
against the chromogenic substrate S-2238 was measured on 
supernatants from these cultures and confirmed the visual observation of 
clot formation. These results demonstrated that lymphocytes, LAK cells 
and A375 cells possessed procoagulant activity, and that A375 cells 
were also fibrinolytic. 
In order to determine the nature of the procoagulant activity by each cell 
type, LAK cells or A375 cells were incubated with fresh citrated plasma 
or plasmas deficient in various coagulation factors (section 5.2) for 4h 
(After this time the fibrinolytic activity of A375 cells would result in fibrin 
degradation) and, as before, thrombin generation was measured in the 
supernatants (section 5.2.2). A375 cells were unable to activate factor X 
directly (section 5.2.2) or to clot factor X deficient plasma, indicating that 
these cells do not possess cancer procoagulant activity (Gordon et al., 
1975). Both A375 cells and LAK cells induced clotting of factor VII 
deficient plasma, suggesting that they both expressed tissue factor 
activity. Subsequent flow cytometric analysis for tissue factor antigen on 
the surface of these cells (section 5.2.2) confirmed these observations. 
The presence of tissue factor on A375 and LAK cells enabled them to 
bypass the intrinsic pathway of coagulation, and thus induce clots in 
factor VIII and factor IX deficient plasma. Although A375 cells produce 
tissue factor, lymphocytes (and thus LAK cells) have not been reported 
to secrete this factor. It is likely therefore that LAK cell surface tissue 
factor was complexed with factor Vila derived from the serum in which 
the cells were previously cultured. The predominant procoagulant 
activities of these cells were therefore via the extrinsic pathway. LAK 
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cells (but not A375 cells) were also able to clot factor V deficient plasma, 
implying that they possessed direct factor V activating activity, or had 
factor V present on their surface. Again, flow cytometric analysis 
confirmed the presence of factor V antigen on the surface of LAK cells 
, 
and its absence on A375 cells. Synthesis of factor V by lymphocytes has 
recently been reported (Shen et a/., 1993). Whether fibrin deposition 
within and around solid tumours is beneficial to the patient or to tumour 
growth is not fully understood. In many inflammatory reactions fibrin 
deposition acts to isolate the inflammatory lesion from the host so that it 
can be easily dealt with by the host immune response. Cancer has been 
likened to an inflammatory lesion, and like other inflammatory conditions 
are characterised by the infiltration of leucocytes. The procoagulant 
activity of LAK cells is therefore consistent with an attempt by the 
immune system to isolate the tumour from the host. On the other hand, 
the procoagulant and fibrinolytic properties of tumour cells would 
suggest that they are able to lay down their own extracellular matrix 
when required and to degrade it in order to grow or metastasise. 
The blood vessels within tumours are more permeable to plasma 
proteins than those of normal tissues,. This is due firstly to a decrease in 
the organisation of the endothelium, with frequent gaps between 
endothelial cells and often incomplete or absent basement membrane; 
and secondly to the release of vascular permeability factors from the 
tumour cells. Extravasated fibrinogen is thus clotted in the tumour 
environment, and often forms the initial matrix for the growth of tumour 
cells prior to the deposition of collagen. In order to grow and 
metastasise, tumour cells must have the capacity to degrade their 
extracellular matrix (i.e. collagen and fibrin). Collagen is degraded by 
collagenases secreted by the tumour cells. There are two ways in which 
fibrinolysis may occur within the tumour stroma. 1. fibrin is susceptible to 
the action of proteolytiC enzymes secreted by the tumour cells such as 
collagenases, cathepsins and elastase. 2. the tumour cells may adsorb 
or specifically bind to the plasminogen-fibrin complex, and subsequently 
secrete plasminogen activators (uPA or tPA) to activate plasminogen to 
plasmin, resulting in fibrinolysis. Within the tumour mass there is a 
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continuous process of fibrin formation, and fibrinolysis at the growing 
edges of the tumour. The fact that there is always solid fibrin within the 
tumour is a result of the continuous supply of fibrinogen from the 
circulation. This is not the case in the in vitro assay plate, where the 
supply of fibrinogen is fixed. In this case, after the fibrinogen has been 
clotted, the fibrinolytic activity of the tumour cells will completely degrade 
the clot, leaving no solid fibrin within the plate. Consequently, the 
effector and target cells can again come into close contact, and 
cytotoxicity is re-established. This is the probable reason why the 
inhibition of cytotoxicity observed in this study was less (around 20% 
maximum) than that observed by Gorelik and others using pure clotting 
factors, where fibrinolysis was not observed. The use of plasma in the 
assays, and hence the observation of both clotting and fibrinolysis, is 
therefore more representative of the role of coagulation within tumours in 
vivo than is the use of purified clotting factors. In this study experiments 
were performed to determine the nature of A375 cell (as well as control 
and LAK cell) fibrinolytic activity. The supernatants taken previously for 
analysis of thrombin generation were also tested for D-dimer, a marker 
of fibrinolytic activity (section 5.2.4). After 18h a sma" amount of D-dimer 
was measured in the cultures containing control or LAK cells alone, 
indicating that these effector cells probably express a low level of 
fibrinolytic activity, although it was insufficient to eliminate all of the solid 
fibrin from the assay well. This low level of fibrinolytic activity by 
lymphocytes and LAK cells may be of use in the process of tumour 
infiltration by these cells, although the process would be relatively slow 
when compared to the fibrinolytic activity of the tumour cells. In a" 
cultures containing A375 cells, very high levels (> 2f.lg/ml) of D-dimer 
were measured, indicating that A375 cells were highly fibrinolytic. This 
correlated well with the observed pattern of clot dissolution in the assay 
plates. To determine if the observed fibrinolytic activity was due to 
plasmin, A375 cells were incubated for 4h with plasma, serum, or plasma 
which had been passed down a Iysine-sepharose column (section 2.4.3) 
in order to remove plasminogen. Serum and plasma (and plasminogen 
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depleted plasma; PDP) were obtained from the same donor. After 
removal of the supernatant (plasmin requires a cell surface 
(phospholipid) for it's activity) the cells were incubated with the plasmin 
specific chromogenic substrate 8-2251 (section 5.2.4). Some plasmin 
activity was seen with PDP and serum at 10 -20% (probably reflecting 
residual plasminogen), but whole plasma showed a considerable 
increase in plasmin activity compared with either serum or plasminogen 
depleted plasma at a concentration of 2.5%> and above. In addition solid , 
clots were still present after 4h incubation of PDP with A375 cells , 
whereas those generated from whole plasma were not. These results 
indicated that the fibrinolytic activity of A375 cells in vitro was primarily 
due to the action of membrane bound plasmin. Addition of PDP to the 
cytotoxicity assay resulted in greater inhibition of LAK cell killing than 
plasma, indicating that the presence of a solid clot throughout the assay 
period was responsible for this increased inhibition. Since PDP is not 
present in cancer patients, and is therefore not representative of the 
physiological state, further inhibition experiments were therefore carried 
out in the presence of eACA, a specific plasmin inhibitor (section 5.2.5) 
which has been used as a therapeutic antifibrinolytic agent (Brockway 
and Castellino, 1971). In the presence of eACA and whole plasma, solid 
clots were still present in the assay wells after 18h, confirming that 
fibrinolysis had been inhibited. Inhibition of A375 cell killing by LAK cells 
in the presence of plasma was significantly increased in the presence of 
eACA, confirming that the presence of solid fibrin throughout the assay 
period resulted in a greater inhibition of cytotoxicity than with plasma 
alone. These results also indicated that inhibition of cytotoxicity was not 
caused by the production of fibrinopeptides since no fibrinolysis had 
occurred (as determined by observation and D-dimer production in 
supernatants. 
In normal systems, fibrin is covalently crosslinked by activated factor 
XIII, with up to six crosslinked bonds per fibrin monomer subunit. This 
results in a polymer which is mechanically much stronger than non-
crosslinked fibrin polymer. It was therefore of interest to investigate if 
fibrin crosslinking was important in the inhibition of cytotoxicity observed 
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using whole plasma. Plasma was obtained from a patient with congenital 
factor XIII deficiency and included in the cytotoxicity assay together with 
normal plasma and serum. A significant reduction in LAK cell cytotoxicity 
of A375 cells was seen by both plasma and factor XIII deficient plasma 
compared with normal serum. Addition of eACA to the assay further 
increased the inhibition of both plasmas to similar levels, demonstrating 
that fibrin crosslinking by factor XIII was not important in the inhibition of 
LAK cell cytotoxicity. 
In addition to the generation of fibrin within and around the tumour mass , 
the majority of cancer patients exhibit some form of systemic activation of 
the coagulation system (Zacharski et al., 1992). As a result activated 
coagulation products such as fibrin monomer (complexed to fibrinogen) 
may be present in the peripheral blood. LAK cells reintroduced into the 
blood stream of cancer patients may therefore bind to fibrin monomer, 
prior to extravasation into the tumour microenvironment. It was therefore 
important to determine whether fibrin monomer also inhibited LAK cell 
killing of tumour cells. 
Fibrin monomer is formed by the thrombin mediated cleavage of the Au 
and B~ chains of fibrinogen. The resultant fibrin monomer then 
spontaneously polymerises to form non-crosslinked fibrin. Fibrin 
polymerisation in the cytotoxicity assay was inhibited by the addition of 
the tetrapeptide Gly-Pro-Arg-Pro (section 5.3.3). In addition, the 
experiments were also performed in factor XIII deficient plasma to 
prevent factor XIII mediated crosslinking of the fibrin monomer subunits. 
In order to prevent fibrinolysis the experiment was also carried out in the 
presence of eACA. (section 5.3.1). As before some inhibition of LAK cell 
killing of A375 cells was seen in the presence of whole plasma and 
factor XIII deficient plasma, but inhibition was greatly increased in the 
presence of eACA. Addition of Gly-Pro-Arg-Pro to the system (section 
5.3.3) caused cytotoxicity levels in both plasma and factor XIII deficient 
plasma to return to just below that observed in serum. Under the 
experimental conditions of these experiments, it would therefore appear 
that fibrin monomer was unable to inhibit LAK cell cytotoxicity against 
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A375 cells in vitro. Extrapolation of these results to the in VIVO 
environment would suggest that in LAK cell immunotherapy, inhibition of 
immune cytotoxic activity occurs within the tumour, and is caused by 
polymerised fibrin, irrespective of whether it is crosslinked by factor XIII. 
This hypothesis is further supported by the previous observation that 
LAK cells are highly cytotoxic to endothelial cells, and that this cell 
damage may account for the vascular leakage syndrome observed 
during therapy. In addition, leucocytes removed from patients 
undergoing LAK cell therapy show considerable LAK cell activity in vitro, 
although the effect of the cell separation procedure on the removal of 
any inhibitory agent cannot be excluded. 
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Appendix I 
LIST OF ABBREVIATIONS 
A23187 Calcium lonophore 
Act-D Actinomycin-D 
ADCC Antibody dependent cellular cytotoxicity 
ADP Adenine nucleotide diphosphate 
APTI Activated partial thromboplastin time 
BBS Borate buffered saline 
BCG Bacillus Calmette Guerin 
CD Cluster determination 
Con A Concanavalin A 
CP Cancer procoagulant 
cpm Counts per minute 
CX Cycloheximide 
DIC Disseminated intravascular coagulation 
eACA epsilon-amino-caproic-acid 
EBV Epstein Barr Virus 
EDTA Ethylene-diamine-tetra-acetic acid 
ELISA Enzyme linked immunosorbant assay 
ELT Euglobulin lysis time 
F/P Fluorophore to protein ratio 
FBP Fibrinopeptide B 
FCS Foetal calf serum 
FOP Fibrin degradation products 
FITC Fluorescein isothiocyanate 
FL-1 Fluorescent channel 1 
FPA Fibrinopeptide A 
FSC Forward light scatter 
GPRP Gly-pro-arg-pro 
GPRP Glycine-Proline-Arginine-Proline 
HUVEC Human umbilical vein endothelial cells 
ICAM-1 Intercellular adhesion molecule-1 
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ICF 
IFNa 
IFNf3 
IFNy 
Ig 
IgG 
IL-1 
IL-1 RA 
IL-1RI 
IL-1 RII 
IL-2 
IL-6 
I. v. 
LAK 
LAL 
LFA-1 
LGL 
LPS 
LT, TNFb 
MAC 
MBSN 
mcab 
MOP 
MESF 
MHC 
MNC 
MPIF 
MWU 
NF-KB 
NIBSC 
NIH 
NK 
Intravascular coagulation and fibrinolysis 
Interferon alpha 
Interferon beta 
Interferon gamma 
Immunoglobulin 
Immunoglobulin G 
Interleukin-1 
Interleukin-1 receptor antagonist 
Interleukin-1 receptor type I 
Interleukin-1 receptor type II 
Interleukin-1 binding protein 
I nterl euki n-2 
Interleukin-6 
intra-venous 
Lymphokine activated killer 
Limulus amoebocyte lysate assay 
Leukocyte function antigen-1 
Large granular lymphocyte 
Lipopolysaccharide 
Lymphotoxin 
Membrane attack complex 
Mean binding site number 
Monoclonal antibody 
Muramyldipeptide 
molecules of equivalent soluble fluorophore 
Major histocompatability complex 
Mononuclear cells 
Monocyte procoagulant inducing factor 
Mann-Whitney U-test 
Nuclear factor-KB 
National Institute for Biological Standardisation and Control 
National institute of Health 
Natural killer 
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NS Not significant 
PA Plasminogen activators 
PCA Procoagulant activity 
PE Phycoerythrin 
Per CP Peridinin chlorophyll protein 
PF4 Platelet factor 4 
PG12 Prostacyclin 
PGE2 Prostaglandin E2 
PHA Phytohaemagg I utin i n 
Poly (I,C) Polyionic:polycytodylic acid 
PT Prothrombin 
SCCL Small cell carcinoma of the lung 
SO Standard deviation 
SOS Sodium dodecyl sulphate 
SEM Standard error of the mean 
SSC Side scatter 
Tc Cytotoxic T cell 
TC flask Tissue culture flask 
TCGF T cell growth factor 
TCR T -cell receptor 
TF Tissue factor 
TIL Tumour infiltrating lymphocytes 
TNFo. Tumour necrosis factor alpha 
tPA Tissue type plasminogen activator 
uPA Urokinase type plasminogen activator 
UPIT Unpaired students T -test 
VPF Vascular permeability factor 
WSR Wilcoxon Signed Rank test 
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Appendix II 
Addresses of Companies Cited 
Alpha Laboratories 
40 Parham Drive 
Eastleigh 
Hants 
S054NU 
Amersham International PLC 
UK Sales Office 
Lincoln Place 
Green End 
Aylesbury 
Bucks 
HP202TP 
Becton Dickinson Immunocytometry 
Systems 
Between Towns Road 
Cowley 
Oxford 
OX43LY 
Flow Cytometry Standards Corporation 
Academic Business Centre 
Neils Bohruieg 11-13 K2 
2333 CA Leiden 
The Netherlands 
Immuno Ltd 
Arctic Hiuse 
Rye Lane 
Dunton Green 
Near Seven Oaks 
Kent 
TN145HB 
Imperial Cancer Research Fund 
Lincoln Inns Field 
London 
NW 
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American Diagnostica 
222 Railroad Avenue 
PO BOX 1165 
Greenwich 
CT 06836-1165 
USA 
BDH (Merck Ltd) 
Hunter Boulevard 
Magna Park 
LuUerworth 
Leic 
LE174XN 
Dako 
16 Manor Courtyard 
Hughenden Avenue 
High Wycombe 
Bucks 
HP135RE 
Genzyme Diagnostics 
50 Gibson Drive 
Kings Hill 
West Mailing 
Kent 
ME196HG 
Immunotech SA 
130 av de LaUre de Tassigny 
BP 177 
13276Marseille Cedex 9 
France 
KabiVitrum Ltd Diagnostica 
Riverside Way 
Uxbridge 
Middlesex 
UB82YF 
Life Technologies 
PO Box 35 
Trident House 
Renfrew Road 
Paisley 
Renfrewshire 
Scotland 
PA34EF 
Marathon Laboratory Supplies 
Unit 6 
55-57 Park Royal Road 
London 
NW101JP 
Nycomed (U K) Ltd 
2111 Coventry Road 
Sheldon 
Birmingham 
B263EA 
Nyegaard Diagnostica UK 
Mylen House 
11 Wagon Lane 
Sheldon 
Birmingham 
B263DU 
Quadratech 
PO BOX 167 
Epsom 
Surrey 
KT172SB 
R+D Systems Europe 
4-10 The Quadrant 
Barton Lane 
Abingdon 
Oxon 
Skatron Ltd 
PO Box 34 
Lynx Court 
Stud lands Park Avenue 
Newmarket 
Suffolk 
CBB 7DB 
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Luckham Ltd 
Victoria Gardens 
Burgess Hill 
Sussex 
RH159GN 
National Blood Transfusion Service 
South Thames Regional Centre 
75 Cranmer Terrace 
London 
SW17 ORB 
Nyegaard Diagnostica 
PO BOX 4220 
Torshov 
Oslo 4 
Norway 
Pharmacia Biosystems Ltd 
Pharmacia LKB Biotechnology Div 
Dory Avenue 
Knowhill 
Milton Keynes 
MKBPH 
R+D Systems 
614 McKinley Place NE 
Minneapolis 
MN 55413 
USA 
Sigma Chemical Co. Ltd. 
Fancy Road 
Poole 
Dorset 
BH177NH 
The Binding Site Limited 
Institute of Research and Development 
Birmingham Research Park 
Vincent Drive 
Birmingham 
B152SQ 
Unistat Limited 
Unistat House 
4 Shirland Mews 
Maida Vale 
London 
W93DY 
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Wallac (U.K.) Ltd. 
20 Vincent Avenue 
Crownhill Business Centre 
Crownhill 
Milton Keynes 
MK80AB 
Appendix III 
Tissue Culture Media 
RPMI - RPMI 1640 tissue culture medium (Life Technologies, 
Renfrewshire, Scotland) supplemented with 10mmoi/L glutamine (Life 
Technologies, Renfrewshire, Scotland), penicillin sodium 50 units/ml and 
streptomycin 50 units/ml (Life Technologies, Renfrewshire, Scotland). 
RPMI/FCS - RPMI supplemented with 10% v/v Australian foetal calf 
serum (Life Technologies, Renfrewshire, Scotland) which had been heat 
inactivated for 30min at 56°C. 
RPMIIAB - RPMI supplemented with 10% v/v human AB serum (South 
London Blood Transfusion Service, Cranmer Terrace, Tooting, London) 
which had been heat inactivated for 30min at 56°C. 
HBSS - Hanks balanced salt solution (without phenol red; Life 
Technologies, Renfrewshire, Scotland) 
HBSS-Ca++I-Mg++ - Hanks balanced salt solution without calcium, 
magnesium or phenol red (Life Technologies, Renfrewshire, Scotland) 
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Appendix IV 
Cytokine Preparations 
Recombinant human tumour necrosis factor-a (TNFa) was obtained from 
Genzyme Diagnostics, Kent.) as a solution containing 2 x 105 U/ml (1 
unit being defined as the amount of TNFa required to generate half 
maximal cytotoxicity of Actinomycin-D stimulated L929 cells). The stock 
solution was aliquotted (1 O~I) into plastic cryotubes (Costar, U.K. Ltd.) 
and stored at _70DC prior to use. For use, 1 O~I of TNFa was diluted to 
2ml with RPMI to give 1000U/ml, and serial dilutions prepared from this 
solution. 
Recombinant human tumour necrosis factor ~ (Iymphotoxin, L T) was 
obtained from Genzyme Diagnostics, Kent., as 25~1 of solution 
containing 5 x 104U/ml (1 unit being the amount of TNFa required to 
generate half maximal cytotoxicity of cycloheximide stimulated L929 
cells). The solution was diluted to 200~1 with RPMI and 10JlI aliquots 
were stored at _70DC prior to use. For use, 1 O~I L T was diluted to 2.5ml 
(1000U/ml) with RPMI to give 1000U/ml which represented the highest 
L T concentration used in the cytotoxicity assay. 
Recombinant human interferon-y (IFNy) was obtained from Genzyme 
Diagnostics, Kent. (Code HG-IFN) as 1 ml of solution containing 40mg 
protein with a specific activity of 2.5 x 107U/mg. One unit is defined as 
the amount of IFNy required to provide equivalent anti-viral activity to 
that expressed by one unit (i.e. 50%) inhibition of viral replication) of the 
NIH human IFNy reference standard (Gg23-901-530). The stock 
preparation was aliquotted into plastiC cryotubes (5~1) which were stored 
at _70DC prior to use. For use, the stock solution was diluted with RPMI 
to 200U/ml which constituted the highest initial concentration 
, 
(representing a final concentration of 100U/ml) used in the cytotoxicity 
assay. In experiments investigating cytokine pre-treatment of tumour 
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cells (section 3.3), IFNy was included In the cell cultures at final 
concentrations up to 1000U/ml. 
Recombinant human interleukin-1 ~ (IL-1~) was obtained from Genzyme 
Diagnostics, Kent. (Code BIL-1-C) as a sterile solution containing 0.5mg 
protein (specific activity 2 x 108 units/mg). One unit of IL-1 ~ activity is 
defined as the amount of IL-1 ~ which induces a 50% decrease in the 
growth of A375 melanoma cells. The stock preparation was aliquotted 
into 5~1 aliquots and stored at -70°C prior to use. For use, the stock 
solution was diluted with RPM I to 200U/ml, which constituted the highest 
initial concentration (representing a final concentration of 100U/ml) used 
in the cytotoxicity assay. 
Recombinant human interleukin-2 (derived from E.coll) was obtained 
from Genzyme Diagnostics, Kent. (Code 2180-01) as Iyophilised powder 
containing 4 x 106 BRMP units/mg IL-2. One BRMP unit of IL-2 activity is 
defined as the amount of IL-2 which is required to support half maximal 
incorporation of tritiated thymidine by CTLL-2 cells (an IL-2 dependent T-
cell line). The powder was reconstituted with 1 ml RPMI and 0.5ml was 
then diluted to 5ml with RPMI/FCS for the preparation of LAK cells. 
Appropriate serial dilutions were prepared as required. 
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Appendix V 
Monoclonal Antibodies 
Fluorescene isothiocyanate (FITC) labelled mouse anti-human 
immunoglobulin type 1 (lgG1) CD25, FITC labelled mouse anti-human 
(lgG1) CD8, and phycoerythrin (PE) labelled mouse anti- human (lgG1) 
p75 were obtained from Becton-Dickinson Immunocytometry Systems, 
Oxford, U.K .. 
FITC labelled mouse anti-human (lgG1) tissue factor was obtained from 
American Diagnostica Inc, Greenwich, U.S.A. and unlabelled mouse 
anti-human (lgG1) factor V was obtained from Sigma Chemical Co. Ltd., 
Poole, Dorset, U. K. 
The isotype control (mouse IgG1 FITC and PE) directly labelled 
antibodies were obtained from Becton-Dickinson Immunocytometry 
Systems, Oxford, U.K. 
The indirect isotype control (mouse IgG1), and Fab" rabbit anti-mouse 
FITC second layer were obtained from DAKO (High Wycombe, Bucks.). 
Recombinant goat anti-human TNFa and TNFB neutralising antibodies 
were obtained from R&D Systems, Minneapolis, USA. 
Mouse anti-bovine retinal antigen-S was obtained from the Immunology 
Department at St Thomas' Hospital. Retinal S-antigen is highly 
conserved between species and reacts well against human retinal S-
antigen (Banga et al., 1989). 
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Appendix VI 
Reagents for Fibrinogen ELISA 
1. Carbonate-Bicarbonate Buffer, 0.05moI/L, pH 9.6 
Distilled water 
-950ml 
Sodium carbonate, anhydrous 
Sodium hydrogen carbonate 
Sodium azide 
adjust pH with 4M Sodium hydroxide to pH 9.6 
make to 11 with distilled water and store at 4°C 
2. Borate Buffered Saline (BBS), 0.02moI/L, pH 7.2 
Distilled water 
Boric acid 
12.363g 
Sodium chloride 
87.740g 
Tween 20 
10.00ml 
adjust pH with 4M sodium hydroxide (pH 7.2) 
make up to 101 with distilled water 
3. Citrate Phosphate Buffer, ).1 mol/L, (pH 5.0) 
Distilled water 
-950ml 
di-sodium hydrogen orthophosphate dodecahydrate 
23.87g 
1.59g 
2.93g 
0.2g 
-9.51 
Citric acid 7.30g 
adjust pH with 4M sodium hydroxide (pH 5.0), make up to 11 with distilled 
water and store at 4°C 
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4. Peroxidase Substrate Solution 
1,2 ortho-phenylenediamine dihydrochloride 
Citrate phosphate buffer 
6% Hydrogen peroxide 
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75mg 
15ml 
15ml 
Appendix VII 
Reagents for Phast Gel Electrophoresis 
1. Coomassie Blue-R Stain (0.2%) 
PORT 1 
Five tablets of stain were added to 400ml distilled water and 
stirred for 10min. Methanol (600ml) was added and the solution filtered 
through a Whatman number 1 filter. For use, SOml of stock stain solution 
was mixed with SOml 10% acetic acid. 
2.Destain 
PORT 2 
methanol 
acetic acid 
distilled water 
300ml 
100ml 
600ml 
3. Preserving Solutions (for 20% gels) 
PORT 3 
acetic acid 
glycerol 
distilled water 
100ml 
100ml 
800ml 
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